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DNA is considered the basis of life; it contains all the necessary information for the 
development of a new organism. When thinking of DNA as the cellular information 
storage, proteins are the true labourers of the cell. Almost every cellular process 
is carried out by proteins, whether it is providing structure, controlling reactions, or 
facilitating them [1]. To be able to take part in that many various reactions with 
high selectivity and specificity, proteins are amongst the most diverse and versatile 
macromolecules [2]. All proteins are generated starting from only 20 basic building 
blocks - called amino acids - to adopt a unique structure relating to their specific 
function. The slightest structural error can hamper biological functioning and cause 
disease [1]. This chapter first describes how architecture of proteins is achieved and 
maintained. Then this chapter focusses on how a small protein engaging aberrant 
interactions is involved in Alzheimer disease.
An introduCtion to protein AggregAtion, the 
Aβ peptide And Alzheimer diseAse.
2Chapter 1
1.1 on protein molecules
1.1.1 the protein Architecture
Within the cellular nucleus the DNA code is transcribed into messenger RNA 
(mRNA). This mRNA is transported to the cytoplasm where it is translated by the 
ribosomal machinery. Many of the produced proteins adopt a specific three-dimensional 
organization that allows them to carry out their specific cellular actions. Generally this 
protein structure is organized from primary to quaternary level (Figure 1.1) [1]. Proteins 
are synthesized as a linear chain of amino acids. The unique combination of number, 
kind and order of these amino acids is called the primary structure of a protein [2] and 
contains all necessary information to adopt the final three dimensional structure (active 
conformation) of the protein [3]. Hydrogen bonding between the amide and carbonyl 
groups of the protein backbone results in the formation of secondary structures. 
These are regular local folds such as α-helices and β-strands. Further compacting 
of the secondary structures into the global conformation of the polypeptide chain 
forms the tertiary structure which sometimes is stabilized by disulfide bonds. For 
most proteins, the tertiary structure is the final active conformation. Some active 
conformations however consist of homogenous or heterogenous protein complexes. 
These are formed when the tertiary structures of the proteins making up the complex 
associate through non-covalent interactions into the quaternary protein structure [2].
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Figure 1.1 Levels of protein structure.
The primary amino acid sequence interacts to adopt secondary local structures. 
Compacting of these structures yields the global tertiary structure. Some proteins are active 
as quaternary complexes in which multiple polypeptide chains have associated. Figure is 
not to scale, adapted from [1].
1.1.2 how proteins fold 
Anfinsen’s experiments showed that the information required to adopt the final 
protein conformation is embedded in the primary amino acid sequence (Anfinsen’s 
dogma) [3]. While proteins typically fold within seconds, Levinthal noted that sampling 
all possible folds to obtain the correct conformation would take longer than the age 
of the universe (Levinthal’s paradox) [4] even when considering the steric hindrance 
posed by amino acid side chains. To solve this paradox he suggested that folding 
occurs along a well-defined pathway of intermediates and transition states [5]. Various 
models for protein folding have been proposed throughout the years [6-12]. The most 
recent concept is the ‘protein energy landscape’ that considers macromolecular states 
as ‘ensembles’ - distributions of conformations. The landscape starts with numerous 
unfolded conformations and whilst going through the narrowing funnel the number of 
conformational possibilities reduces. The idea of parallel transitions leads away from 
the sequential pathway [13,14] and the roughness of the landscape accounts for the 
presence of transient intermediates in local minima, and kinetically trapped ‘misfolded’ 
intermediates. 
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1.1.3 some proteins do not (completely) fold 
Proteins are considered to fold during synthesis or immediately thereafter and their 
function is assumed to be very closely related to their conformation (structure-function 
paradigm). The structural characterization of the protein database is considered key in 
understanding the biological role of these sequences. Many protein domains or even 
whole proteins are found to be unfolded or to adopt a non-globular conformation 
under physiological conditions [15]. As more and more of these unstructured proteins 
are discovered, they are classified as ‘intrinsically disordered proteins’ (IDPs) [16]. 
IDPs are often located in the cell nucleus where they perform key regulatory functions. 
These include DNA and RNA binding, signaling, cell cycle control and regulation of 
transcription [16,17]. The rapid turn-over of IDPs provides an extra advantage for these 
processes as it allows for quick responses to changing cellular needs. The lack of 
order in IDPs moreover creates functional advantages. When retaining their loose fold 
upon binding, IDPs display a larger intermolecular interface allowing for more contact 
points than a globular protein of similar size [18]. On the other hand their induced 
folding upon interaction allows for transient binding to multiple ligands [19] as opposed 
to specific and strong binding to one or two ligands for folded proteins. Many IDPs are 
reported to ‘moonlight’, that is exerting different (even opposing) functions on (different) 
molecules [20]. The induced folding of IDPs seemed to follow the classical structure-
function paradigm, but a more detailed characterization of IDPs bound to a partner 
molecule revealed that large portions of the sequence remained disordered. These 
observations led to the idea that the classical structure-function paradigm needs to be 
re-considered [16].
Dunker and colleagues compared a comprehensive set of ordered and disordered 
domains and trained a neural network to predict disorder from amino acid sequences. 
Their results indicated that regions with a high tendency to disorder are enriched 
in preferentially exposed R, S, P, E and K and significantly depleted of W, C, I, Y 
and V which are mostly buried. This sequence preference allows for identification or 
prediction of disordered regions [21]. Analysis of the Swiss Protein database using 
a predictor for disorder revealed many disordered domains and proteins indicating 
that IDPs are very common within the protein kingdom [22]. Combined with the key 
functional role of IDPs, it can be argued that specific features of IDPs are maintained 
throughout evolution. IDPs are now generally accepted as a distinct class of proteins 
and the “database of protein disorder” (DisProt) gathers and collects structural and 
functional information on IDPs [23].
1.1.4 protein quAlity is monitored And mAintAined
To monitor and maintain the balance of the protein network, described as 
proteostasis, the cell has developed an elaborate machinery controlling the synthesis, 
folding, trafficking and clearance of proteins. Protein folding in vivo is considerably 
challenging due to the crowded environment with protein concentrations in the range 
of hundreds of mg ml-1 [24]. In such conditions non-functional interactions of non-
native polypeptide chains, i.e. newly synthesized, denatured, misfolded or damaged, 
are a likely scenario. To avoid, or resolve, these interactions an extensive network of 
molecular chaperones has evolved to ensure that proteins adopt and maintain their 
functional fold [25]. Molecular chaperones are defined as any protein that interacts 
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with, stabilizes or helps another protein to acquire its functionally active conformation, 
without being present in its final structure [26]. Molecular chaperones bind nascent 
polypeptide chains when released from the ribosome. They aid de novo protein folding 
by protecting the uncompleted sequence from hydrophobic interactions with other 
newly synthesized polypeptides [27]. Further, incorrectly folded proteins are recognized 
by specific chaperones that sequentially unfold and rescue them by providing a second 
chance to fold correctly [28] or deliver them to the correct quality control compartment 
[29]. When chaperones cannot aid or rescue a non-native polypeptide chain to adopt 
its correct conformation they can assign the sequence for degradation [30]. 
Several regulating mechanisms have evolved to ensure proteostasis. When the 
influx of nascent polypeptide chains directed to the secretory pathway exceeds the 
protein folding capacities of the endoplasmic reticulum (ER), the unfolded protein 
response (UPR) is activated to return the ER to its normal state. The UPR is threefold: 
(i) decreasing demand by downregulation of transcription and translation of secretory 
proteins, (ii) increasing clearance of misfolded proteins through ER-associated 
degradation (ERAD) or through autophagy (encapsulation of cytoplasmic components 
into the autophagosome and subsequent fusion with lysosome for degradation), and (iii) 
increasing synthesis of ER localized chaperones [31]. On the other hand, environmental 
stresses like temperature increase, tissue injury, or presence of heavy metals as well 
as metabolic stresses such as increased production of reactive oxygen species or 
nutrient imbalance can enhance the incorrect folding of proteins. To counter-act the 
possible detrimental consequences of these external conditions, the negative regulation 
on the transcription of chaperones is removed, and chaperones accumulate [32]. 
The question arises how IDPs fit in the cellular quality control. Primarily, some 
IDPs are part of the quality control system acting as chaperones [33] or serving as 
a signal for degradation [34]. Concerning the quality control of IDPs, the depletion of 
preferentially buried amino acids from their sequence minimizes aberrant hydrophobic 
interactions [35] and thus the need for chaperone assistance. Further, IDPs are reported 
to have short half-life, and are very sensitive for degradation in vitro [34]. This might 
indicate that non-interacting IDPs are rapidly degraded while they are rescued from 
degradation by their binding partner. Analysis of high-throughput studies indicates that 
chaperones mainly interact with globular proteins and not with IDPs [36] suggesting 
a fundamental difference between IDPs and non-native globular proteins. However 
IDPs might need chaperone assistance during the assembly of protein complexes or 
when their concentration is high and they are at risk of making aberrant hydrophobic 
interactions [37]. 
1.1.5 when proteostAsis is disturbed
Proteostasis can be disturbed by several mechanisms. Viral infections and 
diseases like cancer manipulate the proteostasis machinery to increase protein 
folding and trafficking capacities for their benefit. On the other hand, upon aging, 
the capacity of the quality control system declines [38] and genetics can increase 
misfolding propensity of proteins or reduce proteostasis mechanisms [39,40]. In the 
latter cases, the proteostasis mechanisms fail, or are overwhelmed by the amount 
of accumulated chemically modified or misfolded proteins. All variation of the proteins’ 
native conformation that affects the normal protein functioning, is called ‘misfolding’. 
Some of the accumulated non-native proteins expose hydrophobic patches that are 
5Introduction
normally buried and which have high tendency to interact with exposed hydrophobic 
patches of other proteins. These hydrophobic interactions cause the proteins to cluster 
- a phenomenon called aggregation [41].   Aggregation is thus only a form of misfolding 
and is determined by many factors as is described in the following section. Although 
there seems to be a preference for clustering with the same proteins, co-aggregation 
with other proteins is possible [42,43].
The often toxic aggregates can be located intra- as well as extracellularly. The 
quality control system attempts to re-solubilize the aggregates through chaperones 
[44,45]. Re-solubilization is often not successful and then the aggregates remain 
insoluble. The intracellular insoluble aggregates can be sequestered into inclusions 
like aggresomes to isolate them from the cytoplasm [46,47] as a protective measure. 
The juxtanuclear quality control (JUNQ) compartment stores soluble misfolded proteins 
that are re-directed to the quality control system. Proteins from the JUNQ can either 
refold or be tagged for degradation. A second compartment, the insoluble protein 
deposit (IPOD), concentrates proteins that are meant for elimination through autophagy 
[29,48]. 
When aggregates cannot be eliminated effectively they can cause toxicity which 
leads to disease (Table 1.1). As these diseases are caused by the failure of a protein to 
adopt or maintain its native conformation, these disease are also called ‘conformational 
diseases’. Many of the aggregating proteins underlying these diseases are IDPs [49].
          diseAse           protein or peptide
   Alzheimer disease amyloid-β peptide / tau protein
   Parkinson disease α-synuclein
   Huntington disease huntingtin
   Spongiform encephalopathies prion protein
   Amyothropic lateral sclerosis (ALS) superoxide dismutase 1
   senile systemic amyloidosis transthyretin
   hemodialysis-related amyloidosis β2-microglobulin
   lysozyme amyloidosis lysozyme
   medullary carcinoma of the thyroid calcitonin
   injection-localized amyloidosis insulin
   type II diabetes amylin
   cataract γ-crystallins
Table 1.1 Overview of some of the best known conformational diseases.
These include neurodegenerative diseases as well as nonneuropathic systemic and 
localized amyloidoses. Table adapted from [49]. 
Two possible mechanisms can underlie toxicity: ‘loss-of-function’ and ‘gain-of-
function’. The ‘loss-of-function’ disorders are linked to inherited mutations that may lead 
to excessive degradation. The ‘loss-of-function’ phenotype is caused by the insufficient 
number of active protein molecules to maintain functionality [50] as well as through 
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entrapping other essential proteins in the aggregates [51]. When the aggregates have 
toxic properties the related disease is considered a ‘gain-of-function’ disorder [50]. 
The recent awareness that IDPs are a common class of the protein kingdom and 
the insights in the formation of aggregates have led to an adaption of the protein 
folding landscape (Figure 1.2). Upon folding, globular proteins make intramolecular 
contacts leading to the native conformation. When engaging non-native, intermolecular 
contacts, globular proteins aggregate into amorphous or fibrillar aggregates or any 
possible intermediate morpholgy. IDPs populate an energy plateau at the top of the 
folding funnel. Intermolecular contacts with specific binding partners can induce the 
folding of IDPs and guide them through the funnel towards the folded complex. On the 
other hand intermolecular interactions with proteins that are not interaction partners 
can lead to aggregation [52].  
energy
conguration
IDPs
folded
conformation
oligomers
brils
amorphous
aggregates
protobrils
intermediate intermediate
unfolded proteins
Figure 1.2 The protein folding landscape.
Unfolded proteins are localized at the top of the energy landscape. Under folding conditions 
the sequence will go down the funnel to adopt the folded conformation. Engaging nonnative 
interactions leads to a second funnel resulting in aggregation. Figure adapted from [49].
1.2 fibrillAr AggregAtes
The first observations of insoluble protein deposits in microscopy slices were stained 
with iodine, a chemical commonly used for the staining of starch (‘amylum’ in Latin), and 
hence led to the name ‘amyloid’. For a while the nature of the deposits was unclear until 
it was discovered that they were in fact of proteinaceous nature [53]. Nowadays the 
term amyloid is used to designate fibrillar aggregates adopting a cross-β structure and 
displaying characteristic tinctorial properties such as green birefringence of Congo Red 
and enhanced fluorescence of thioflavin T [54-56]. As amyloid deposits were at first 
observed in conformational diseases (Table 1.1) it was assumed that amyloid formation 
was a property limited to the small set of proteins related to these diseases. Later, it 
became clear that aggregation is an intrinsic property of the protein backbone since 
almost any protein can be induced to form amyloid under conditions that destabilize 
the native conformation or enhance intermolecular interactions [57]. The generic nature 
of protein aggregation is also seen in some organisms that exploit this property for a 
specific purpose. The silk fibers of the spider web [58], the silk moth’s eggshell [59] 
and some bacterial surface structures [60] are composed of amyloidogenic proteins 
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which are assembled under strict regulation, also termed functional amyloids.
1.2.1 the fibrillAr orgAnizAtion
Various proteins without any sequence or conformational homology can form 
amyloid fibrils with similar characteristics. This suggests that the main interactions 
within the fibril are made through the common protein backbone and not by the 
individual amino acid side chain residues [61]. Additional evidence for the intrinsic nature 
of amyloid formation came from the observation that polythreonine and polylysine 
sequences could form amyloid [61]. Electron microscopy or atomic force microscopy 
images showed that amyloid fibrils are long, unbranched and often twisted structures 
with a diameter of 7-13 nanometer. They consist of a number of aligned or rope-
like twisted smaller protofilaments of 2-5 nanometer diameter each [62,63]. X-ray 
diffraction patterns of fibrils display typical cross-β patterns indicating that the proteins 
in the protofilaments are structurally organized as β-strands oriented perpendicular to 
the fibril axis with hydrogen bonds running parallel to the long of the fibril [55]. Individual 
molecules are stacked every 4.7 Å along the axis; parallel, in register and stabilized 
by hydrogen bonding. Each protofilament contains two or more β-sheets with an 
intersheet distance of 10 Å  (Figure 1.3) [64,65]. 
intersheet distance
10 Å
bril axis
a b
interstrand distance
4.7 Å
Figure 1.3 Structure of the fibril core.
(a) The fibril consists of various β-sheets running along the fibril axis. (b) The individual sheets 
are spaced at 10 Å while the β-strands within the sheet are oriented perpendicular to the 
fibril axis and have an interstrand spacing of 4.7 Å. Figure adapted from [66],[67].
This specific structural organization is recognized by the dyes Congo Red and 
thioflavin T. When bound to fibrils these compounds display green birefringence and 
enhanced fluorescence respectively [68]. Aside of these common traits, heterogeneity 
in fibril structure exists as well. Variation can occur at the level of amino acid side 
chains as well as in the loops connecting intramolecular β-sheets. Further both length 
and orientation of the individual β-strands and the number of β-sheets in the fibril can 
vary. Variation can also be observed between fibrils of the same protein that adopt 
different internal fibrillar organization due to thermodynamic or kinetic determinants 
under given conditions [69].  
1.2.2 Amyloid chArActeristics on Amino Acid level
The observation that co-aggregation is significantly decreased between sequences 
with a sequence identity lower than 30-40% suggests the presence of amino 
acid sequence determinants for aggregation [70]. The aggregation rate of a given 
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sequence correlates with the net charge, hydrophobicity and propensity to adopt 
β-sheet structure of that sequence [71,72]. In general a low net positive or negative 
charge allows for the formation of ordered fibrils as a result of these charges allowing 
a limited number of orientations of the individual amino acids in the fibril structure that 
maximize the distance between charges of the same sign. Stacking of β-sheets of 
neutral sequences that have no charge compensations is not limited in orientation and 
therefore forms amorphous aggregates. Extremely high net charged proteins have too 
many uncompensated charges that make it energetically unfavorable to aggregate and 
hence discourage self-assembly [72,73]. Sequence stretches with high hydrophobicity 
or high propensity to form β-sheet are usually the regions triggering aggregation [71]. 
Evolutionary pressure developed mechanisms to prevent aggregation in vivo such as 
the incorporation of β-sheet breakers like proline and so-called ‘gatekeepers’, charged 
residues flanking aggregation-prone regions. These gatekeeper residues are also the 
recognizing motifs for chaperone binding in the process of preventing aggregation [74]. 
Moreover, IDPs are generally significantly more charged than globular proteins, have 
low β-sheet propensity and thus contain far less aggregation nucleating regions than 
globular proteins minimizing their risk of aggregation [33,75,76]. 
The fact that the aggregation of a sequence is partially determined by the physico-
chemical properties of the amino acids in that sequence raises the opportunity for 
prediction of aggregation based on sequence. Over the years several algorithms were 
developed to identify and score aggregating regions [77-79], as well as a specific 
predictor of amyloid aggregation [80]. 
1.2.3 the formAtion of Amyloid
Aggregation of globular proteins can start from unfolded polypeptides, partially 
folded intermediates or native conformations. The partially folded state generates from 
both partial unfolding of the globular conformation under de-stabilizing conditions and 
kinetic trapping of partially folded intermediates during folding (Figure 1.4) [81]. 
unfolded
disordered
aggregates
partially folded
native
conformation
functional
brils
disordered
aggregates
functional
oligomers
native-like
aggregates
protobrils amyloid
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Figure 1.4  Schematic representation of protein folding and misfolding pathways.
Protein sequences adopt various conformations and undergo transitions from one 
conformation to the other. Aggregation might start from any of these conformations. Figure 
adapted from [49].
The unfolded and partially folded states initially form disordered aggregates that 
can reorganize into oligomers and further assemble to form amyloid [49]. The native 
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conformation of some proteins associates to form fibrils which may be functional as 
described under section 1.2. Other proteins assemble into fibrils with characteristic 
tinctorial properties but maintaining their native structure, and activity as is the case 
for actin, Pmel17 and glutamate dehydrogenase [82-84]. For IDPs the scheme as 
depicted in Figure 1.4 is sligthtly different as IDPs do not need to partially unfold 
to make intermolecular contacts and aggregate. IDPs might interact in their native, 
unfolded conformation and aggregate further. On the other hand, analogous to partial 
(un)folding, IDPs first may have to undergo a transition from a predominant cellular 
form to an abnormal form - like the prion protein - before aggregation occurs [52].  
The association of proteins during aggregation may result in amorphous aggregates 
or fibrillar amyloid or an intermediate thereof (Figure 1.5). The processes leading to these 
structures are highly sensitive to environmental conditions and protein concentration. 
Variation of pH, temperature or the presence of salts affects the possible interactions 
between polypeptides and hence determines whether amyloid rather than amorphous 
aggregates are formed [73]. Although typical amyloid fibrils have been primarily defined 
by cross-β structure, amorphous aggregates are now recognized to not just consist of 
random clumps of sticky protein without dominant structure characteristics but often 
also consist of cross-β structure [85].
a b c
 
Figure 1.5 The macromolecular morphology of aggregates.
Aggregates as observed using transmission electron microscopy can appear either (a) 
amorphous, (b) fibrillar or (c) as a mixture of these.
The aggregation processes of some proteins including actin, glutamate 
dehydrogenase, tubulin, amyloid-β and calcitonin have been studied in detail [86]. The 
unravelling of the aggregation mechanism involves detailed characterization of key 
intermediates as well as determination of the thermodynamic and kinetic properties 
of the conversions of these intermediates. It has been recently suggested that the 
association mechanisms of all the various amyloidogenic proteins share some key 
determinants [87]. A number of models have been developed to describe these general 
association mechanisms. The first model described aggregation as a monomer-addition 
reaction [88] where aggregation only occurred above a critical protein concentration. 
While applying this model to the kinetics of sickle-cell hemoglobin gelation, nucleation 
and  polymerization were distinguished, introducing the ‘nucleation and polymerization’ 
model [89]. This concept described the thermodynamically unfavorable addition of 
monomers until a nucleus was formed. Further thermodynamically favorable addition 
led to polymerization. Later, Benedek and colleagues described the formation of a 
micelle at concentrations above the critical micelle concentration [90] reminiscent to the 
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process of lipid association at concentrations above the critical micelle concentration. 
Nucleation occurs within the micelle followed by elongation. Detailed characterization 
of glutamate dehydrogenase raised the idea of random association in which two 
units - monomeric or oligomeric - could associate to form the polymer [91]. The 
aggregation of the prion protein in which the cellular form, PrPc, converts to the 
prion form, PrPsc, before aggregation occurs has been described by the nucleation-
dependent polymerization mechanism [92]. This model has been used later to describe 
the aggregation mechanisms of other amyloidogenic proteins [93]. Recently, the two-
step model originally describing the formation of transition-metal nanoclusters [94] 
has been shown to apply to the aggregation of various proteins [95], although being 
very simplistic and having some limitations [86]. Elongation of fibrils has been shown 
to occur through monomeric peptide binding [96]. Two models are formulated to 
describe fibril elongation: a ‘dock-and-lock’ model and a ‘fast deposition’ model. The 
‘dock-and-lock’ model is a two-step mechanism in which the monomer attaches to 
the fibril end through diffusion. The monomer/fibril complex then reorganizes, possibly 
undergoing conformational change, to lock the monomer in an aggregated state 
[97]. The ‘fast deposition’ model on the other hand is a one-step mechanism. The 
conformation of the monomeric peptide fluctuates and adopts an aggregation-prone 
state. As this state, while diffusing, encounters a fibril end it will deposit [98]. Increased 
computational power and available simulations are nowadays used to understand the 
thermodynamics and kinetics of protein aggregation [87].
As previously mentioned, aggregation is a very complex reaction and consists of 
many intermediates such as oligomers, critical nuclei, and protofilaments. The general 
model describing aggregation (Figure 1.6) is based on the nucleation-dependent 
polymerization [92]. In this model no aggregation is observed at concentrations below 
a critical concentration. When concentrations are above the critical concentration a lag 
phase is observed during which monomers associate into an ordered nucleus (rate-
limiting step), although in some cases nucleation is very rapid so that no lag phase 
is observed. The nuclei then rapidly elongate through monomer or oligomer addition 
during an exponential growth phase to reach an equilibrium between monomers and 
ordered aggregates. 
nucleus
Figure 1.6 Schematic representation of the aggregation mechanism.
Monomers associate into oligomers and form a critical nucleus. The critical nucleus is the 
starting point for further polymerization. Figure adapted from [86]. 
Detailed understanding of the in vitro behavior of amyloidogenic proteins, and the 
mechanisms leading to amyloid formation has contributed significantly to the current 
insights in the various conformational diseases. Currently, interest has shifted away 
from the fibrillar structures towards the smaller, soluble species of the aggregation 
pathway. Oligomers are nowadays considered the true harmfull species exerting 
toxic effects [99-104], although this hypothesis remains to be unequivocally proven. 
Biophysical understanding and characterization of the oligomers is combined with cell 
culture set-ups and in vivo models to unravel the mechanisms and pathways leading 
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to toxicity. Better understanding of these mechanisms is a new opportunity to identify 
drug targets and therapeutic approaches.
1.3 Alzheimer diseAse 
In 2010 about 35 million people worldwide were estimated to suffer from dementia. 
Estimates are that the number of patients will be tripled by 2050 [105]. Currently, the 
total cost related to the medical and social care are rated to exceed 600 billion US 
dollar [106]. The increasing number of patients will challenge society on social, medical 
and economical level. About 50-75% of above mentioned patients with dementia 
suffer from Alzheimer disease, the most well-known form of dementia [105]. Currently 
no cure or treatment to halt or reverse disease progress is available for Alzheimer 
disease. Better insight into the mechanisms leading to Alzheimer disease can improve 
diagnosis, treatment and patient care. 
1.3.1 diseAse course
The course of Alzheimer disease progress is divided into three stages: mild, moderate 
and severe (Table 1.2) [107]. Early on when symptoms of dementia become noticeable 
but do not interfere with normal functioning, the term ‘mild cognitive impairment’ (MCI) 
is used. MCI can be related to normal aging, or can be the earliest sign of Alzheimer 
disease [108].The illness then progresses to a stage where symptoms compromise 
daily living. The mild phase is characterized by a ‘simple’ loss of memory, manifested 
by having trouble finding the right word and misplacing objects. These early symptoms 
evolve into more advanced memory loss, having problems recognizing family and 
friends and inability to learn new tasks. At this stage accomplishing basic daily tasks 
becomes challenging or even impossible. During the last, severe stage patients lose 
control of many normal physiological functions, are no longer able to speak coherently 
and suffer from weight loss and infections [107].
mild moderAte severe
getting lost confusion weight loss
poor judgement difficulties with multistep tasks loss of communication
trouble handling money paranoia difficulty swallowing
repeating questions personality changes increased sleeping
mood & personality changes impulsive behavior skin and lung infections
vocabulary problems not recognizing family - friends
misplacing & losing objects not learning new tasks
anxiety language & number problems
aggression shortened attention span
loss of logic thinking
Table 1.2 Overview of the most common symptoms related to Alzheimer disease.
Symptoms of Alzheimer disease are grouped in stages of disease progress [107].
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1.3.2 diAgnosis
Currently, Alzheimer disease cannot be diagnosed with 100% accuracy. As there is 
no specific test to identify Alzheimer disease in the living patient several tests are used, 
mainly to rule out all other possible causes for the symptoms. As a consequence 
diagnosis is either possible or probable. Diagnosis can only be confirmed by 
postmortem examination of brain tissue [109]. Diagnosis of Alzheimer disease follows 
the criteria stated in the Diagnostic and Statistical Manual (DSM IV) [110]. A first 
indication for Alzheimer disease comes from medical and family history and is followed 
by neurological and physical examination to make a diagnosis and determine the 
stage of the disease. A first test is the ‘mini-mental state examination’ (MMSE) [111] 
examining global cognitive functions. Further, memory function and attention span are 
assessed using word recall or pictures naming tests [112] and the Wisconsin card 
sorting test [113], respectively. Psychological examination of patients can indicate the 
presence of apathy, depression, anxiety or hallucinations, all symptoms of Alzheimer 
disease. Blood tests and cerebrospinal fluid (CSF) analysis for biomarkers such as 
total tau and phospho-tau provide additional indications as well as the use of imaging 
techniques such as computed tomography (CT), magnetic resonance imaging (MRI) 
and positron emission tomography (PET). The presence of other disorders such as 
infections, anorexia and cardiovascular disease can worsen the state of the patient 
and thus need to be examined and treated [114].
1.3.3 pAthology
Alzheimer disease is a progressive neurodegenerative disease characterized by 
pathological neuronal cell death and corresponding loss of neuronal function and 
synaptic connections. Neuronal loss occurs gradually throughout different brain regions 
and eventually leads to severe shrinkage of the brain (Figure 1.7). The first region 
affected is the hippocampus, involved in the formation of new memories and recalling 
recent memories. Neurodegeneration then spreads to the cerebral cortex responsible 
for i.a. thought, attention, language, and reasoning. In the last stage of the disease 
neurodegeneration is spreaded throughout the brain [107]. 
a b c
Figure 1.7 Spreading of neuronal brain loss.
(a) Neuronal loss starts in the hippocampus (marked) in mild Alzheimer disease, (b) 
progresses throughout the brain in moderate disease stages and (c) affects almost all 
areas of the brain in the severe stage. Figure adapted from [107].
On a molecular level, Alzheimer disease is characterized by the presence of 
amyloid plaques and neurofibrillary tangles in the brain [115]. Amyloid plaques are 
extracellular deposits mainly build up from amyloid-β (Aβ) peptides but also containing 
smaller amounts of many other cellular components [116,117]. Tangles are intracellular 
helical filaments of hyperphosphorylated tau proteins [118]. The hyperphosphorylated 
tau proteins no longer associate with microtubules. As a consequence, microtubules 
dissociate and microtubule-associated transport and cellular shape are no longer 
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supported [119]. Hardy and Allsop proposed the ‘amyloid cascade hypothesis’ 
suggesting that the processing of amyloid precursor protein (APP) to generate Aβ is 
the key event in developing Alzheimer disease. The subsequent aggregation of Aβ 
and the formation of neuritic plaques then triggers a cascade of events such as the 
formation of neurofibrillary tangles leading to neuronal death and dementia [120]. The 
formulation of this hypothesis led to an exponential increase of experimental study 
of the Aβ peptide and the amyloid deposits. Accumulating evidence from mutations 
leading to early-onset familial forms of Alzheimer disease [121], neurotoxicity of the Aβ 
peptide [99] and the correlation between the amounts of soluble Aβ and the severity 
of neurodegeneration [102] led to reconsideration of the hypothesis. In its current form, 
the hypothesis emphasizes the importance of soluble toxic oligomers and Aβ is no 
longer thought to be the only culprit [122]. 
1.3.4 sporAdic And fAmiliAl forms 
Both sporadic and hereditary familial forms of Alzheimer disease are known (SAD 
and FAD respectively). FAD cases, in contrary to SAD, are characterized by early-
onset (before the age of 65) of the disease [123]. The familial forms of Alzheimer disease 
are caused by mutations in either the APP gene [124] or in the genes encoding for 
presenilin-1 or -2 (PS-1, PS-2), subunits of the APP processing γ-secretase complex 
(http://www.molgen.ua.ac.be/ADMutations) [125]. Mutations in APP (Table 1.3) are 
clustered around the secretase cleavage sites suggesting their phenotype is the 
result of affected secretase activity [126]. Mutations located near the β-secretase 
cleavage site generally induce an increased Aβ production while mutations close to 
the γ-secretase cleavage site modulate γ-secretase activity and cause a shift in the 
spectrum of produced Aβ peptides towards longer forms without necessarily affecting 
the quantity of Aβ peptides produced [126,127]. Mutations in PS-1 or PS-2 affect 
the active site of the γ-secretase complex and increase the release of Aβ42 [121]. 
Increased production of APP, located on chromosome 21, as seen in patients with 
Down syndrome (trisomy 21) also leads to early-onset Alzheimer disease [128]. 
nAme mutAtion nAme mutAtion
Swedish K670N / M671L Austrian T714I
Tottori D678N French V715M
Flemish A692G German V715A
Dutch E693Q Florida I716V
Arctic E693G London V717I
Italian E693K Indiana V717F
Iowa D694N Australian L723P
Iranian T714A
Table 1.3 Selection of the known mutations of APP
The mutations of APP are named after the nationality or location of the first family in which 
the mutation was demonstrated [129].
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1.3.5 therApeutic ApproAch
Current drugs available for the treatment of Alzheimer disease are cholinesterase 
inhibitors (donepezil hydrochloride, rivastigmine and galantamine) and an NMDA-
receptor antagonist (memantine). The cholinesterase inhibitors prevent the breakdown 
of acetylcholine. The increased levels of acetylcholine improve communication between 
neurons and hence temporarily improve or stabilize symptoms of Alzheimer disease. 
The NMDA-receptor antagonist memantine blocks the effect of glutamate. Glutamate 
is released by damaged neurons, and causes damage to healthy brain cells. Hence, 
blocking the action of this molecule protects neurons against damage [130]. 
The current therapeutic approach thus mainly provides symptomatic relief by mild 
improvement of cognitive function in the early phases of disease progress, but is not 
able to reverse or prevent disease progress. The increasing number of patients and 
the related social and economical burden create an urgent need for development of 
such therapeutics. Various strategies acting on Aβ, tau or other cellular targets are 
being investigated and some of these have reached the stage of clinical trials, albeit 
with little success.
One of the strategies in the fight against Alzheimer disease directly targets the Aβ 
peptide. The possible different approaches act on (i) the release of Aβ, (ii) prevention 
of Aβ aggregation, or (iii) reducing deposited protein levels [131].
When trying to reduce or prevent the release of Aβ peptides, the secretases 
cleaving APP are the main targets. Upregulation of α-secretase activity has been 
explored with the aim to shift APP processing towards the non-amyloidogenic 
pathway, producing p3 peptide instead (Figure 1.8). This pathway is considered 
protective towards Alzheimer disease as it precludes the release of Aβ. However, 
the p3 peptide released in the non-amyloidogenic pathway is highly hydrophobic and 
has been reported to be present in amyloid plaques [132]. Moreover, the catalytic site 
of α-secretase activity is composed of a series of membrane-associated proteases, 
all members of the ADAM (a disintegrin and metalloproteinase) family [133]. This 
heterogeneity makes it difficult to specifically target α-secretase activity. Compounds 
indirectly activating α-secretase activity have been developed and are being tested in 
clinical trials [134]. A second strategy to reduce Aβ burden is inhibition of β-secretase 
activity. The β-secretase enzyme (BACE) cleaves multiple transmembrane proteins 
[135] and thus careful dosage is needed to find an equilibrium between sufficient BACE 
inhibition and minimal side effects. Compound CTS21166 is currently being evaluated 
in clinical trials [136]. Although the precise function of Aβ remains elusive, evidence is 
accumulating that the peptide performs an essential role [137]. Preventing, or reducing 
the Aβ production might induce side effects. The γ-secretase complex cleaves various 
transmembrane substrates such as Notch1, essential for cell-cell communication and 
neuronal function a.o. [138]. The inhibition of γ-secretase activity obstructs the cleavage 
of these substrates and hence causes important side effects [139]. The high degree of 
variability of the proteolytic complex however enables the specific inhibition of certain 
complexes to minimize side effects [140] as could be the case for so-called ‘Notch-
sparing’ γ-secretase inhibitors [141]. Another strategy that received ample attention is to 
shift the spectrum of produced Aβ peptides towards shorter Aβ as many FAD-related 
mutations do not affect total Aβ production but specifically increase Aβ42 generation. 
This shift is accomplished by molecules that modulate the cleavage site of γ-secretase 
to produce less Aβ42 and more of the shorter lengths without inducing side-effects [142].
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An alternative approach aims at inhibiting the self-assembly of Aβ thereby preventing 
the formation of soluble toxic species and eventually plaque deposition. One attempt 
using synthetic glycosaminoglycan 3-amino-1-propaneosulfonic acid (3APS) has been 
evaluated in clinical trial phase II. Results showed decreased CSF Aβ42 levels but 
no significant cognitive improvement [143]. Another attempt used a zinc and copper 
binding drug as in vitro Aβ aggregation is effectively inhibited by metal chelators. The 
changes in plasma Aβ levels after administration of the compound were significant in 
patients with mild disease but not in severe cases [144].
A third strategy directly targeting Aβ focussed on reducing plaque load using 
immunotherapy. A clinical trial for Aβ vaccination was set-up after promising animal 
studies but had to be interrupted due to low antibody response and occurrence of 
meningoencephalitis [145]. Despite significant decrease of plaque load, no cognitive 
improvements or delay of disease progress was obtained using active immunization 
[146]. As proteostasis of Aβ is a subtle equilibrium between production and clearance 
of the peptide, accumulation of the peptide can be the consequence of increased 
production, or of defective clearance. Various enzymes are reported to degrade Aβ 
in vivo or in vitro. Amongst them insulin degrading enzyme, angiotensin-converting 
enzyme, neprilysin and cathepsin D [147]. It has been observed that Aβ clearance 
is impaired in patients with Alzheimer disease, providing a possible mechanism for 
disease development [148]. Upregulation of Aβ clearance might therefore be an 
alternative approach to prevent plaque formation.
Complementary to Aβ targeting, drugs promoting neuroprotection are being explored. 
Compounds aiming at inhibition or reduction of oxidative stress, neuroinflammation 
or mitochondrial dysfunction in neurodegeneration could have potential to minimize 
the neuronal damage and contribute to improved cognitive function [149]. Further, 
effective therapy against Alzheimer disease has been hypothesized to use combined 
action against Aβ and tau hyperphosphorylation or tangle formation [131] as the loss 
of microtubule-associated cellular transport and structure is an important event in 
neurodegeneration.
1.4 the Amyloid-β peptide
The Aβ peptide (sequence details provided in Appendix A) is widely studied in 
the light of its role in Alzheimer disease. The production of the intrinsically disordered 
Aβ peptide is a physiologically normal process that occurs in healthy subjects as 
well as in Alzheimer disease patients. Hence, the generation of the peptide itself is 
unlikely to represent the primary cause of Alzheimer disease [150]. It remains however 
elusive what the actual cellular role of Aβ comprises. The last decade several possible 
functions of Aβ were hypothesized, but none of these have been confirmed. The 
property to reduce the metal charge state of some metal ions led to the suggestion 
that Aβ could protect against metal-induced oxidative damage [151] although this 
mechanism is also reported to induce toxicity [152]. Further Aβ was suggested to have 
a signaling function in secretase activity [153], to be involved in cholesterol transport 
[154] or to act intracellular as a transcription factor [155]. An increased production of 
Aβ as observed in some early-onset FAD cases and patients with Down syndrome, 
has been shown to be sufficient for development of Alzheimer disease [126,128]. 
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1.4.1 generAtion of Aβ
The Aβ peptide is generated from APP by proteolytic cleavage. The proteolysis 
of APP can occur through two pathways (Figure 1.8). Both pathways release an 
extracellular soluble fragment (APPs) and a second membrane-spanning C-terminal 
fragment (CTF) [156]. The non-amyloidogenic pathway is selected when APP is first 
cleaved by α-secretase, generating APPsα and CTF83. This cleavage precludes the 
generation of Aβ as the α-secretase cleavage site is located within the Aβ sequence. 
The amyloidogenic pathway is entered when APP is first cleaved by β-secretase 
instead of α-secretase. The β-secretase cleaves at the N-terminus of the Aβ sequence, 
releasing APPsβ and CTF99. The CTF83 and CTF99 fragments are subsequently 
cleaved by γ-secretase and respectively generate the p3 and Aβ peptides as well 
as an APP intracellular domain (AICD) [156]. The soluble secreted APPs is reported 
to have a neuroprotective function and is important for neurogenesis [157]. AICD on 
the other hand impairs generation of new neurons [158], has a signaling function 
and is a transcription regulator [159]. The p3 peptide is generally accepted as non-
amyloidogenic although it has been reported as highly hydrophobic, aggregating and 
has been found in amyloid plaques [132].
APPAPPsαp3 APPsβ Aβ
non-amyloidogenic amyloidogenic
AICD AICDCTF83 CTF99
γ-secretaseγ-secretase
α-secretase
β-secretase
Figure 1.8 Proteolytic processing pathways of APP.
A first cleavage by α-secretase generates p3 peptides while primary cleavage by 
β-secretase releases Aβ upon subsequent proteolysis by γ-secretase. Figure adapted 
from [160]. 
α-Secretase activity is mediated by members of the ADAM membrane-bound 
protease family while β-secretase, also known as BACE (β-site APP cleaving enzyme), 
is a transmembrane aspartic protease [161]. However, the recognition that γ-secretase 
is largely responsible for the generation of Aβ lead to large scale research into its 
functioning and structure. γ-Secretase is a large proteolytic complex in which the 
catalytic core is formed by presenilin 1 and 2 (PS-1 and PS-2), complemented by 
nicastrin, presenilin enhancer protein 2 (PEN2) and anterior pharynx-defective 1 (APH-
1) [161]. The γ-secretase complex first cleaves APP at the ε-site producing Aβ peptides 
of 48 or 49 amino acids long [162]. The γ-secretase complex then proceeds towards 
the γ-site releasing three to four residues at each step which results into two product 
lines: Aβ48 > Aβ45 > Aβ42 > Aβ38 and Aβ49 > Aβ46 > Aβ43 > Aβ40 [162,163]. 
These two product lines finally result in the generation of about 90% of the 40 amino 
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acid form with minor amounts of Aβ42 [164]. Besides the two predominant forms Aβ40 
and Aβ42 both shorter and longer Aβ peptides have been detected in vivo [165,166]. 
Further heterogeneity of Aβ is introduced at the N-terminus during proteolytic 
release or afterwards by further modifications such as oxidation, isomerization or 
racemization [167]. These modifications can alter the hydrophobicity or resistance to 
proteolytic degradation of the peptides possibly with far-reaching consequences on 
disease progress [168].   
1.4.2 AggregAtion of Aβ 
The behavior of the predominant Aβ40 and Aβ42 peptides is the subject of 
scientific research since the early nineties when Aβ peptides were identified as the main 
constituents of brain plaques [116]. The 42 amino acid isoform is the main component of 
plaques with smaller amounts of Aβ40 and other molecules [51,167,169,170]. Studies 
showed that the biophysical and biochemical behavior of both isoforms markedly differ 
despite a difference of only C-terminal amino acids. The longer Aβ42, being more 
hydrophobic compared to Aβ40 as a result of an additional C-terminal isoleucine and 
alanine, rapidly polymerizes into fibrils while Aβ40 is more soluble and displays a lag 
phase before fibril formation [171]. Differences between these two isoforms are also 
reflected at the level of early aggregation events and toxicity and indicates that both 
peptides aggregate through different pathways [172]. When mixing both peptides, 
Aβ40 reduces the aggregation rate of Aβ42 in a concentration-dependent manner 
while Aβ42 strongly enhances aggregation of Aβ40. Analogous, toxicity of Aβ42 is 
moderated by Aβ40 [173,174] which correlates with the finding of increased fractions 
of elongated Aβ in the brain of Alzheimer disease patients. This effect of Aβ40 on Aβ42 
is also observed in vivo where increasing amounts of Aβ40 seem to be protective 
against plaque formation [175].   
Recently, focus shifted from the fibrillar forms of Aβ towards the more soluble 
oligomeric forms. A first indication that fibrillar Aβ was not the main cause of Alzheimer 
disease came from the low correlation between disease progress and plaque load 
[100]. The finding that synthetic Aβ peptides had to aggregate to cause neurotoxicity 
was one of the first clues that aggregated forms of Aβ, and not the monomeric 
form, were the main culprits in the relation between Aβ and Alzheimer disease [99]. 
Additionally, studies showing that variable amounts of oligomers found in brain samples 
correlated well with the severity of dementia, and that memory impairment in transgenic 
mice occurred before plaque deposition could be observed, confirmed the hypothesis 
that oligomeric Aβ is the main toxic species [101,102]. Extra evidence came from the 
observation that conditioned medium containing Aβ oligomers could block long-term 
potentiation when injected in mice and that anti-Aβ treatment reversed memory deficits 
in mice, but had no effect on plaque burden [103,104]. Various toxic soluble species 
have been identified since. Amongst them protofibrils [176], Aβ-derived diffusible 
ligands (ADDLs) [177], a 56 kDa species - Aβ*56 - [178] and amylospheroids [179]. 
Characterization of the structural and cytotoxic properties of these various species 
which all exert significant toxic properties in cell culture and animal studies confirms the 
importance of soluble oligomers in Alzheimer disease progress. Even though a common 
building block [180] has been proposed and many intermediates have been identified, 
a unique toxic species has not been identified so far. The possibility remains thus 
that toxicity is related to more than one assembly, or to a specific structural feature 
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that has yet to be defined [181]. Toxic oligomers formed by Aβ, α-synuclein, insulin or 
prion protein e.g. are all recognized by the same A11 oligomer-specific antibody which 
indicates a relationship between a structural ‘fingerprint’ and toxicity [182].  
1.4.3 structure of AggregAted Aβ
Fibrils of Aβ adopt, like other amyloid fibrils, a cross-β sheet structure with β-strands 
oriented perpendicular to the fibril axis [183]. Fibrils of both Aβ40 and Aβ42 are build 
out of stacked ‘β-strand - turn - β-strand’ (β-turn-β) units which are oriented parallel 
and in-register [184]. The N-terminus does not take part in this β-turn-β motif as it 
is thought to be unstructured [185,186], although recently stable fibrillar organization 
involving the first three to four residues of Aβ has been reported [183]. Both isoforms 
of Aβ adopt the β-turn-β motif in which residues 25 to 29 form the 180˚ bend [187] 
and which is stabilized by a salt bridge between residues 23 and 28 [185] (Figure 
1.9). Structural differences occur at the level of the sidechain interactions. In Aβ42 
intermolecular contacts are made between residues 17, 19 and 21 on one sheet and 
the residues 34, 36 and 40 on the other sheet [185]. Aβ40 on the other hand makes 
intramolecular sidechain interactions and the two β-sheets have shifted to be slightly 
out-of-register [185,187].
a b
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Figure 1.9 Suggested structure of the Aβ40 and Aβ42 monomer in fibrils.
The turn conformation is stabilized by the interactions of the hydrophobic residues (grey) 
and a salt bridge is formed between residue 23 and 28 (a) Residues 1-10 of the Aβ40 
monomer are unstructured. Side chain packing occurs between residues 13-40, 15-36, 
19-32/34/36 (dashed grey line). (b) Residues  1-17 are unstructured in the Aβ42 monomer. 
Residue 19 is reported to make molecular contacts with residue 38, residue 35 interacts 
with residue 42 (dashed black line). Adapted from [188].
1.5 outline of this thesis
Since the purification of the Aβ peptide from Alzheimer disease brain plaques 
the peptide has been the subject of numerous studies. Throughout the years it was 
discovered that Aβ is produced under normal cellular conditions. As the majority of 
peptide produced is the Aβ40 isoform, most studies investigating aggregation behavior 
of Aβ focussed on the Aβ40 peptide. Extensive research on the mutations that are 
linked to early-onset familial cases of Alzheimer disease revealed that upregulation 
of total Aβ production, or specifically of the Aβ42 isoform leads to disease progress. 
These findings resulted in an increased interest in the characteristics of this Aβ isoform, 
and the link to disease. The characterization of the aggregation of the Aβ40 and Aβ42 
peptides in isolation is well reported, as well as the fact that both isoforms can influence 
the behavior of the other. Although multiple other, both shorter and longer, Aβ peptide 
lengths have been detected in brain samples, plasma and CSF, information on the 
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prevalence, aggregation and cytotoxicity of these isoforms remains scarce. The recent 
findings that the levels of these other Aβ peptide lengths vary upon disease progress 
suggest that these isoforms contribute to the development of Alzheimer disease. How 
these peptides could act, however, remains elusive as very little is known about the 
aggregation behavior and toxic properties of these Aβ peptides.
The aim of this thesis is to report how small variations of the Aβ sequence could 
relate to Alzheimer disease progress. As the Aβ sequence is very susceptible to 
variation, only a selection of the known variations are included in this thesis with a 
focus on peptide length heterogeneity. The various Aβ peptides were investigated 
using a mainly biophysical approach to characterize the aggregation profile of the 
peptides in isolation, and in mixtures to investigate the influence of one isoform on 
the other. In addition cell-culture and mouse studies were used to determine the toxic 
properties of the peptides. Aside from the detailed in vitro study of the peptides, the 
pathways generating Aβ were explored to understand how C-terminal heterogeneity 
in the Aβ sequence is generated.
The thesis starts with the description of the protocol used to solubilize the Aβ 
peptides (Chapter 2). The proposed method generates pure, monomeric solutions 
of Aβ, virtually free of seeds and contaminants of chemical solvents. Starting from 
a monomeric solution is of major importance for the characterization of aggregation. 
Furthermore the absence of traces of solvents makes the Aβ solution compatible for 
cell culture and mouse studies. Moreover, the presence of minute quantities of solvents 
would influence the aggregation reaction under study.
Chapter 3 provides a comparative study of the aggregation of a selection of the 
most common Aβ peptides identified in vivo. The oligomerization and aggregation of 
this extensive set of peptides are compared. The experiments showed that small 
variation of the Aβ sequence can significantly affect the aggregation properties of the 
peptide. In the next chapter (Chapter 4) a newly identified mutation of APP, called the 
‘Leuven mutation’ is described. The consequences of this mutation on APP processing 
and Aβ behavior are evaluated. The novel mutation is found to interact with APP 
processing while the resulting mutation in Aβ has little effect on the behavior of the 
peptide. Understanding APP processing and how it is affected by mutations gains 
novel insights in the generation of Aβ. These insights contribute highly to the unravelling 
of Alzheimer disease as the aberrant Aβ production might be the primary event in 
disease onset.
The following part of the thesis focuses on the interaction between Aβ40 and Aβ42. 
Chapter 5 describes how the behavior of Aβ42:Aβ40 mixtures varies with variation 
of the ratio between these two peptides. A minor increase of the Aβ42:Aβ40 ratio 
induces significant changes in aggregation rate and results in stabilized toxic oligomers. 
In Chapter 6 the Aβ42:Aβ40 mixtures are further analyzed to understand how both 
peptides interact and how this interaction affects oligomerization. The data presented 
suggest that toxic properties of Aβ are the result of a dynamic structure, and are not 
associated with a specific assembly.
In the last part of the thesis other Aβ peptide lengths which are less abundant in 
vivo are investigated. In Chapter 7 the mechanisms by which FAD mutations affect 
APP processing are unravelled. The mutations mainly act through shifting the profile 
of Aβ peptides produced. The observed changes do not only affect the levels of 
Aβ42 but also concern Aβ38 and Aβ43 levels. Analogous to the study of Aβ42:Aβ40 
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mixtures as described in chapter 6, the effects of Aβ38 and Aβ43 on the behavior 
of Aβ40 and Aβ42 are described in Chapter 8. The results show that mixtures of Aβ 
display complex, unexpected and unpredictable behavior. Moreover Aβ38 was shown 
to induce toxicity of Aβ40 while tempering that of Aβ42. These data shine new light on 
current therapeutic strategies aiming to decrease Aβ42 levels and at the same time 
increasing Aβ38 levels.
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We provide a validated and rapid protocol for the solubilization of Aβ. This 
procedure involves sequential solubilization using structure-breaking organic solvents 
hexafluoroisopropanol and dimethyl sulfoxide followed by column purification. The low 
solubility and tendency of Aβ to aggregate considerably impede the in vitro handling and 
biophysical or biological investigation of Aβ, despite the interest in this peptide because 
of its implication in Alzheimer disease. The main advantage of the proposed protocol 
over others is that it results in standardized aggregate-free Aβ peptide samples that 
are biocompatible for cell culture studies and yield reproducible aggregation kinetics 
and cytotoxicities. This three-step protocol also enables the co-solubilization of the 
longer Aβ42 variant with Aβ40 in ratios relevant to Alzheimer disease.
The results described in this chapter have been published in:
Broersen K, Jonckheere W, Rozenski J, Vandersteen A, Pauwels K, Pastore A, Rousseau F, 
and Schymkowitz J (2011). Prot. Eng. Des. Sel., 24:743-750.
A stAndArdized And biocompAtible prepA-
rAtion of AggregAte-free Aβ for biophysicAl 
And biologicAl studies of Alzheimer diseAse. 
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2.1 introduction
Among the proteins identified in amyloid plaques, Aβ peptides are special 
because they constitute what could be considered as the prototype of an intrinsically 
unstructured sequence with an unusually high amphipathic character. Although the 
majority of the Aβ pool is composed of Aβ40 and Aβ42 [1,2], it is now thought that 
the Aβ variation pattern in the brains of patients with Alzheimer disease is reflected by 
a general elongation of the Aβ peptides through a modulated γ-secretase activity [3-
5]. These longer Aβ peptides appear to be directly involved in plaque formation in the 
brains of patients with Alzheimer disease [1,2,6]. The extra residues in the elongated 
Aβ are hydrophobic thus drastically influencing the solubility and amyloidogenicity of 
the peptide. To effectively study the impact of Aβ on toxicity and to elucidate the 
structural pathway of aggregation and formation of toxic oligomers, it is crucial to 
initiate the studies with a well-defined aggregate-free Aβ species. It is, however, difficult 
to deal with Aβ peptides precisely for the very reason that makes them interesting: 
they are poorly soluble and aggregation-prone in aqueous solutions. Proteins that are 
prone to aggregate under physiologically relevant conditions are usually characterized 
by high hydrophobicity and/or low net charge [7-10]. Apart from their tendency to 
induce pathological conditions and high aggregation propensity, the low solubility of 
these peptides also results in inherent difficulties in the experimental handling and 
investigation by biophysical techniques and in cell culture. Nevertheless, high-resolution 
characterization of these proteins may provide the information required to tackle key 
questions aiming at therapeutic targeting. In response to these technical difficulties 
that significantly hamper the research into neurodegenerative diseases, a variety of 
protocols to aid the solubilization of Aβ are available in the literature. However, these 
procedures often involve the use of extremely alkaline [11] or acidic solutions [12] or 
rely on the presence of organic solvents [13], thus introducing biologically incompatible 
compounds and/or conditions that are toxic to cell cultures. Filtration of freshly prepared 
Aβ samples is also frequently used to remove pre-existing aggregates, but often leads 
to significantly reduced recovery of soluble Aβ material [14]. It is therefore essential to 
develop a robust and reproducible preparation protocol that allows the solubilization of 
these peptides under biocompatible buffer conditions.
In this chapter, a new and validated procedure to solubilize the Aβ peptide that 
circumvents the above-mentioned problems and allows to obtain appreciable quantities 
of virtually aggregate-free material is described. The method relies on the use of a 
sequential solubilization procedure with organic solvents, followed by the complete 
removal of these chemicals to provide a non-toxic environment that is suitable for 
biophysical characterization. The procedure is validated by demonstrating complete 
solubilization of the peptide and providing evidence that all chemicals involved are 
effectively removed from the peptide solution without introducing oxidation of the 
peptide. By using thioflavin T fluorescence (thioT) assays and cell culture studies, we 
show that the resulting solutions exert highly reproducible aggregation kinetics and 
toxicities. We conclude that our procedure provides monomeric Aβ preparations in a 
cell-biology-compatible environment, and is suitable for biophysical characterization.
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2.2 results And discussion
2.2.1 overview of the protocol And compArison with other methods
The proposed protocol provides for a method to dissolve Aβ peptide via a rapid 
three-step procedure. Dissolving recombinant produced Aβ42 directly into buffer 
shows that a thioT curve to follow the kinetic aspects of the aggregation curve lacks 
the typical sigmoidal shape commonly observed for aggregating peptides and proteins 
(Figure 2.1a). No lag phase is apparent and also the thioT fluorescence intensity is 
already increased on starting the assay, both indicative for the presence of pre-
formed seeds or aggregates in the solution. Fourier transform infrared spectroscopy 
(FTIR) is used for a wide range of applications and also has shown its applicability in 
the field of protein conformation determination [15]. Aβ42 that has been prepared using 
the proposed three-step dissolving procedure is intrinsically unstructured directly after 
solubilization in aqueous solution, characterized by a broad peak centered around 
1654 cm-1, but assumes a β-sheet aggregate fold (peak at 1627 cm-1) on incubation 
for 24 h. Aβ42 that has been directly dissolved in buffer on the other hand exerts 
a high degree of β-sheet structure (Figure 2.1b), while monomeric dissolved Aβ is an 
intrinsically disordered peptide. These results underline the necessity to develop an 
alternative procedure to dissolve Aβ.
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Figure 2.1 Solubilization of Aβ42 directly into buffer indicates the presence of pre-formed 
aggregates. 
(a) Comparison of aggregation kinetics probed by thioT fluorescence of Aβ dissolved 
directly into buffer and the novel proposed three-step procedure. A concentration of 50 
μM Aβ was either dissolved directly into buffer or solubilized using the proposed three-
step procedure. (b) FTIR spectroscopy of Aβ42 dissolved into buffer using the three-step 
dissolving procedure (black). Directly on elution off the column the broad FTIR spectrum is 
characteristic for an unstructured peptide while after 24 h incubation at a concentration of 
100 μM at 25 °C the intensity at 1627 cm-1 increases characteristic for β-sheet amyloid 
aggregation. FTIR spectroscopy of Aβ42 dissolved directly into buffer (grey). Directly on 
solubilization the spectrum is characteristic for a mixture of unfolded peptide and β-sheet 
aggregation with a main intensity at 1627 cm-1 and a broad shoulder at 1654 cm-1. After 
24 h incubation at a concentration of 100 μM at 25 °C the intensity at 1627 cm-1 increased 
slightly and the shoulder at 1654 cm-1 is smaller.
We first exploited the structure-promoting properties of hexafluoroisopropanol (HFIP). 
From a number of tested alcohols, HFIP was shown to most effectively denature the 
model protein β-lactoglobulin and to induce a non-native α-helix conformation [16]. 
Dilute solutions of HFIP (1-4%) promote fibril formation of the islet amyloid polypeptide 
[17] but concentrated HFIP solutions have been shown to actively remove pre-formed 
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aggregate seeds from solutions
containing amyloidogenic proteins [18-20]. Later studies confirmed similar observations 
for Aβ [20]. HFIP owes its activity due to its high degree of fluorination and induces 
helical formation [21,22]. Even though HFIP has been shown to dissociate fibrils, β2-
microglobulin aggregates can resist the application of this solvent [21]. The insufficient 
ability of HFIP to completely dissociate amyloid fibrils has been ascribed to its non-
polar character that weakens hydrophobic interactions but cannot dissolve rigid 
fibrils [21]. Therefore, in the presented procedure HFIP solubilization is followed by 
dimethyl sulfoxide (DMSO), as this polar compound has been shown to completely 
dissociate amyloid fibrils based on its ability to destruct a hydrogen bond network [23]. 
HFIP can be removed using oxygen-free nitrogen gas or, alternatively, argon gas as 
methionine-35 of the Aβ peptide is susceptible to oxidation [24]. A molecular dynamics 
simulation of the effects of DMSO on the structure and function of subtilisin confirmed 
that DMSO acts as a highly effective hydrogen bond acceptor and, hence, can strip 
away water from the protein surface [25]. Many published methods to solubilize 
Aβ suggest preparation of concentrated Aβ stock solutions in DMSO followed by a 
10- to 100-fold dilution in buffer to induce aggregation. However, as a result of the 
effect of DSMO on the hydrogen network of proteins, the kinetics and mechanism 
of the aggregation of Aβ are adversely affected by the presence of small (± 5%) 
concentrations of DMSO (Figure 2.2) [26] in a non-physiologically relevant manner. 
We therefore apply a column-exchange step to remove all traces of DMSO. Other 
published methods often employ the effects of HCl and NaOH to aid Aβ solubility 
at a pH far removed from its isoelectric point (± pH5.3). In order to adjust the pH of 
the solution to approach more physiologically relevant pH values from an acidic pH 
requires transition through the isoelectric point at which the peptide is most prone to 
aggregate. Also the addition of these pH-affecting compounds introduces an additional 
factor that could induce artifacts in the aggregation mechanism of Aβ.
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Figure 2.2 Different solubilization procedures affect the aggregation of Aβ. 
The presence of traces of DMSO affects the aggregation kinetics of Aβ42. Dilution of 
concentrated Aβ stocks in DMSO into buffer followed by monitoring of the aggregation 
rate of Aβ by thioT fluorescence. The aggregation of Aβ is linearly inhibited with increasing 
concentrations of DMSO.
2.2.2 experimentAl design
The protocol for Aβ solubilization that provided best results consists of sequential 
treatment using HFIP and DMSO followed by exchange of DMSO into buffer using a 
desalting column (Figure 2.3a). The use of a high concentration (± 100%) of HFIP, a 
fluorinated alcohol, provides a means of interaction with the backbone and removal 
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of water from the surface. Subsequently, the HFIP is evaporated off by the use 
of oxygen-free nitrogen gas or argon gas that protects the peptide from oxidative 
modification. The hydrophobic methyl groups of DMSO have the ability to then interact 
with hydrophobic side chains of the Aβ peptide while the polar S=O group interacts 
with water molecules. DMSO is then removed by buffer exchange using a desalting 
column resulting in Aβ virtually free from aggregating seeds in buffer (Figure 2.3b). The 
electrophoretic analysis of the elution of Aβ from the column shows that fractions 2 
to 5 are enriched with Aβ (150-750 μl). Aβ40 elutes as a pure monomeric solution 
while Aβ42 elutes as a primarily monomeric solution containing small quantities of 
an SDS-resistant species with an apparent molecular weight resembling trimeric Aβ. 
No higher-molecular-weight aggregates were observed. As the presence of small 
amounts of HFIP and DMSO can modify the aggregation rates of Aβ [20] (Figure 
2.2), it is important to validate their complete removal. We use FTIR that provides 
characteristic and sensitive fingerprints for the presence of trace amounts of HFIP [27] 
or DMSO. FTIR spectra of the various elution fractions after column elution show that 
with increasing elution fraction the concentration of DMSO increases (Figure 2.3c). It is 
also shown that HFIP has been effectively removed during the procedures supported 
by the lack of characteristic intensity in the FTIR spectrum between 1300 and 1100 
cm-1. A 1% DMSO solution in buffer has two characteristic peaks: at 1011 cm-1 and at 
951 cm-1. Plotting the intensity at these two wavelengths against the fraction number 
shows that only from fraction 9 (1350 μl) up the concentration of DMSO starts to 
increase (Figure 2.3c). In addition, the absence of a detectable signal at 2.5 p.p.m., 
which is characteristic of DMSO, in the one-dimensional 1H NMR spectrum of the Aβ 
preparations, confirms that elution of the first 1 ml of Aβ from the column yields DMSO-
free Aβ (Figure 2.3d). The electrospray ionization mass spectrum shows that Aβ42, 
using the protocol, eluted free of contaminants and without apparent modifications 
(Figure 2.3e), such as dityrosine-formation that is commonly observed for Aβ peptides 
as a function of oxidation [28].
We tested the reproducibility of the behavior of the prepared Aβ solutions and 
their performance in a variety of assays related to aggregate formation or cell viability 
commonly used to study the effects of Aβ. Commonly used assays to study the 
aggregation of Aβ in vitro consist of thioT fluorescence [29], electron microscopy [29]
[30,31] and FTIR [30,32] and the effect of Aβ on the toxicity is usually assayed by 
viability assays on neuroblastoma cells [31,33] or neuronal cultures [29,30,34].
2.2.3 nucleAr mAgnetic resonAnce
NMR analysis shows that Aβ40 and Aβ42 prepared by our procedure are mainly 
monomeric species as shown by the sharp resonances in 2D HSQC experiments 
(Figure 2.4). NMR analysis also assures us that the protocol does not induce oxidation 
of Met35: oxidation of this residue is known to result in a notable chemical shift that 
affects several crosspeaks in the HSQC [35]. Our spectra of Aβ40 and Aβ42 are in 
excellent agreement with literature data reporting NH of Met35 in the reduced state 
at ± 8.5 p.p.m. for the 1H-frequency, while the NH of Met35 of the oxidized state 
appeared upfield at ± 8.8 p.p.m. (Figure 2.4 a,b) [35]. This observation is an important 
point to note because pre-treatment with HFIP might occasionally promote oxidation 
of the Aβ peptide [35].
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Figure 2.3 Novel solubilization procedure for Aβ leads to primarily monomeric Aβ and 
absence of contaminating chemicals. 
(a) Treatment of the Aβ peptide to dissolve it into buffer involves sequential dilution in HFIP, 
and DMSO followed by buffer exchange by means of a desalting column. Details of the 
procedure are described in the text. (b) Non-reducing SDS-PAGE analysis of fractions 
of 150 μl each eluted off the desalting column shows that fractions 2-5 (300-750 μl) are 
enriched in Aβ peptide. Aβ40 is primarily monomeric on elution while Aβ42 is primarily 
monomeric with a small fraction of apparently trimeric peptide. (c) Up to and including 
fraction 8 (1200 μl) can be eluted off the desalting column without contamination by DMSO. 
The intensities of FTIR peaks characteristic for the presence of DMSO (1011 and 951 cm-1) 
are plotted against eluted fraction number. (d) One-dimensional 1H NMR spectrum of an 
Aβ42 preparation confirms the complete removal of DMSO because of the absence of 
characteristic solvent signal at 2.5 p.p.m., as indicated by the arrow. (e) Electrospray mass 
spectrum of Aβ42 in positive mode.
2.2.4 thioflAvin t fluorescence
ThioT fluorescence is a useful probe to assay the aggregation of proteins. The 
quantum yield for fluorescence of this weakly fluorescent dye increases strongly on 
complexation with amyloid fibrils [36]. The differences in aggregation rates between the 
aggregating Aβ42 and less aggregation-prone Aβ40 can be distinguished using in situ 
thioT fluorescence (Figure 2.5a). Reproducibility of the obtained results is an
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Figure 2.4 NMR 15N-1H HSQC spectra 
(a) Aβ40 and (b) Aβ42 recorded at 600 MHz and 25 and 5 °C, resp. Oxidation of Met35 
residue in Aβ is prevented by the novel solubilization procedure. Spectrum assignment is 
shown only for those crosspeaks that would undergo a chemical shift displacement as a 
function of the redox state of Met35 (i.e. Leu34-Met35-Val36 in Aβ40 and Leu34-Met35-
Val36-Gly37-Gly38 in Aβ42) [35].
important parameter to evaluate the quality of the developed procedures. Figure 2.5a 
shows thioT fluorescence curves obtained for three independent experiments. The 
standard error between the experiments is ± 7-10% and the differences between the 
aggregation rates of Aβ40 and Aβ42 are therefore significant.
2.2.5 trAnsmission electron microscopy
We used transmission electron microscopy (TEM) to characterize fibril morphology 
of aggregates formed by Aβ40 and Aβ42 on incubation at a concentration of 100 μM 
for 24 h at 25 °C. Amyloidogenic Aβ42 (Figure 2.5b) forms aggregates characterized 
by short fibrils which intertwine and appear rigid. Aβ40 (Figure 2.5c) on the other hand 
forms long semi-flexible negatively stained fibrils with a characteristic periodic twist that 
is regularly found in fibrils of other origin, such as insulin [37].
2.2.6 toxicity on sh-sy5y cells
The toxicity of 1.5 h incubated 100 μM Aβ40 and Aβ42 preparations was tested 
using neuroblastoma SH-SY5Y cells plated at a cell density of 20 000 cells/well 
in serum-deprived medium. To this end, Aβ preparations were diluted to various 
concentrations ranging from 1 to 50 μM in serum-deprived medium and 100 μl was 
added to each well in 6-fold. After 48 h incubation cells were tested for cell death using 
Cell Titer-Blue viability assay. Figure 2.5d shows that cell viability is Aβ concentration 
dependent and that Aβ42 aggregates induce cell death at lower concentrations (from 
7.5 μM) compared with Aβ40 aggregates (from 30 μM). The results in Figure 2.5d are 
obtained from three independent experiments and the standard error is maximum 12% 
(for 30 μM Aβ40) but in most cases > 5%.
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Figure 2.5 Anticipated results for commonly used biophysical and cell biological 
characterization methods of Aβ dissolved by the HFIP/DMSO/column procedure.
(a) Aβ40 (grey) and Aβ42 (black) aggregation monitored by thioT fluorescence: the 
nucleation phase for Aβ40 is extended significantly compared with Aβ42. The rate of 
polymerization is faster for Aβ40 than for Aβ42. Reproducibility of thioT curves shown by 
error bars of Aβ40 and Aβ42 prepared at three different occasions from three different 
batches of Aβ peptide. The limited variability in the obtained results illustrates that differences 
in aggregation rates between different Aβ peptides are significant. (b) Transmission electron 
microscopy (TEM) image for Aβ42 aggregates matured at 100 μM at 25 °C for 24 h. The 
fibrils are short and intertwined. (c) Aggregates of Aβ40 matured at 100 μM at 25 °C for 24 
h and imaged by TEM show long, semi-flexible and twisted fibrils. The length of the segment 
is 0.2 mm for both micrographs depicted in (b) and (c). (d) Toxicity of Aβ matured for 1.5 h 
at 100 μM at 25 °C and then added at various final concentrations in medium to SH-SY5Y 
neuroblastoma cells. Cell viability is measured using Cell Titer Blue (Promega) assay. The 
cell viability of cells incubated with Aβ42 (black bars) is lost between 7.5 and 10 μM while 
cells incubated with Aβ40 (grey bars) only lose cell viability at an Aβ concentration of 30 μM.
2.3 conclusions
A robust and validated three-step procedure is presented to prepare biocompatible 
virtually aggregate-free solutions with an efficient recovery of amyloidogenic Aβ42 
implicated in Alzheimer disease. The procedure involves the sequential use of HFIP, 
DMSO and a column exchange step. While the use of organic solvents also allows 
the reliable preparation of biologically relevant quantities of Aβ42 and Aβ40 and their 
mixtures, the incorporation of a desalting column in the solubilization procedure makes 
it possible to obtain the Aβ peptide in any desirably buffer system. The resulting Aβ 
preparation shows highly reproducible biophysical and cell biological behavior. The use 
of this protocol may  be extended to the solubilization of other highly amphipathic or 
hydrophobic polypeptides.
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2.4 experimentAl procedures
2.4.1 prepArAtion of Aβ peptide solutions
Escherichia coli expressed human recombinant Alzheimer’s beta peptide 1-40, Ultra 
Pure HFIP, 1-42 Ultra Pure HFIP and their uniformly 15N-isotope-labeled variants were 
purchased from rPeptide. Various ratios of Aβ42:Aβ40 were prepared starting from 
material previously stored in a -20 °C freezer. The vials containing 0.5 mg Aβ-HFIP 
films were allowed to defrost at room temperature (25 °C) for 10 min. A quantity of 0.5 
mg Aβ40 or Aβ42 was dissolved in 500 μl hexafluoroisopropanol (HFIP). The sample 
was mixed vigorously using a vortex for 1 min and visually inspected for efficient 
solubilization. To prepare Aβ42:Aβ40 ratios, a gas tight syringe was used to add 
together specific volumes of Aβ40 in HFIP and Aβ42 in HFIP to obtain a defined ratio of 
Aβ42:Aβ40 followed by mixing using a vortex for 1 min [38]. The HFIP was evaporated 
using a gentle stream of oxygen-free nitrogen gas and, alternatively, argon gas can be 
used. Based on an HFIP volume of 500 μl in each vial prior to drying with nitrogen gas, 
the peptide/HFIP films were redissolved in 500 μl dimethyl sulfoxide (DMSO). Samples 
were mixed using a vortex for 1 min and visually inspected for efficient solubilization. 
Immediately thereafter, the Aβ peptide solutions were separated from the DMSO by 
means of a desalting column that was pre-equilibrated with 25 ml of a 50 mM Tris-
HCl, 1 mM EDTA buffer, pH 7.4. Other buffer systems, including phosphate-buffered 
saline can also be used. The 500 μl sample was applied to the column using a 1 ml 
syringe followed by additional injection of 1 ml buffer, the flow-through was discarded. 
Subsequently, the peptide was eluted from the column by the additional injection of 1 
ml buffer. Typically, the first 500 μl flow-through contained ± 100-120 μM peptide and 
the second 500 μl contained lower Aβ concentrations (40-50 μM), which results in a 
yield of original Aβ peptide of 80% based on Bradford determination of the peptide 
concentration. The Aβ-containing samples were collected in pre-cooled low adhesion 
resin-coated polypropylene centrifuge tubes. After concentration measurement using 
the Bradford assay for protein determination [39], both fractions were combined to 
yield the required concentration of Aβ. Samples were kept on ice directly on elution 
and further experiments were proceeded with within 20 min after elution from the 
desalting column.
2.4.2 oligomerizAtion And fibrillizAtion of Aβ
Oligomer-enriched fractions (1.5-2 h incubation) or amyloid fibrils (>1 week incubation) 
of Aβ were prepared by incubation of 50-100 μM Aβ at 25 °C under quiescent 
conditions in 50 mM Tris-HCl, 1 mM EDTA, pH 7.4 using low-adhesion resin-coated 
polypropylene centrifuge tubes.
2.4.3 sodium dodecyl sulfAte-polyAcrylAmide gel electrophoresis
Non-reducing SDS-PAGE was performed by incubating 10 μl Aβ-containing solution 
in 15 μl Novex Tris-Glycine SDS sample buffer. Samples were then loaded onto a 
10-20% Tricine gel and the gel was run at 170 V for 40 min followed by staining with 
Imperial Protein Stain.
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2.4.4 thioflAvin t fluorescence
Aggregate-free Aβ42 solutions at a concentration of 50 μM were prepared as 
described above by further dilution using 50 mM Tris-HCl, 1 mM EDTA containing 
buffer and a final concentration of 12 μM thioT. In order to evaluate the effect of DMSO 
on the aggregation kinetics, various concentrations of DMSO (1-10%) were added to 
the elution buffer of Aβ. In order to validate the effectiveness of the proposed three-step 
solubilization procedure, Aβ42 was also directly dissolved into buffer without organic 
solvent treatment. The fibrillization kinetics of Aβ were monitored in situ at an excitation 
wavelength of 440 nm and an emission wavelength of 480 nm. Fluorescence readings 
were recorded every 10 min for a period of 7 h. Measurements were performed in 
triplicate, the recorded values were averaged and standard deviations were calculated. 
Background measurements included buffer or buffer containing DMSO and 12 μM 
thioT.
2.4.5 trAnsmission electron microscopy
Aliquots (5 μl) of the Aβ preparation were adsorbed to carboncoated FormVar film 
on 400-mesh copper grids for 1 min. The grids were blotted, washed twice in droplets 
of Milli-Q water and stained with 1% (wt/vol) uranyl acetate. Samples were studied with 
a JEOL JEM-1400 microscope at 80 kV.
2.4.6 fourier trAnsform infrAred spectroscopy
An aggregate-free Aβ42 solution was prepared as described in section 2.4.1. The 
Aβ concentration was adjusted to 100 μM by dilution using 50 mM Tris-HCl, 1 mM 
EDTA containing buffer. Spectra of Aβ42 were recorded directly on elution from the 
column and after 24 h incubation at 25 °C under quiescent conditions. To evaluate 
the contribution of organic solvent components to the FTIR spectrum, 1% DMSO or 
1% HFIP were directly dissolved into 50 mM Tris-HCl, 1 mM EDTA containing buffer. 
Buffer was used to record a blank signal. The InfraRed spectra were recorded using 
a Bruker Tensor 27 infrared spectrophotometer equipped with a Bio-ATR II accessory. 
Spectra were recorded at a spectral resolution of 4 cm-1 and 120 accumulations 
were performed per measurement at a wavenumber range from 900 to 3500 cm-
1. Analysis of the spectra involved blank (buffer) and baseline subtraction from the 
obtained spectra and rescaling in a wavenumber range from 900 to 1800 cm-1.
2.4.7 electrosprAy-ionizAtion mAss spectrometry
Aβ42 was prepared as described in section 2.4.1, but the column elution step 
was disregarded. The concentrated Aβ42 solution in DMSO was diluted 100x in 
acetonitrile:water (1:1) containing 1% acetic acid to a final concentration of 2 μM Aβ. 
Positive-ion mass spectra were recorded on an orthogonal acceleration quadrupole 
time-of-flight mass spectrometer equipped with a standard electrospray probe 
(Z-spray) and controlled by a datasystem running MassLynx 3.4 and cone voltage 
was set to 30 V, capillary voltage was 3 kV. Spectra were recorded from m/z 600 
to m/z 1600. Scan time was set to 4.9 s with an interscan time of 0.1 s. At least 10 
spectra were acquired and averaged. Deconvolution was performed using the MaxEnt 
algorithm included in the software.
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2.4.8 nucleAr mAgnetic resonAnce spectroscopy
Uniformly 15N-labeled Aβ40 and Aβ42 peptides were treated as described above 
using 1 ml HFIP and 1 ml DMSO. Peptide concentrations were adjusted to 60 μM for 
Aβ42 and 100 μM for Aβ40 with 50 mM Tris-HCl, 1 mM EDTA (pH 7.4) buffer and 
the samples contained 10% (vol/vol) 2H2O. A 15N-1H heteronuclear single quantum 
coherence (HSQC) spectrum for Aβ42 was recorded on a Bruker Avance spectrometer 
equipped with a cryoprobe and operating at 700 MHz at 5 °C. The Aβ40 15N-1H-
HSQC spectrum was recorded at 25 °C on a Varian Inova spectrometer operating 
at 600 MHz. Spectral assignment was verified using 15N-NOESY-HSQC and 1H,1H-
TOCSY experiments. Spectra were processed using NMRPipe/NMRDraw [40] and 
analyzed by XEASY/CARA software [41].
2.4.9 cell viAbility in neuroblAstomA cells
Neuroblastoma SH-SY5Y cells were used with a maximum passage number of 
15. Cells were cultured in Dulbecco’s modified eagle medium (DMEM) 1x, 1% (vol/
vol) penicillin/streptomycin and 10% (vol/vol) fetal calf serum at 37 °C, 5% CO2 to a 
confluency of 85% in a 75 cm2 flask. On trypsinization, cells were resuspended at a 
concentration of 200 000 cells/ml in DMEM/F12 (1:1), containing 1% (vol/vol) penicillin/
streptomycin. The resuspended cells were plated at a volume of 100 μl and a cell 
density of 20 000 cells/well in a 96-well plate. The plated cells were incubated for 48 
h at 37 °C at 5% CO2. Aβ40 and Aβ42 oligomer-enriched fractions were prepared 
at a concentration of 100 μM as described under section 2.4.2 and incubation for 
1.5 h under quiescent conditions at 25 °C. After incubation, the Aβ was diluted to 
final concentrations of 1-50 μM in buffer and then diluted 1:1 with prewarmed (37 °C) 
DMEM/F12 (1:1), containing 1% (vol/vol) penicillin/streptomycin. The Aβ or medium as a 
control was added at a volume of 100 μl in medium to each well and left to incubate 
for 48 h. After 48 h, 10 μl Cell Titer-Blue Cell Viability Assay compound was added to 
each well and incubated for 4-6 h at 37 °C to allow viable cells to convert resazurin 
into resorufin. Fluorescence intensity of resorufin was measured on a 96-well plate 
reader at an excitation wavelength of 544 nm and an emission wavelength of 590 
nm. Measurements were performed in three independent experiments and statistical 
analysis was performed to calculate average values and standard deviations.
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Early aggregated forms of the amyloid-β peptide are hypothesized to act as the 
prime toxic agents in Alzheimer disease. The in vivo Aβ peptide pool consists of 
both C- and N-terminally truncated or mutated peptides, and the composition thereof 
significantly determines risk of Alzheimer disease. Other variations, such as biotinylation, 
are introduced as molecular tools to aid the understanding of disease mechanisms. 
Since these modifications have the potential to alter key aggregation properties of the 
Aβ peptide, we present a comparative study of the aggregation of a substantial set of 
the most common in vivo identified and in vitro produced Aβ peptides.
A CompArAtive AnAlysis of the AggregAtion 
behAvior of Aβ vAriAnts.
The results described in this chapter have been published in:
Vandersteen A*, Hubin E*, Sarroukh R, De Baets G, Schymkowitz J, Rousseau F, Subramaniam 
V, Raussens V, Wenschuh H, Wildemann D, and Broersen K (2012). FEBS Letters, first published 
online on October 24, 2012. 
* Annelies Vandersteen and Ellen Hubin are joint first authors.
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3.1 introduction
 Early aggregated forms of Aβ have been considered the basis for development 
of Alzheimer disease [1,2]. Despite extensive research, the exact link between Aβ 
and Alzheimer disease remains elusive. One of the underlying reasons is that APP 
processing in vivo does not generate a single, well-defined species. The main cause 
for peptide heterogeneity stems from the identification of two main APP processing 
pathways, termed ‘non-amyloidogenic’ and ‘amyloidogenic’. The non-amyloidogenic 
pathway involves APP cleavage by α- and γ-secretase and generates the p3 peptide, 
a N-terminally truncated form of Aβ, while the amyloidogenic pathway releases Aβ 
by action of β- and γ-secretase [3]. Besides the dual processing of APP generating 
either p3 or Aβ, the γ-secretase cleavage site is ill-defined resulting in variation at the 
C-terminus of Aβ [4,5]. As a result thereof, released Aβ peptides vary in length from 
27 to 49 amino acids [6,7]. Additional variation in the in vivo Aβ pool is attained by 
mutations within the Aβ domain of APP. Known mutations inducing familial Alzheimer 
disease (FAD) include the Flemish (Ala21 to Gly), Dutch (Glu22 to Gln), Italian (Glu22 to 
Lys), Arctic (Glu22 to Gly), Iowa (Asp23 to Asn), and Tottori (Asp7 to Asn) mutations 
(reviewed by [8]). An additional source of peptide variation results from the introduction 
of biotinylation as a research tool for interaction studies [9-12]. All modifications 
described above could affect peptide behavior due to altered aggregation properties. 
In this study we systematically compared the aggregation behavior of p3 and Aβ 
peptides resulting from heterogeneous APP processing as well as a selection of FAD-
associated Aβ mutants and biotinylated variants.
3.2 results
 We present a comparison of the aggregation profiles of an extensive set of Aβ 
peptides with N- or C-terminal variation [p317-40, p317-42, Aβ37, Aβ38, Aβ40, Aβ42, 
Aβ43], FAD-related mutations [Aβ42 D7N, A21G, E22G, E22K, E22Q, D23N], and 
biotinylated forms of Aβ [biotin-Aβ40, biotin-Aβ42, Aβ40-K-biotin, Aβ42-K-biotin]. Aβ 
peptides were prepared by peptide synthesis. Identity and purity were confirmed by 
MALDI-TOF MS and LC-MS (see appendix A).
3.2.1  c-terminAl elongAtion increAses AggregAtion propensity And induces An Amorphous 
fibrillAr stAte. 
Aggregation kinetics of various Aβ lengths were recorded by thioT fluorescence 
and two different aggregation profiles could be distinguished: slow aggregation 
accompanied with long nucleation times and high final fluorescence intensity were 
detected for Aβ37, Aβ38 and Aβ40, while Aβ42 and Aβ43 aggregated rapidly with 
almost immediate onset resulting in low final fluorescence intensity (Figure 3.1 a,b). 
Fibril morphology has been related to different affinities for thioT binding, affecting 
the extent of thioT fluorescence intensity [13,14]. Visualization of fibrils by TEM indeed 
revealed morphologically distinct aggregates, showing extended negatively-stained 
fibrils for Aβ37, Aβ38 and Aβ40, and heavily intertwined networks for Aβ42 and Aβ43 
(Figure 3.1c). Structural analysis by ATR-FTIR at early time points confirmed that these 
peptides adopted a β-sheet conformation, as seen by strong absorption at 1630 cm-1 
(Figure 3.1e). Apart from affecting fibril properties, increasing peptide length also leads 
to a more pronounced oligomerization as detected through dotblotting with the
45
Aggregation of Aβ variants
20151050
A
11
 re
ac
tiv
ity
in
te
ns
ity
 (a
.u
.)
Time (h)
Th
io
T 
u
or
es
ce
nc
e 
(a
.u
.)
0
1
2
a b
Th
io
T 
flu
or
es
ce
nc
e
in
te
ns
ity
 (a
.u
.)
d
c
0
 
1
 
2
0
20
40
60
80
100
120 *
e
Wavenumber (cm-1)
A
bs
or
ba
nc
e 
(a
.u
.)
16
00
16
10
16
20
16
30
16
40
16
50
16
60
16
70
16
80
16
90
17
00
-0.2
0.0
0.2
0.4
0.6
0.8
1.0
Figure 3.1 Increased aggregation and oligomerization of Aβ with increasing peptide length 
(a) Aggregation of C-terminal varying Aβ peptides monitored by ThioT fluorescence. (b) 
ThioT fluorescence intensities after 20 h of incubation. (c) TEM images of 2 week incubated 
Aβ at 25 °C. The scale bar represents 0.1 μm. (d) A11-reactivity of 0.5 h pre-incubated Aβ 
in a dotblot assay. (e) Deconvoluted ATR-FTIR spectra of Aβ peptides (2 μg) recorded after 
1.5 h incubation at 25 °C.
oligomer-specific A11 antibody (Figure 3.1d). Aβ37, Aβ38 and Aβ40 showed less 
oligomer accumulation after 0.5 h of incubation than Aβ42 and Aβ43. Accordingly, 
ATR-FTIR spectra observed for pre-fibrillar Aβ42 and Aβ43 suggested higher β-sheet 
content compared to oligomers produced from shorter Aβ peptides which appeared 
more as a mixture of β-sheet, random coil and α-helical secondary structure elements 
(Table 3.1). This confirms the earlier report that the conversion of monomeric Aβ 
peptide into oligomers and mature fibrils coincides with the accumulation of a β-sheet 
enriched conformation [15]. The shorter Aβ37, Aβ38 and Aβ40 displayed a higher 
β-sheet index [calculated as the ratio of the (1695 cm-1/1630 cm-1) intensities] than the 
longer Aβ42 and Aβ43. This suggests a higher content of antiparallel β-strands which 
reflects a less extended conversion from the oligomeric, antiparallel conformation into 
the fibrillar, parallel conformation after 1.5 h of incubation [16].
3.2.2 fAd mutAtions Affect the AggregAtion rAte to vArious extents but hAve little 
effect on fibril morphology And secondAry structure.
Familial mutations of Aβ42 displayed a short nucleation phase similar to that 
observed for wild type Aβ42, but affected the rate of fibril elongation and final thioT 
fluorescence intensity (Figure 3.2 a,b). The slow polymerization of the D23N mutation 
coincided with a very low final thioT fluorescence, while A21G and E22Q mutations of 
Aβ42 aggregated at a higher rate with an increased final thioT fluorescence intensity 
compared to wild type Aβ42. All mutants of Aβ42 displayed a β-sheet enriched 
conformation (Figure 3.2e, Table 3.1) and eventually formed similar dense fibrillar 
networks (Figure 3.2c).  
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β-sheet Random coil + α-helix TurnPeptide identity β-sheet index
Secondary structure element (%)
36 44 20 0.28
37 43 20 0.26
47 33 20 0.27
55 32 13 0.18
56 28 16 0.14
55 30 15 0.19
51 33 16 0.22
41 37 22 0.18
45 39 16 0.16
50 32 19 0.21
46 32 23 0.14
34 44 22 0.31
42 39 19 0.21
54 34 12 0.17
44 38 17 0.15
39 40 20 0.25
49 34 17 0.19
Aβ43
Aβ42
Aβ40
Aβ38
Aβ37
D23N
E22Q
E22K
E22G
A21G
D7N Aβ42
Aβ42
Aβ42
Aβ42
Aβ42
Aβ42
Aβ42-K-biotin
biotin-Aβ42
Aβ40-K-biotin
biotin-Aβ40
p317-42
p317-40
Table 3.1 Quantification of the secondary structure content using ATR-FTIR.
Curve-fitting was performed on the non-deconvoluted FTIR spectra and resulted in 
estimated contributions of β-sheets (1613-1637 cm-1 and 1682-1689 cm-1),α-helices and 
random coil (1637-1662 cm-1), and turns (1662-1682 cm-1) to the secondary structure 
content of every Aβ peptide sample. The β-sheet index is defined as the ratio of the (1695 
cm-1/1630 cm-1) intensities.
Oligomerization of the mutated Aβ42 peptides showed little variability as seen by 
A11-reactivity (Figure 3.2d), with exception of D23N Aβ42, and β-sheet index analysis 
indicated similar oligomer-content for the various peptides (Table 3.1).
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Figure 3.2 Some FAD-mutations affect aggregation and oligomerization of Aβ42 
(a) Aggregation of Aβ42 FAD mutations monitored by thioT fluorescence. (b) ThioT 
fluorescence intensities after 20 h of incubation. (c) TEM images of 2 week incubated Aβ 
at 25 °C. The scale bar represents 0.1 μm. (d) A11-reactivity of 0.5 h pre-incubated Aβ in 
a dotblot assay. (e) Deconvoluted ATR-FTIR spectra of Aβ peptides (2 μg) recorded after 
1.5 h incubation at 25 °C.
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3.2.3 biotinylAtion Affects AggregAtion of Aβ40 And Aβ42.
N- and C-terminal biotinylation increased the lag time of aggregation (Figure 3.3a) 
while decreasing final thioT fluorescence for Aβ40 (Figure 3.3 a,b), indicative of inhibited 
aggregation, without affecting fibril morphology (Figure 3.3c). Oligomerization of 
biotinylated Aβ40, as probed by A11-reactivity, was unaffected (Figure 3.3d). Structural 
analysis of the peptides by ATR-FTIR however revealed absorption differences in 
the 1680-1640 cm-1 region (Figure 3.3e, Table 3.1). Biotinylation of Aβ42 reduced 
polymerization of the peptide compared to wild type Aβ42 (Figure 3.3a) without 
significantly affecting final ThioT fluorescence (Figure 3.3b), fibril morphology (Figure 
3.3c) or secondary structure content (Figure 3.3e, Table 3.1). For Aβ42 the impact of 
biotinylation on oligomerization depended on the location of the modification. C-terminal 
biotinylation did not affect A11-reactivity (Figure 3.3d) but resulted in a reduced β-sheet 
index (Table 3.1). N-terminal modification on the other hand strongly impaired A11-
reactivity (Figure 3.3d) but did not influence the β-sheet index (Table 3.1). The β-sheet 
index of biotinylated peptides however needs to be interpreted with caution as the 
biotin tag might absorb around 1695 cm-1, leading to an overestimation of this value.
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Figure 3.3 C- and N-terminal biotinylation of Aβ42 and Aβ40 differentially affect 
aggregation 
(a) Aggregation of C- and N-terminally biotinylated forms of Aβ40 and Aβ42 monitored 
by thioT fluorescence. (b) ThioT fluorescence intensities after 20 h of incubation. (c) TEM 
images of 2 week incubated Aβ at 25 °C. The scale bar represents 0.1 μm. (d) A11-
reactivity of 0.5 h pre-incubated Aβ in a dotblot assay. (e) Deconvoluted ATR-FTIR spectra 
of Aβ peptides (2 μg) recorded after 1.5 h incubation at 25 °C.
3.2.4 n-terminAl truncAtion of Aβ induces rApid onset AggregAtion.  
Both N-terminally truncated forms of Aβ40 and Aβ42, p317-40 and p317-42 
respectively, were characterized by rapid onset of aggregation compared to their 
corresponding full-length forms with decreased final thioT fluorescence intensity (Figure 
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3.4 a,b). From a morphological perspective, visualization by TEM revealed short fibrillar 
fragments for p317-40 dissimilar from the long extended networks observed for full-
length Aβ40 (Figure 3.4c). Truncation of Aβ42 to p317-42 only slightly affected fibril 
morphology resulting in less curly fibrils (Figure 3.4c). Structural analysis by ATR-FTIR 
indicated that p317-40 displayed less β-sheets and more random coil and α-helical 
content than full-length Aβ40. A similar observation was made for p317-42 compared 
to Aβ42 (Figure 3.4e, Table 3.1). Oligomerization of the truncated p3 peptides, as 
analyzed by A11-reactivity and the β-sheet index, was not significantly affected 
compared to the full-length counterparts (Figure 3.4d, Table 3.1).
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Figure 3.4 p3 peptides show pronounced aggregation 
(a) Aggregation of p317-40 and p317-42 monitored by thioT fluorescence. (b) ThioT 
fluorescence intensities after 20 h of incubation. (c) TEM images of 2 week incubated Aβ 
at 25 °C. The scale bar represents 0.1 μm. (d) A11-reactivity of 0.5 h pre-incubated Aβ in 
a dotblot assay. (e) Deconvoluted ATR-FTIR spectra of Aβ peptides (2 μg) recorded after 
1.5 h incubation at 25 °C.
3.3  discussion
 The in vivo Aβ pool contains a high degree of variability, consisting of peptides with 
C-terminal variations, mutations related to familial Alzheimer disease, and N-terminal 
truncations. To elucidate the mechanisms leading to Alzheimer disease some peptides 
have been additionally modified, e.g. biotinylated, to enable their investigation in 
experimental research. The chemically synthesized Aβ peptide variants were compare 
in terms of aggregation and oligomerization behavior using biophysical techniques. Our 
observations show that variations in the Aβ sequence can have consequences for the 
propensity of the Aβ peptide to aggregate and oligomerize. 
C-terminal variation was previously shown to affect aggregation propensity, and it 
has been generally reported that Aβ42 aggregates at a higher rate than Aβ40 [17,18]. 
Even though approximately 90% of the Aβ peptide pool is composed of these two 
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peptides, it was recently recognized that also Aβ37, Aβ38, and Aβ43 are present 
in the brain and may modulate disease progress [19]. We show that C-terminal 
extension generally results in faster aggregation and gradual transformation into 
densely networked β-sheet rich aggregates compared to shorter peptides, which form 
extended fibrils characterized by a primarily disordered structure. We further observed 
that Aβ37 and Aβ38 generally behave similar to Aβ40 while the behavior of Aβ43 
strongly resembles that of Aβ42. The dense fibril networks formed by Aβ42 and Aβ43 
possibly provide less access to the thioT dye compared to the more extended fibrils 
of shorter peptides, resulting in a lower final thioT fluorescence intensity. Alternatively, 
the denser peptide networks can be more prone to precipitation in the test tube which 
would lead to a similar observation. Although the effect of mutations of Aβ42 related 
to familial Alzheimer disease on aggregation has been investigated in the past [20-
23], no comprehensive study has been reported that directly compares the majority 
of the currently known mutations. Different Aβ preparation methods and experimental 
conditions have led to considerable variation in reported effects of these mutations. 
ThioT fluorescence data in this study were measured at a physiologically relevant Aβ 
concentration of 1 μM. Most mutations related to familial Alzheimer disease are located 
in or near the central hydrophobic cluster of the Aβ peptide, which has been predicted 
and reported to play an important role in aggregation [24-28]. These mutations can thus 
either inhibit or induce aggregation depending on the suitability of the replacing amino 
acid to accommodate an amyloidogenic or aggregated structure. Molecular dynamics 
simulations have suggested the depletion of the E22-K28 salt bridge to explain the 
enhanced aggregation of E22Q Aβ42, while the switch of a bend motif to a turn in the 
region 22-28 could result in slower aggregation of the D23N Aβ42 mutant [22]. Overall 
fibril morphology is however not affected, as has been shown previously for a subset 
of mutants leading to familial Alzheimer disease [20]. The central hydrophobic region 
is however not the absolute key in determining aggregation tendency as a subset of 
the mutations in this region has no effect on the aggregation rate and most likely exert 
their pathological function through aberrant APP processing or reduced proteolytic Aβ 
degradation [29-31]. We further show that C-terminal elongation, which does not affect 
the central region of Aβ, also affects aggregation. Moreover, complete destruction of 
the central aggregation zone by deletion of the first 17 N-terminal amino acids, as 
naturally occurs by APP processing via the non-amyloidogenic pathway, does not 
abolish the aggregating character of the peptides, as was observed before [32] and 
upregulation of the α-secretase cleavage pathway initiating the non-amyloidogenic 
processing of APP has served as a template for the generation of various potential 
disease modulating drugs [33]. It is thus likely to suggest that, even though the central 
Aβ region can play a regulating role in the aggregation process, the C-terminal region 
may dominate this effect by determining fibril morphology. Biotinylation of Aβ can be 
used as a tool to pool or detect via interaction with streptavidin. Our data show that 
this modification can affect the onset of aggregation substantially depending on the 
type of biotinylation applied and its location, either N- or C-terminally, without affecting 
fibril morphology or oligomer formation. These observations underline the importance of 
selecting and validating the type of labeling  required for experiments without inducing 
changes in the peptide behavior that are subject to study.
 In this work we systematically compared a wide range of Aβ peptides for their 
aggregation properties. The overall aggregation profile was determined by thioT 
50
Chapter 3
fluorescence while we attempted to gain insight in early aggregation events by probing 
oligomerization of the peptides. We therefore used A11-reactivity as well as analysis of 
secondary structure content which were however not always completely in agreement. 
This could be attributed to the polyclonal nature of the A11 antibody [34] that can be 
hypothesized to recognize more than one conformation. On the other hand, it might be 
likely that both methods detect different oligomeric species. In conclusion, the results 
highlight that minor sequential variations may have consequences for the aggregation 
of Aβ.
3.4 experimentAl procedures
3.4.1 Aβ peptide synthesis
Aβ and p3 peptides were produced by JPT Peptide Technologies. Peptides 
were synthesized on preloaded TentaGel® S TRT resins using an ABI 433A peptide 
synthesizer. Synthesis was performed using 2-(1H-7-azabenzotriazol-1-yl)-1,1,3,3-
tetramethyl uronium hexafluorophosphate as an activation reagent and standard 
procedures of Fmoc-based solid phase peptide synthesis were applied. Peptides 
were cleaved from the resin with trifluoroacetic acid and purified by preparative high 
performance liquid chromatography. Following synthesis the purity and identity of Aβ 
peptides was assessed by matrix-assisted laser desorption/ionization time-of-flight 
mass spectrometry and LC-MS (see appendix A). The LC-MS system was used in 
combination with a C18 Gemini-NX column at a flow rate of 1 ml min-1 and a gradient 
of 5-95% acetonitrile was set in 6 minutes.
3.4.2 solubilizAtion of Aβ peptides
Peptides were dissolved according to the standard procedure described in Chapter 
2. In short, Aβ peptides were dissolved in HFIP which was evaporated and the resulting 
peptide film was redissolved using DMSO. The peptide was separated from DMSO by 
elution from a desalting column into a 50mM Tris pH 7.5 buffer containing 1mM EDTA. 
The resulting samples were kept on ice until experiments started with a maximum lag 
time of 30 min. Peptide concentration was determined using the Coomassie (Bradford) 
Protein Assay kit and diluted to 25 μM in 50mM Tris pH 7.5 buffer containing 1mM 
EDTA. Incubation of Aβ peptides occurred for the given time periods at 25 °C under 
quiescent conditions. 
3.4.3 thioflAvin t fluorescence
Aβ concentrations were adjusted to 1 μM using 50mM Tris pH 7.5 buffer containing 
1mM EDTA and a final concentration of 12 μM thioT. The fibrillation kinetics of the 
various Aβ preparations were monitored in situ at excitation and emission wavelengths 
of 440 and 480 nm respectively. Fluorescence readings were recorded every 5 
min for a period of 20 h. Measurements were performed as independent triplicates. 
Recorded values were averaged and background measurements (buffer containing 
12 μM ThT) were subtracted.
3.4.4 trAnsmission electron microscopy
After 2 weeks of incubation, Aβ aliquots (5 μL) were adsorbed to carbon-coated 
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Formvar 400-mesh copper grids for 1 min. The grids were blotted, washed, and 
stained with 1% (wt/vol) uranyl acetate. Samples were studied with a JEOL JEM-1400 
microscope at 80 kV. Images were collected from three independently prepared Aβ 
solutions.
3.4.5 dotblot
After 0.5 h of incubation a volume of 5 μL Aβ was spotted onto a nitrocellulose 
membrane. The membranes were blocked in phosphate buffered saline (PBS) 
containing 0.2% Tween-20 (1 h, 25 °C), and incubated (1 h, 25 °C) with primary A11 
antibody, diluted 1:4000 in 100mM Hepes, pH 7.0 [34]. After incubation (0.5 h, 25 °C) 
with a secondary anti-rabbit-HRP-tagged antibody, diluted 1:5000 in PBS containing 
0.05% Tween-20, the membranes were visualized using the ImmobilonTM Western 
chemiluminescent HRP substrate system. Spots were manually selected and their 
intensities were analyzed as mean grey values using ImageJ software [35]. Images 
were background subtracted.
3.4.6 AttenuAted totAl reflectAnce-fourier-trAnsform infrAred spectroscopy
ATR-FTIR spectra were recorded on an Equinox 55 IR spectrophotometer. The 
Aβ solubilization procedure and buffer composition were slightly adapted to obtain 
ATR-FTIR spectra with sufficient intensity and without interference by EDTA or salts. 
In short, Aβ peptide samples were dissolved in HFIP. HFIP was evaporated and the 
resulting peptide film was redissolved in 10mM Tris pH 7.5 to a concentration of 1 
mg ml-1. Samples were incubated for 1.5 h at room temperature under quiescent 
conditions. Two μg of Aβ was spread on the diamond surface of the internal reflection 
element and was washed with excess milliQ water to eliminate salts. Excess water 
was evaporated under nitrogen flow. Each spectrum represents the mean of 128 
repetitions, recorded at a resolution of 2 cm-1. The ATR-FTIR data were processed by 
subtracting the water vapor contribution with 1562-1555 cm-1 as reference peak and 
spectra were baseline corrected. Spectral intensities were normalized to the intensity 
of the 1630 cm-1 peak, and were smoothed at a final resolution of 4 cm-1. All spectra 
were self-deconvoluted and curve-fitting was performed on the non-deconvoluted 
ATR-FTIR spectra. The proportion of a particular structure is computed to be the sum 
of the area of all the fitted bands divided by the area of all the Lorentzian bands. The 
β-sheet index was defined as the ratio of the 1695 cm-1/1630 cm-1 intensities. 
3.4.7 stAtisticAl AnAlysis
The intensities of A11-positive spots as determined with ImageJ software were further 
analyzed using the two-tailed unpaired t-test for significance. Significant differences are 
denoted by a star: *p<0.05, **p<0.01, ***p<0.001.
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BACE1 cleaves the amyloid precursor protein (APP) at the β-cleavage site to initiate 
the generation of amyloid peptide Aβ. Besides, BACE1 is also known to cleave at 
a much less well-characterized β’-cleavage site. The novel APP mutation E682K is 
located at this β’-site in an early onset Alzheimer disease case. Functional analysis 
revealed that this E682K mutation blocked the β’-site and shifted all cleavage of APP 
to the β-site, causing increased Aβ production. This work demonstrates the functional 
importance of APP processing at the β’-site and shows how disruption of the balance 
between β- and β’-site cleavage may enhance the amyloidogenic processing and 
consequentially the risk for Alzheimer disease. Increasing exon- and exome-based 
sequencing efforts will identify many more putative pathogenic mutations without 
comclusive segregation-based evidence in a single family. This study shows how 
functional analysis of such mutations allows to determine the potential pathogenic 
nature of these mutations. We propose to classify the E682K mutation as probable 
pathogenic awaiting further independent confirmation of its association with Alzheimer 
disease in other patients.
Amyloid preCursor protein mutAtion e682K 
At the AlternAtive β-seCretAse CleAvAge β’-site 
inCreAses Aβ generAtion.
The results described in this chapter have been published in:
Zhou L, Brouwers N, Benilova I, Vandersteen A, Mercken M, Van Laere K, Van Damme P, 
Demedts D, Van Leuven F, Sleegers K, Broersen K, Van Broeckhoven C, Vandenberghe R, 
and De Strooper B (2011). EMBO Mol. Med., 3:1-12.
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4.1 introduction
BACE1, a membrane-bound aspartic protease, is the β-secretase which cleaves 
APP at the β-site Met671-Asp672 of APP (Asp1 of the Aβ sequence) [1-5]. This 
cleavage generates the APP carboxyterminal fragment CTF99, which is a substrate 
for the γ-secretase complex, an intramembrane cleaving protease [6]. γ-Secretase 
processing of CTF99 yields a mixture of Aβ peptides including Aβ38, Aβ40, and Aβ42 
as the most abundantly detected species in cell culture and biological fluids [7].
Additionally BACE1 cleaves APP at a β’-site, a secondary cleavage site between 
Tyr681 and Glu682 (Glu11 of Aβ) to generate CTF89, which is further processed 
by γ-secretase to produce truncated Aβ11-40/42 species. BACE1 cleavage at the 
β’-site was originally discovered in cell cultures overexpressing this protease [3]. An 
in vitro study showed that purified BACE1 cleaves synthetic peptides mimicking the 
sequence around the human APP β’-site in an enzymatic assay, but the enzymatic 
efficiency was lower than towards peptides containing the ‘canonic’ β-site sequence 
[8]. Additional evidence suggested that the relative abundance of BACE1 cleavage at 
these two adjacent sites is governed by the expression levels of the protease: when 
BACE1 levels are low, β-site cleavage products are the major species, when BACE1 
levels are high, β’-site cleavage products become predominant [9,10]. These findings 
were also taken to suggest that β’-site processing was only a minor event in APP 
processing [9]. The abundance of the β’-site cleavage for human APP processing as 
well as the functional significance of this alternative β-secretase cleavage site remains, 
therefore, elusive.
In this work, we identify a novel and unusual APP mutation in a Belgian patient 
showing early onset Alzheimer disease and seen in the University Hospital in Leuven. 
This mutation - E682K - is located at the β’-site within the Aβ sequence (Figure 4.1). 
We examined the effect of this mutation on the proteolytic processing of APP and 
found that this mutation caused significant increases in total Aβ and in Aβ42/40 
levels. We further analysed APP processing in neuronal cultures by short metabolic 
labelling experiments demonstrating that β’-site cleavage is a major processing event 
of wild-type (wt) human APP in neuronal cultures. The E682K mutation blocked this 
processing step and consequentially shifted BACE1 cleavage towards the β-site. 
The data demonstrate the functional significance of β’-site cleavage in preventing 
overproduction of Aβ, which may potentially cause Alzheimer disease.
            β                      β’           α                                                     γ              ε
              1                         11            17                                                      38 40 42        49
ISEVKMDAEFRHDSGYEVHHQKLVFFAEDVGSNKGAIIGLMVGGVVIATVIVITLVMMLK
K
Figure 4.1 Schematic overview of APP E682K mutation and secretase cleavage sites. 
Numbers were indicated according to the Aβ sequence (in grey).
4.2 results
4.2.1 clinicAl description of the index pAtient cArrying the App e682K mutAtion
The index patient presented at the Memory Clinic, University Hospitals Leuven, at 
the age of 50 years with a prior diagnosis of early onset clinically probable Alzheimer 
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disease. Around the age of 47, she had developed symptoms of depression followed 
by gradually progressive cognitive decline with significant impact on her instrumental 
activities of daily living. At presentation, the index patient was on citalopram 10 mg 
twice per day and donepezil 10 mg once per day. Neuropsychological evaluation of 
the patient revealed a significant memory deficit as indicated by the standard testing. 
Magnetic resonance imaging T2-weighted sequence revealed bilateral hippocampal 
volume loss. Analysis of cerebrospinal fluid revealed decreased Aβ42 and increased 
total and 181T-phosphorylated tau (Table 4.1), a pattern corresponding to Alzheimer 
disease. Sequencing of the APP gene revealed a G to A substitution at g.278228G, 
which is predicted to result in an amino acid substitution at codon 682 (E682K). Such 
mutation was absent in 940 control samples.
control AD control patient (E682K)
7 (5/2) 10 (6/4)
62.3 ± 4.4 66.6 ± 5.0 51
986.8 ± 255.8 368.2 ±  63.7 165
168.7 ± 63.7 926.8 ± 487.8 834
57.8 ± 16.17 122.2 ± 34.1 104phospho-tau (pg/ml)
total-tau (pg/ml)
Aβ1-42 (pg/ml)
age
n (male/female)
values are mean ± SD
Table 4.1 Aβ and tau protein levels in cerebrospinal fluid.
The patient is from a small family. Her father received a diagnosis of dementia at 
the age of 75 and died at the age of 83 years. His genetic status is unknown as no 
sample was available for genomic analysis. The patient’s brother, however, is clinically, 
at the age of 53, an asymptomatic carrier. We considered the possibility that the APP 
E682K mutation could have a variable penetrance in this family. A strong variation 
in age of onset (range 45-88 years) has previously been observed with Alzheimer 
disease causing mutations in PS2 as well [11]. We thus turned to functional assays to 
evaluate whether the identified mutation could be a genetic risk factor for Alzheimer 
disease or not.
4.2.2 e682K mutAtion increAsed Aβ generAtion 
We introduced the E682K mutation by site directed mutagenesis into human WT 
APP695 and expressed WT or mutant APP in mouse primary neuronal cultures and 
in transiently transfected CHO cells. The expression levels of WT and mutant full length 
APP were checked by Western blotting, and neuronal or CHO cell cultures expressing 
similar amounts of APP were subjected to further analysis. Conditioned media were 
analysed using Aβ enzyme-linked immunosorbent assay (ELISA) (Table 4.2). In both 
neuronal and CHO cell cultures, the E682K mutation caused a two- to three-fold 
increase in Aβ40 and Aβ42 levels, but also a slightly higher Aβ42:Aβ40 ratio (Table 
4.2). The alterations are quantitatively and qualitatively comparable to those caused 
by the previously characterized disease-causing ‘Flemish’ A692G mutation, which also 
caused increases in the Aβ levels and a slightly higher Aβ42:Aβ40 ratio (Table 4.2) 
[12-17].
4.2.3 e682K mutAtion enhAnced β-site cleAvAge of App 
We next analysed the effects of the E682K mutation on APP processing in further 
detail. In primary neuronal cultures, this mutation increased CTF99 and APPsβ levels 
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Aβ42 (pg/ml) Aβ40 (pg/ml) Aβ42/Aβ40 ratio
37.7 ± 1.2 355.6 ± 17.2 0.1065 ± 0.0051
94.6 ± 4.7 604.6 ± 18.0 0.1563 ± 0.0049**
77.5 ± 2.4 621.3 ± 27.2 0.1251 ± 0.0039*
60.0 ± 1.9 546.3 ± 14.3 0.1101 ± 0.0046
189.9 ± 5.1 1005.3 ± 10.1 0.1890 ± 0.0040**
131.7 ± 1.5 1049.2 ± 42.7 0.1257 ± 0.0037*
A692G (Flemish)
E682K
APPwt
CHO cells
A692G (Flemish)
E682K
APPwt
primary neurons
Data were normalized to APP expression level (**p<0.001, *p<0.05; mean ± SEM; n=3)
Table 4.2 Aβ42 and Aβ40 levels as well as Aβ42:Aβ40 ratio in conditioned media from 
transfected CHO cells or transduced neurons
two- to three-fold (Figure 4.2 a-c), which correlates well with the overall increases in Aβ 
levels as measured by ELISA. Similar effects were observed in transiently transfected 
CHO cells, in which the E682K mutation caused a two- to three-fold increase in 
CTF99 and APPsβ levels (Figure 4.2 d-f). These data show that the E682K mutation 
increased Aβ generation by favouring the β-site cleavage of APP. In contrast to 
the E682K mutation, the ‘Flemish’ A692G mutation did not significantly affect the 
β-secretase processing (as measured by CTF99 and APPsβ generation), confirming 
that the increased Aβ generation with this mutant is caused by a different mechanism. 
It has indeed been shown that the ‘Flemish’ mutation affects an inhibitory domain in the 
APP sequence that modulates γ-secretase activity [17].
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Figure 4.2 Effects of E682K mutation on APP processing in cultured neurons (a-c) and 
in CHO cells (d-f).
(a) Primary cultured neurons were transduced with SFV expressing WT or mutant APP 
and (d) CHO cells were transiently transfected with constructs expressing WT or mutant 
APP. Cell lysates were analysed by Western blotting using APP C-terminal antibody B63. 
Conditioned medium was analysed by Western blotting to determine secreted total APPs 
(using 22C11 antibody) and APPsβ (using anti-APPsβ antibody). 
(b,c)(e,f). Semi-quantification of APPsβ and CTF99 levels from Western blotting, data were 
normalized to APP levels (b,c) **p<0.01; ns, statistically not significant; mean±SEM; n=4 (e,f) 
**p<0.01; mean ±SEM; n=3 
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4.2.4 e682K mutAtion blocKed the β’-site cleAvAge, which is A mAjor processing event 
of humAn App in neuronAl cultures 
We further examined how the E682K mutation might enhance β-site cleavage. This 
mutation is located at the previously identified β’-site in APP and the WT residue Glu11 
is known to occupy the P1’ subsite of BACE1 involved in β’-site cleavage. A previous 
kinetic study has shown that the P1’ subsite of BACE1 favours several residues 
including Asp, Glu, Met, Ala, Ser, and Gln, but that positively charged residues like Lys 
or Arg decrease affinity [18]. The E682K mutation was thus predicted to block the 
β’-site cleavage. However, until now, β’-cleavage of human APP is considered as a 
minor processing event in cells expressing endogenous levels of BACE1, and has been 
mainly documented in cells overexpressing BACE1 [9,10,19,20].
Here, we reanalyse the metabolism of human APP in neuronal cultures. We 
expressed WT or mutant human APP in neuronal cultures using the SFV system and 
then metabolically labelled the cells for 4 h. The carboxyterminal fragments (CTFs) 
of APP were immunoprecipitated from cell lysates using an APP carboxyterminal-
specific antibody and separated by gel electrophoresis for further analysis. We 
identified five species of CTFs (Figure 4.3a), as previously described [21,22]. We 
conclude that the two highest molecular weight bands are phosphorylated CTF99 
and nonphosphorylated CTF99; the next faint band is phosphorylated CTF89; the 
fourth band is a mixture of non-phosphorylated CTF89 and phosphorylated CTF83; 
and the lowest molecular weight band is non-phosphorylated CTF83. In another group 
of experiments, we treated the immunoprecipitates with lambda protein phosphatase 
(LPP) (Figure 4.3b) to remove the confounding phosphorylation, and this resulted, as 
predicted, in three species of CTFs, i.e. non-phosphorylated CTF99, CTF89, and 
CTF83. Quantification of phosphor images showed that CTF99, CTF89, and CTF83 
accounted for 51.7, 24.9, and 23.4%, respectively, of the total of the three species 
(Figure 4.3c). These data indicate that β’-site cleavage is a major processing event 
that occurs with human APP in neuronal cultures. Interestingly, the E682K mutation 
(Figure 4.3a), when expressed in neuronal cultures, generated more CTF99 (both 
phosphorylated and non-phosphorylated), no detectable phosphorylated CTF89, and 
apparently less of the mixture of non-phosphorylated CTF89 and phosphorylated 
CTF83 compared to WT APP (Figure 4.3a). The level of the latter band was equal to 
that of the band isolated from neuronal cultures treated with a highly selective BACE1 
inhibitor compound 3 (Figure 4.3a), which is in accordance with our hypothesis that the 
E682K mutation blocked CTF89 generation. After treatment with LPP, this hypothesis 
was confirmed as only CTF99 and CTF83 were detected (Figure 4.3b).
We also immunoprecipitated Aβ related peptides from the conditioned medium using 
Aβ40/42 carboxyterminal specific monoclonal antibodies (mAbs). WT APP generated 
two major species (Figure 4.3d), and both peptides were eliminated after treatment with 
BACE1 inhibitor (Figure 4.3d), but remained after treatment with α-secretase inhibitor 
TAPI-1 (Figure 4.3d). We thus concluded that these two peptides were products 
from BACE1 cleavage, i.e. they are Aβ40/42 and Aβ11–40/42 species. In agreement 
with the results obtained from analyzing the CTF levels, the E682K mutation blocked 
the generation of the Aβ11-40/42 peptide while it enhanced generation of Aβ40/42 
peptide (Figure 4.3d).
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Figure 4.3 E682K mutation blocked β’-cleavage of human APP by BACE1 in cultured 
neurons.
Primary cultured neurons were transduced with SFV expressing WT or E682K mutant APP 
and were metabolically labelled with [35S] cysteine/methionine for 4 h. 
(a) Cell lysates were subjected to IP with antibody B63 specific to the C-terminus of APP. 
Eluates were separated on 16% Tricine gels and analysed by phosphorimager. Five species 
of CTFs were detected from neurons expressing WT APP (lane 1), including phosphorylated 
CTF99, CTF99, phosphorylated CTF89, CTF89/phosphorylated CTF83, and CTF83 (from 
high to low MW). Neurons expressing E682K APP (lane 2) eliminated the generation of 
phosphorylated CTF89 and CTF89. CTF89 can bemeasured by subtracting the density 
of the phosphorylated CTF83 band (lane 4) from the CTF89/phosphorylated CTF83 band 
(lane 2). In lanes 3 and 4, neurons were treated with BACE1 inhibitor, therefore, only 
phosphorylated and non-phosphorylated CTF83 is observed. 
(b) Immunoprecipitates from cell lysates were treated with LPP. Neurons expressing WT 
APP (lane 2) generated CTF99, CTF89, and CTF83, while neurons expressing E682K APP 
(lane 3) largely eliminated the generation of CTF89. 
(c) Quantification of radioactive bands of CTFs. Statistics were analysed by comparing 
each CTF species generated from E682K APP with that generated from WT APP (**p<0.01; 
***p<0.0001; ns, statistically not significant; mean±SEM; n=4). 
(d) Conditioned media were subjected to IP with JRFcAβ40/42 antibodies specific to the 
C-terminus of Aβ40 or Aβ42, eluates were resolved on 10% Bis–Tris gels and analysed 
by phosphorimager. Neurons expressing WT APP generated Aβ40/42 and Aβ11–40/42 
species (lane 1), and production of both peptides was eliminated after treatment with 
BACE1 inhibitor (lane 3), but was unaffected by the treatment with α-secretase inhibitor 
TAPI-1 (lane 5). E682K mutation enhanced the generation of Aβ40/42 but eliminated the 
generation of Aβ11–40/42 (lanes 2 and 6).
4.2.5 e682K mutAtion hAd little effects on α-secretAse cleAvAge 
The E682K mutation (Glu11 to Lys) is located close to the α-secretase cleavage site 
Lys17. Therefore, we decided to investigate whether this mutation affected α-secretase 
cleavage as well. Typical α-secretase generated CTF83 which remained unchanged 
(Figure 4.3c), while total APPs levels showed a slight increase probably due to the 
increase in APPsβ (Figure 4.2a), suggesting that this mutation had little effects on the 
α-site cleavage of APP. In contrast, the ‘Flemish’ A692G mutation appeared to slightly 
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affect the generation of CTFα (Figure 4.2a), as published before [13,15].
4.2.6 e682K mutAtion modulAted γ-secretAse Activity 
One interesting observation is that the E682K mutation increased the Aβ42:Aβ40 
ratio in neuronal and CHO cell cultures. It is known that pathogenic mutations near the 
C-terminus of the Aβ sequence in APP can lead to increased generation of Aβ42 by 
modulating the active sites of γ-secretase. A recent report has shown that the ‘Flemish’ 
A692G mutation, which is located in the middle of Aβ, has unexpectedly, in addition 
to its slight inhibitory effect on α-secretase processing [13,15], a quite pronounced 
effect on γ-secretase activity [17], suggesting that the interaction between γ-secretase 
and CTF99 may also occur at sites that are remote from the actual cleavage site in 
CTF99. Therefore, we wondered whether the increase in the Aβ42:Aβ40 ratio caused 
by the E682K mutation might be caused by an additional effect on the modulation 
of γ-secretase. We transiently transfected CHO cells with WT or E682K mutant 
CTF99. This APP fragment is the direct substrate of γ-secretase and its processing 
will, therefore, largely be determined by γ-secretase. The expression levels of both 
CTF99WT and CTF99E682K were investigated by Western blotting, no difference 
was observed. Conditioned media were analysed by Aβ ELISA (Figure 4.4). The E682K 
mutation generated the same amounts of Aβ42 but significantly less Aβ40, leading to 
an increased Aβ42:Aβ40 ratio. These data suggested that the E682K mutation affects 
also to a certain extent the Aβ42:Aβ40 ratio via modulation of γ-secretase.
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Figure 4.4 Effects of E682K mutant CTF99 on γ-secretase activity in cell-based assay. 
(a-c) CHO cells were transfected with WT or E682K mutant CTF99, conditioned media were 
analysed by Aβ ELISAs (**p<0.01; *p<0.05; ns, statistically not significant; mean±SEM; n=3). 
(d) Western blotting analysis of CTF99 expression levels. Cell lysates containing either 
CTF99WT or CTF99E682K were loaded in a series of two times dilution.
4.2.7 limited effects of e682K mutAtion on the AggregAtion Kinetics And cytotoxicity of 
Aβ peptide 
We studied the in vitro aggregation properties of synthetic Aβ peptide carrying 
the E682K mutation (E11K mutant Aβ). The aggregation kinetics of WT and mutant 
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Aβ42 peptide were monitored by a thioT fluorescence assay. Compared with WT 
Aβ42 peptide, E11K mutant Aβ42 showed a slight increase in the initial aggregation 
rate during the first 3 h of the aggregation process (Figure 4.5a); however, the overall 
change in aggregation kinetics was small. TEM images further underlined that the 
aggregation process of E11K mutant Aβ42 was not significantly different from that of 
the WT Aβ42 peptide (Figure 4.5b). In parallel, we also analysed the cytotoxicity of 
E11K mutant and WT Aβ42, no significant difference was detected (Figure 4.5c).
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Figure 4.5 Biophysical determination of the aggregation kinetics of WT Aβ42 and mutant 
E11K Aβ42.
(a) ThioT fluorescence of aggregating WT Aβ42 (black) and mutant Aβ42 E11K (grey). 
Indicated are the error bars for each time point based on three measurements. The 
aggregation kinetics is not dramatically affected by the E11K mutation, apart from a small 
increase in the initial rate during the first 3 h of aggregation process. 
(b) TEM images further underline that the aggregation process of Aβ42 upon introduction of 
the E11K mutation is not significantly modified. After 1.5 h aggregates are observed which 
become larger upon further incubation. 
(c) Neurotoxicity of wild type and E682K (E11K) Aβ42 peptide. One week old mouse 
hippocampal neurons were treated with wild type or E682 (E11) Aβ42 preaggregated for 
1.5 hours, and cell viability was determined by cell titer blue assay after 72 hours treatment 
(mean ±SEM; n=6; the difference between wt and mutant Aβ42 peptide is not statistically 
significant; p>0.05 as evaluated by unpaired two-tailed Student’s t test).
4.3 discussion
This work describes the identification and characterization of a novel APP mutation 
E682K from a single case of early onset Alzheimer disease. The index patient is a Belgian 
female; she was diagnosed as probable Alzheimer disease at the age of 49 years. 
Neuropsychological evaluation and CSF biomarkers (Aβ42, total-tau and phospho-
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tau) confirmed the diagnosis of Alzheimer disease. The patient’s father developed 
late onset Alzheimer disease, while the brother is an asymptomatic mutation carrier 
currently at the age of 53, and there is no extended familial information. This raised the 
interesting question whether the identified mutation is a benign polymorphism or should 
be considered a genuine genetic risk factor for disease. The issue of rare genetic 
variants contributing moderate risk to disease is hotly debated in genetic research, as 
it is very difficult to detect such mutations while they are likely to contribute significantly 
to the total genetic risk for disease [23]. We hypothesized that the APP E682K 
mutation could have variable penetrance, which has previously also been proposed 
for disease causing mutations in PS2, carriers of which display a strong variation in 
age of onset [11] and decided to use functional assays to test whether the identified 
mutation could be considered as pathogenic or not. 
Our analysis showed that this novel mutation increased full length Aβ release and 
also the Aβ42:Aβ40 ratio to similar extents as found with a previously well characterized 
disease associated APP A692G or ‘Flemish’ mutation. While the observed effects 
on Aβ processing suggest the possibility that this novel mutation is pathogenic, the 
genetic support is inconclusive. According to the criteria discussed by Guerreiro and 
coworkers [24], the APP E682K mutation was found in a single case of early onset 
Alzheimer disease. This mutation was absent from 940 healthy controls and affects 
Aβ generation. Although strictly spoken a second case with this mutation needs to 
be identified as independent confirmation [24], we propose that the accumulated 
evidence is clearly in favour to classify this mutation as probable pathogenic. Further 
follow up of the brother of the index case could yield final confirmation, but because 
of the study design, we are not allowed to contact the brother for further investigation. 
Therefore, we will have to wait for additional cases from other investigations in the 
future to classify this mutation as definitively pathogenic. Nevertheless, the functional 
analysis of this mutation provided an important and interesting novel insight in the 
biological significance of the β’-site processing of APP, which appeared quantitatively 
much more important for normal APP metabolism than previously thought.
Our data indicate indeed that processing at this site should be considered anti-
amyloidogenic, counteracting partially the amyloidogenic β-secretase cleavage of APP. 
In agreement with this assumption, rodents, which tend to cleave their endogenous 
APP at the β’-site [15], do not spontaneously develop amyloid plaques. The functional 
significance of β’-site cleavage of APP by BACE1 has indeed been debated since a 
long time. On the one hand, it was previously suggested that this cleavage is a minor 
part of physiological APP processing [9]. Our new study now clarifies that this is not 
the case and that about one-fourth of the major APP CTF species is generated by this 
pathway under our experimental conditions. Second, it was reported that N-terminal 
truncation of Aβ may enhance the aggregation properties as well as the cytotoxic 
effects of Aβ [25] and that in sporadic Alzheimer disease cases, significant amounts 
of Aβ11–40/42 species were found in the plaques in the brain [19,26]. Therefore, β’-site 
cleavage was proposed to contribute to Alzheimer’s pathogenesis [19,26]. However, 
our data argues for a protective role of β’-site cleavage, as blocking this cleavage 
disrupted the balance of APP processing by BACE1 leading to increased full length 
Aβ. The fact that the β’-site mutation E682K is associated with early onset Alzheimer 
disease speaks clearly in favour of this argument.
Of note, our data suggest additional effects of the E682K mutation on γ-secretase 
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activity as well. APP carrying the E682K mutation increased significantly the 
Aβ42:Aβ40 ratio in cell-based assays. This effect occurs at the γ-secretase level 
because expressing a CTF99 construct that bypasses the ectodomain shedding 
step needed for γ-secretase [27] led to a similar increase in this ratio. It has been 
recently reported that a substrate inhibitory domain (ASID) located at the middle of Aβ 
(residues 17–23) is modulating γ-secretase activity by binding to an allosteric site within 
the γ-secretase complex and that the ‘Flemish’ mutant CTF99 increased γ-secretase 
activity via disruption of this ASID [17]. The E682K mutation is located at the Aβ11 site, 
which is not part of the previously delineated ASID, but had nevertheless a significant 
effect on Aβ40 levels and little effects on Aβ42 levels. We suggest the possibility that 
the interaction domain between γ-secretase and CTF99 is more extended than ASID 
and mutations such as the E682K mutation, as well as other similar substitutions, 
may be considered as new tools to investigate the possible allosteric modulation of 
γ-secretase by APP substrate.
The current data indicate that BACE1 cleaves APP at two distinct sites and that 
both are physiologically significant events in APP processing. So far, BACE1 is the most 
attractive drug target for Alzheimer disease treatments, and the evaluation of inhibitors 
under development for treatment of the disease focuses on the effect of blocking the 
β-site cleavage. This could be problematic because BACE1 inhibitors will also affect 
β’-site cleavage. Kinetic data showed that the BACE1 has a much higher enzymatic 
efficiency towards peptide containing the β-site than peptide containing the β’-site 
sequence [8], which raises a theoretical possibility that BACE1 inhibitors may have 
differential inhibition effects on the two distinct sites depending on the concentrations 
used. This could cause relative shifts from β’- to β-site cleavage, as observed with the 
current mutation. We thus propose that inhibitor drugs should be carefully monitored 
for their dose-effect on both BACE1 cleavage sites and to measure, therefore, the 
effects on Aβ11–40/42 of any such drug when used in patients.
Finally it is likely that in the near future, increasing exon- and also exome-based 
sequencing efforts will increase the number of putative pathogenic mutations identified 
without further conclusive segregation-based evidence in a single family. Functional 
analysis of such mutations as demonstrated here will allow to determine the putative 
pathogenic nature of some of these mutations as more extensively discussed by 
Guerreiro and colleagues [24]. Such functional study may also be crucial to fill part 
of the existing gap in genetic research with regard to the postulated low frequency, 
moderate risk genetic loci that are now very difficult to identify and were called the 
‘dark matter of disease risk’ [23,28].
4.4 experimentAl procedures
4.4.1 plAsmids And site-directed mutAgenesis 
The plasmids pSG5-huAPP695, pSFV-huAPP695 [15] and pSG5-APPC99-
FLAG [30] have been described previously. Mutagenesis was performed using 
the Quick-Change site-directed mutagenesis kit according to the manufacturer’s 
instructions. Following primers were used to introduce the E682K mutation: 
50-CCGACATGACTCAGGATATAAAGTTCATCATCAAAAATTGGTG-30 (forward) 
and 50-CACCAATTTTTGATGATGAACTTTATATCCTGAGTCATGTCGG-30 (reverse).
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 Antibodies And compounds
Rabbit polyclonal antibody B63 raised against the C-terminus of APP has been 
described previously [31]. mAbs JRFcAβ40/28, JRFcAβ42/26 recognizing the 
C-terminus of Aβ species terminating at 40 or 42, respectively, and JRFAβN/25 
recognizing the N-terminal 1–7 amino acids of human Aβ were provided by Janssens 
Pharmaceutica. The following antibodies were purchased: mAb 22C11 recognizing 
the N-terminus of APP; APPsβ polyclonal antibody recognizing the N-terminus to the 
β-secretase cleavage site of APP. Compound TAPI-1 was purchased from Calbiochem; 
BACE1 inhibitor compound 3 was kindly provided by Merck Research Laboratories.
4.4.2 cell culture And trAnsfection
CHO cells were maintained at 37 °C in a humidified, 5% CO2 controlled atmosphere 
in DMEM supplemented with 10% foetal bovine serum (FBS). Transfections were 
performed using Fugene according to the manufacturer’s instructions. When 80% 
confluence was reached, cells were transiently transfected with APP or C99 cDNA 
constructs. After 24 h, media were replaced with DMEM supplemented with 5% FBS 
and conditioned for 16-24 h and then collected for Aβ ELISA assays in the presence 
of complete protease inhibitor cocktail. Conditioned media were also analysed by 
Western blot for the detection of APPs, while cell lysates were analysed by Western 
blot for the detection of APP CTFs.
4.4.3 neuronAl cultures And semiliKi forest virus trAnsfection
Primary cortical neurons were derived from E14 embryos from C57BL/6 mice, 
the preparation procedures have been described previously [32]. Briefly, the brains 
of E14 embryos were dissected in HBSS medium, trypsinized and plated on 6-cm 
dishes precoated with poly-L-lysine. Cultures were maintained in neurobasal medium 
supplemented with B27. A 5 μM cytosine arabinoside was added to prevent glial 
cell prolification. Semliki Forest viruses (SFV) were produced as described [32]. Three 
days cultured neurons were transduced with SFV expressing WT or mutant human 
APP695. After 1 h, media were replaced with normal culture media and left for 2 h. 
Media were refreshed and conditioned for ~6 h. Conditioned media were analysed by 
Aβ ELISA or Western blot for the detection of APPs, while cell lysates were analysed 
by Western blotting for the detection of APP CTFs. 
4.4.4 metAbolic lAbelling And immunoprecipitAtion
Neuronal cultures were transduced with SFV for 1 h and left in normal culture 
medium for 2 h as described above. Media were then replaced with methionine-free 
MEM containing 100 μCi/μl [35S] methionine. After 4 h metabolic labelling, supernatants 
were collected, cells were washed and lysed in DIP buffer (20mM Tris-HCl pH 7.4, 
150mM NaCl, 1% Triton X-100, 1% sodium deoxycholate, 0.1% SDS) supplemented 
with complete protease inhibitors. Supernatants were immunoprecipitated using 
a combination of JRFcAβ40 and JRFcAβ42 antibodies and incubated with protein 
G-Sepharose at 4 °C overnight. The immunoprecipitants were resolved on 10% 
NuPAGE gels running with MES buffer. Cell extracts were immunoprecipitated using 
APP C-terminal antibody B63. The immunoprecipitants were resolved on 16% Tricine 
gels running with Tricine-SDS buffer. The intensity of the radioactive bands was 
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quantified using a phosphorimager and Aida Image Analyzer v.4.22 software. 
4.4.5 Aβ elisA 
The concentration of Aβ in conditioned medium was measured by end-specific 
ELISAs. JRFcAβ40/28 or JRFcAβ42/26 was used as capturing antibodies for Aβ 
species terminating at 40 or 42, respectively. HRP-conjugated JRFAβN/25 recognizing 
the N-terminal 1–7 amino acids of human Aβ was used as detecting antibody for full 
length Aβ. The affinity of JRFAβN/25 for E11K mutant Aβ peptide was not different from 
its affinity for WT Aβ peptide. Plates were coated with 60 μl capturing antibodies at 2 
μg ml-1 at 4 °C overnight in coating buffer (10mM Tris-HCl, 10mM NaCl, 10mM NaN3, 
pH 8.5). The next day, plates were rinsed once in phosphate buffer saline (PBS) and 
blocked with blocking buffer (0.1% casein in PBS, pH7.4) either at 4 °C overnight or 
at room temperature for 4 h. Plates were then rinsed twice with PBS. Thirty μl of 
detecting antibody diluted in blocking buffer was first added to each well, followed 
by adding 30 μl conditioned medium diluted in blocking buffer. Plates were incubated 
at 4 °C overnight, and rinsed and developed the next day using 60 μl mixture of 
3,3’,5,5’-tetramethylbenzidine (TMB) solution. The reaction was stopped by addition of 
60 μl of 2N H2SO4. Plates were read immediately at 450nm.
4.4.6 prepArAtion of Aβ peptide
Aβ peptide (JPT Peptide Technologies GmbH) was dissolved using the procedure 
described in chapter 2. Briefly, Aβ was dissolved in HFIP which was evaporated using 
a gentle stream of argon gas and the peptide film was resolved using DMSO. The 
peptide was separated from DMSO with a 5 ml HiTrapTM Desalting column and 
eluted into a 50mM Tris, 1mM EDTA buffer, pH 7.5. The peptide concentration was 
measured using Bradford assay. The samples were kept on ice until experiments 
started, with a maximum lag time of 20 min.
4.4.7 thioflAvin t fluorescence
Aβ protein concentrations were normalized to 25 μM by further dilution using 50mM 
Tris, 1mM EDTA containing buffer and a final concentration of 12 μM ThioT was added. 
The fibrillation kinetics were followed in situ using a Fluostar OPTIMA fluorescence plate 
reader at an excitation wavelength of 440nm and an emission wavelength of 480 nm. 
Readings were recorded in triplicate every 10 min for a period of 10 h.
4.4.8 trAnsmission electron microscopy
Aliquots (5 μl) of the Aβ preparation were adsorbed to carbon-coated FormVar film 
on 400-mesh copper grids for 1 min. The grids were blotted, washed twice in droplets 
of Milli-Q water, and stained with 1% w/v uranyl acetate. Samples were studied with 
a JEOL JEM-1400 microscope at 80 kV. 
4.4.9 cell viAbility AssAy
Mouse primary hippocampal neurons were grown in neurobasal medium for 1 
week, and then were treated with different concentrations of Aβ42 (wt or mutant) pre-
aggregated for 1.5 h. After 72 h treatment, 10 μl Cell-Titer-Blue dye (Promega) was 
added to 200 μl of the growth culture medium on the cells. After 3 h, the fluorescence 
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intensity of the samples was measured at an excitation wavelength of 560 nm and an 
emission wavelength of 590 nm.
4.4.10 stAtisticAl AnAlyses
Statistical significance was determined by the Student’s t-test.
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The amyloid peptides Aβ40 and Aβ42 involved in Alzheimer disease are thought to 
contribute differentially to the disease process. Although Aβ42 seems more pathogenic 
than Aβ40, the reason for this is not well understood. The results described in this 
chapter show that small alterations in the Aβ42:Aβ40 ratio dramatically affect the 
biophysical and biological properties of the Aβ mixtures reflected in their aggregation 
kinetics, the morphology of the resulting amyloid fibrils and synaptic function tested 
in vitro and in vivo. A minor increase in the Aβ42:Aβ40 ratio stabilizes toxic oligomeric 
species with intermediate conformations. The initial toxic impact of these Aβ species is 
synaptic in nature, but this can spread into the cells leading to neuronal cell death. The 
fact that the relative ratio of Aβ peptides is more crucial than the absolute amounts of 
peptides for the induction of neurotoxic conformations has important implications for 
anti-amyloid therapy. Our work also suggests the dynamic nature of the equilibrium 
between toxic and non-toxic intermediates.
neurotoxiCity of Alzheimer diseAse Aβ peptides 
is induCed by smAll ChAnges in the Aβ42 to 
Aβ40 rAtio.
The results described in this chapter have been published in:
Kuperstein I, Broersen K, Benilova I, Rozenski J, Jonckheere W, Debulpaep M, Vandersteen A, 
Segers-Nolten I, van der Werf K, Subramaniam V, Braeken D, Callewaert G, Bartic C, D’Hooge 
R, Martins I, Rousseau F, Schymkowitz J, and De Strooper B (2010). EMBO J., 29:3408-3420.
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5.1 introduction
Aβ40 is the major species recovered from serum, cerebrospinal fluid and cell 
culture supernatants [1,2]. Interest in a second peptide, Aβ42, which is detected at 
about 10-fold lower levels, was strongly stimulated by the observation that familial 
Alzheimer disesase causing mutations increased the relative production of Aβ42 
relative to Aβ40 [2-4]. We reported earlier [5] that clinical mutations in presenilin mainly 
affect the spectrum of the Aβ peptides generated by γ-secretase. As patients with 
such mutations present an early and aggressive form of the disease, it seems then 
logical to propose that the absolute quantity of Aβ peptides produced in the brain 
might be less important than the quality of the Aβ peptides (reflected in a changed 
Aβ42 to Aβ40 ratio) for the generation of elusive toxic Aβ species [6]. The implication of 
such hypothesis for current efforts in drug development is important because lowering 
the absolute amounts of Aβ in patients would then be less crucial than the restoration 
of the correct ratios of Aβ peptides. Earlier studies have already provided evidence 
that Aβ40 and Aβ42 affect each other’s aggregation rates and toxic effects [7-13]. 
Generally, it is found that Aβ42 has fast aggregation kinetics, which can be inhibited 
by Aβ40 in a concentration-dependent manner. Interesting in vivo studies have further 
shown that increased levels of Aβ40 peptides in the brain actually might have a 
protective effect [10,11].
More recently, the discrepancy between the total burden of Aβ peptide deposited 
into plaques in the brain and the degree of neurodegeneration in the patients has been 
confirmed with modern amyloid imaging techniques [14,15]. Obviously, it is possible 
that these patients are in a preclinical phase of the disease, and follow-up studies are 
underway to investigate this. Nevertheless, these observations support the concept that 
the amyloid fibrils are biologically largely inert and that not all conformations of Aβ are 
equally toxic [16,17]. A series of intermediate soluble aggregates of Aβ peptides have 
recently been identified [18,19]. The mechanism of their neurotoxic activity remains not 
only subject of intense investigation, but also the precise conformation(s) of the toxic 
species remains uncertain [20,21]. Various oligomeric conformations were reported 
to exert toxicity to various extent, affect synapse function and even impair memory 
formation in mice [16-18,22-26]. It should be noted that in many of the publications, the 
identified toxic species are presented as stable, defined structures, although it seems 
logical to assume that their assembly and disassembly is a dynamic and continuous 
process, at least in the initial stages. Hence the alternative possibility that toxicity is 
present over a series of conformers or sizes should not be disregarded [16,21,27]. The 
question is thus how biophysical parameters influence this process in vivo and affect 
the relative distribution of Aβ species over toxic and non-toxic conformations over time. 
Given the complexity of the biophysical environment in which Aβ aggregation occurs 
in vivo, such question is extremely difficult to address. Nevertheless, it is possible to 
analyse the dynamic features of this process in simplified and controlled conditions in 
vitro, and to evaluate the effect of the relative concentrations of Aβ40 and Aβ42 to the 
generation of neurotoxic species over time.
We hypothesized here that the early onset of Alzheimer disease by APP and/
or presenilin mutations that increase the Aβ42:Aβ40 ratios can be explained by 
interactions between Aβ40 and Aβ42, which provide stability to intermediate, neurotoxic 
species. Using biophysical methods and a novel cellular assay we analysed the 
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establishment of neurotoxicity over time in different Aβ mixtures. We found that very 
minor changes in the relative amount of Aβ42 versus Aβ40 has dramatic effects on 
the dynamic behaviour of toxic Aβ species. Our findings provide an important biological 
addition to the original ‘Aβ42 seeding hypothesis’ [28], which focused on amyloid fibril 
formation. These dynamic oligomeric species exhibit initial synaptotoxicity and cause 
later neurotoxicity in primary hippocampal neurons and affect memory formation in 
mice, underlining their potential importance for the understanding of Alzheimer disease.
5.2 result
As the objective of this study was to investigate how Aβ40 and Aβ42 affect 
each others’ biophysical and biological properties, it was important to prepare a pre-
aggregate-free Aβ solution and to validate the mixtures using mass spectrometry (see 
appendix B) and anti-Aβ40- and anti-Aβ42-specific antibodies (Figure 5.1). Peptides 
were dissolved in HFIP and mixtures of Aβ were prepared. Further handling of the 
solutions was according to the procedure described in Chapter 2.
   
anti-Aβ40
anti-Aβ42
Aβ42:Aβ40 0:10
0h
1:9
0h
3:7
0h
10:0
0h
Figure 5.1  Preparation of Aβ ratios.
Dot blot confirming the presence of both Aβ40 and Aβ42 in ratios by employing carboxy-
terminus specific antibodies
5.2.1 AggregAtion rAte of Aβ peptides is strongly influenced by the rAtio Aβ42:Aβ40
Aβ peptide was incubated at a concentration of 50 μM in 50 mM Tris-HCl, 1 
mM EDTA, pH 7.5 at 25 °C. The aggregation process of a range of Aβ42:Aβ40 
ratios (10:0 to 0:10) tested by thioT fluorescence yielded a typical sigmoidal curve 
as generally observed for aggregating proteins and peptides (Figure 5.2a) [29]. Both 
the length of the lag phase and the rate of aggregation were affected by the ratio 
of Aβ42:Aβ40 (Figure 5.2 b,c). The lag phase for pure Aβ40 was ~2.5 h (±0.3 h). 
Addition of 10% Aβ42 (Aβ42:Aβ40 1:9) resulted in a small, but reproducible increase 
in the lag phase (~2.9±0.3 h) (Figure 5.2B). A further increase in the Aβ42:Aβ40 ratio 
decreased paradoxically the length of the lag phase to ~0.5±0.01 h. From a ratio of 
3:7 onwards, no difference was observed compared with Aβ42 alone. The elongation 
rate was fastest for pure Aβ40 and was slowed down by addition of Aβ42 (Figure 
5.2c). Remarkably, judging from the lag phase of aggregation, the 1:9 and the 3:7 
ratio showed two opposite ends of the spectrum (Figure 5.2b). These ratios, in addition 
to 10:0 and 0:10 were selected for our further studies. The choice for 3:7 can be 
also rationalized as it reflects roughly the ratio of Aβ42 and Aβ40 in patients with 
familial Alzheimer disease [2,4,30,31]. Thus, both time and the Aβ42:Aβ40 ratios are 
two important parameters when considering the biophysical properties of Aβ, and 
we decided to investigate how these parameters determine Aβ-oligomer toxicity. We 
describe in the rest of the paper the different Aβ mixtures as an Aβ42:Aβ40 ratio, 
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Figure 5.2 Aβ42 determines the kinetics of Aβ aggregation. 
(a) Aggregation kinetics of 50 μM Aβ ratios in 50mM Tris, 1mM EDTA at 25 °C for 6 h by 
thioT assay shows how the ratio of Aβ42:Aβ40 (e.g. 3:7) influences the aggregation kinetics. 
(b) Quantitative analysis of lag phase, showing the time (hours) of the initial part of curves 
as in (a), during which no increase in thioT fluorescence signal is detected using different 
Aβ42:Aβ40 ratios as indicated. 
(c) Quantitative analysis of the elongation rate, derived from (a) as rate of fluorescence 
change, which is the slope of the linear phase of exponential growth in (a), using different 
Aβ ratios as indicated. 
Numbers are averages of three independent experiments. Error flags indicate s.d. 
calculated over the three independent experiments. Statistical significance of the results 
was established by p-values using paired two-tailed t-tests, and only shown for the four 
ratios further studied in the text. Statistical significance levels were in (b,c): *p<0.005, 
**p<0.001, ***p<0.0001. p-value of Aβ40 (0:10) and (1:9)=0.09, and p-value of Aβ40 (0:10) 
and (1:9)=0.0058 in panels (b) and (c), respectively.
incubated for an indicated time at an Aβ concentration of 100 μM in 50 mM Tris-HCl, 
1 mM EDTA, pH 7.5 at 25 °C. Thus, (3:7, 2 h) means a ratio of three Aβ42 versus 
seven Aβ40 peptides incubated for 2 h under given buffer conditions before addition 
to the cell culture. Final concentration of Aβ in cell culture is in most experiments 1 μM 
apart from a few in which 10 μM was used as indicated. On the basis of our further 
experiments, it appeared that at any time point only a small fraction of the peptides is 
in a toxic active conformation.
5.2.2 the Aβ42:Aβ40 rAtio is A driver of Acute synAptic AlterAtions 
One problem with Aβ toxicity assays is the delay between the actual preparation 
of the oligomer samples used for the biophysical analysis and the moment when 
the biological read out becomes available to assess the neurotoxicity. We, therefore, 
sought to set up an assay that allows verifying biological effects of Aβ preparations 
within the time frame of the biophysical experiments. We plated mouse hippocampal 
neurons on microelectrode array (MEA)-based chips (Figure 5.3a) [32] and recorded 
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spontaneous firing rates in the neuronal networks before and after treatment with Aβ 
mixtures at a final concentration of 1 μM. Representative traces of responses of cultures 
treated with different Aβ mixtures are displayed in Figure 5.3b. Interestingly, treatment 
with pure Aβ40 mixtures (0:10, 2h) appeared to enhance synaptic activity measured 
as spontaneous firing rate, whereas (1:9, 2 h) mixtures had no effect on spontaneous 
synaptic activity (Figure 5.3 b,c). In contrast, Aβ42 alone (10:0, 2 h) or with Aβ40 (3:7, 
2 h) readily suppressed spontaneous neuronal activity within 40 min after addition of 
the peptides (Figure 5.3 b,c). As a control of the oligomeric species status during the 
course of the recording, we followed changes in fluorescent thioT emission over 40 
min of Aβ mixtures at 1 μM in neuronal culture medium at 37 °C, which mimics the 
conditions of the cell culture experiments (Figure 5.3d). The Aβ mixtures appeared 
stable over the time frame of the experiment at least as far as it concerns thioT 
incorporation. We next assayed how different Aβ42:Aβ40 ratios evolve over time with 
regard to synaptotoxic properties. Aβ42:Aβ40 ratio mixtures were incubated for 0, 1.5, 
4, 6 and 20 h before addition to the cultures. Synaptic firing rates were recorded for 
40 min as above using MEA. Figure 5.3e shows that synaptic effects were little after 
treatment of the cells with mixtures of Aβ shortly after dissolving them in buffer (0 h, 
Figure 5.3e). Toxicity was, however, already significantly high after 1.5 h of aggregation 
in the (3:7, 1.5 h) and the (10:0, 1.5 h) mixtures. The synaptotoxic potential in the (3:7) 
and (10:0) ratios remained stable up to 20 h (Figure 5.3e). Remarkably, (1:9) or (0:10) 
ratios did not result in major synaptic effects at any incubation point (Figure 5.3e). To 
validate the findings, we performed double immunostaining for the synaptic marker 
synaptophysin and Aβ oligomers using the A11 antibody [20]. Figure 5.3f shows that 
Aβ (3:7) and (10:0) mainly co-localized with the synaptic marker, whereas staining 
was not observed with the (1:9) and (0:10) ratio. Extensive washing of the neurons to 
remove Aβ species did not interfere with consecutive A11 staining, indicating the rather 
irreversible nature of the binding of these synaptic active species to the neurons (not 
shown).
To prove Aβ specificity of the observed effects, we pre-incubated cells with anti-
oligomer A11 or anti-Aβ antibody 6E10 before treatment with Aβ (10:0, 2 h) ratio. The 
alterations in the synaptic activity by toxic intermediates are indeed Aβ specific, as 
cells pre-incubated with antibodies are no longer susceptible to the neurotoxic effects 
(Figure 5.3g). We also further explored the reversibility of these Aβ effects on synaptic 
function. Removal of Aβ (3:7, 2 h) and Aβ (10:0, 2 h) after 40 min of incubation on the 
neuronal cultures by extensive washes with medium did not restore synaptic activity 
over the next 6h in line with the immunofluorescence data (Figure 5.3h). However, 18 
h after the wash out of Aβ (3:7, 2 h) and Aβ (10:0, 2 h), we found partial synaptic 
activity recovery at some electrodes, although the profile of the action potentials (AP) 
displayed a slightly different character than the ones recorded before the treatment 
(Figure 5.3h). Given the long time needed for some recovery and the fact that the 
profiles after recovery were different from those before, it seems likely that this partial 
restoration of neuronal activity is due to the generation of novel synaptic contacts 
rather than recovery of existing synapses.
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Figure 5.3 Mixed Aβ oligomers result in a rapid synaptotoxic response in primary neurons. 
(a) Neurons stained with Fluo-4 were cultured 8 days in vitro (DIV) on the MEA chip. 
(b) Firing pattern of neurons from representative electrodes at 0, 10, 20 and 40 min 
treatment with different Aβ ratios prepared as indicated. Note the significantly decreased 
firing rate and amplitude for Aβ42:Aβ40 ratios 10:0 and 3:7 after 20 min of treatment. (c) 
Spontaneous electrical synaptic activity recordings of hippocampal neurons during 40 min 
of treatment with 1 μM Aβ ratios incubated for 2 h prior to the addition to cells. Values are % 
of initial firing rate±s.e.m. of 3–5 independent experiments. Statistical significance (unpaired 
two-tailed t-test) of the data versus control is indicated by *p<0.01 or **p<0.001 in the figure. 
Notice that a strong reduction in spontaneous synaptic firing versus correspondent control 
(buffer-treated chips) can be observed after 20 and 40 min in the medium of the 3:7 and 
10:0 Aβ42:Aβ40 ratios. 
(d) Oligomers dissolved in culture medium remain stable with regard to thioT tinctorial 
properties for at least 40 min. Aβ ratios were prepared and at specific time intervals of 
incubation, that is 0, 1.5, 4 and 22 h, Aβ aliquots were removed and diluted to 1 μM in 
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cell culture medium containing thioT. The stability of the aggregates at 37 °C in cell culture 
medium was deduced from the stability of the thioT signal over 40 min. Blue bars represent 
different Aβ42:Aβ40 ratios as indicated in the figure. Compare signals directly upon dilution 
into cell culture medium (‘0 min’) at 37 °C with signals obtained after 40 min incubation at 
37 °C (‘40 min’). Values are averages of three experiments. 
(e) Different ratios of Aβ peptides were generated and added to neuronal cultures diluted 
to a final concentration of 1 μM, either immediately (0 h) or after 1.5 h; 4 h, 6 h or 20 h 
of incubation. Synaptotoxicity was measured by recording a decreased rate of firing 40 
min after adding the Aβ mixtures to the neurons. Statistical significance levels determined 
as a function of s.e.m.: ***p<0.0001, n=6 chips, **p<0.001, n=3 chips, *p<0.01, n=3 chips, 
difference between 6 h ratio (3:7) and (10:0): *p<0.012 (unpaired two-tailed t-test). 
(f) Synaptic localization of mixed Aβ oligomers. Fluorescence microscopy images of 
hippocampal neurons stained for synaptophysin (red) and Aβ oligomers (A11 antibody) 
(green) after 1 h treatment with 1 μM of the indicated Aβ ratios, incubated for 2 h prior the 
addition to cells. Right panel: magnification of selected region stained with synaptophysin 
(red) and Aβ oligomers (A11 antibody, green). Oligomeric Aβ co-localizes with synapses. 
(g) Rescue of spontaneous electrical synaptic activity after the treatment with ratio (10:0, 2 h) 
in the presence or absence of anti-oligomer A11 or anti-Aβ 6E10 antibody, final concentration 
10 μg ml–1. Values are % of initial firing rate±s.e.m., of three independent experiments, 
except for the control with non-specific antibody, which was performed only once. 
(h) Example of firing recovery after treatment with 10 μM (10:0, 2 h). Raw data streams 
are shown in black, and corresponding spike shapes are in red. The treatment completely 
inhibited spontaneous activity in 6 min. Then the medium was refreshed, and signals were 
measured after overnight recovery (18 h). Note partial restoration of initial firing profile along 
with appearance of another spike population endowed with slightly different waveform and 
amplitude. Spike sorting is performed in MC Rack software.
In an alternative paradigm to validate the MEA measurements and to evaluate 
the effect of Aβ on the postsynaptic response only, we performed patch-clamp 
experiments on 2-week-old neurons and recorded spontaneous electrical activity 
comprising APs and excitatory postsynaptic potentials (EPSP) (Figure 5.4). The effects 
of Aβ addition were already observed after a few minutes [33] and the changes in AP 
and EPSP frequency were, therefore, assessed at 7 min and compared with those 
measured during 1 min before Aβ was applied (time point ‘-1 min’). It is clear that the 
Aβ (3:7, 2 h) has a profound effect on the EPSP frequency, indicating a block of 
spontaneous postsynaptic depolarizations. Neither AP nor EPSP were affected by Aβ 
(1:9, 2 h), and significant increase in AP rate was observed in case of Aβ (0:10, 2 h), 
in line with the MEA data. As it can be seen, synaptotoxic signatures of Aβ42:Aβ40 
ratios are similar regardless of extra- or intracellular mode of measurement.
5.2.3 toxic Aβ species Are oligomeric And dynAmic structures 
We used transmission electron microscopy (TEM) to characterize the morphology 
of the species populated during fibril formation. At the starting point of incubation, no 
fibrils are detected with any of the different Aβ ratios (Figure 5.5a, column 0 h). With 
time, the pure Aβ42 (10:0) solution showed mature fibril formation consistent with the 
fast nucleation observed by thioT fluorescence. The fibrils have typical long, negatively 
stained amyloid fibril morphology as is frequently observed for other amyloid-forming 
proteins or peptides [34]. Upon longer incubation, these fibrils progressively transform 
into a dense network of clustered fibrils. Aβ42:Aβ40 (0:10) and (1:9) ratios developed 
fibrils after ~6 h, which have similar characteristics to the fibrils observed in the (10:0) 
ratio, but display in addition a regular twist pattern, which is not observed in the Aβ42 
fibrils (Figure 5.5a, most right column, arrows indicate twist pattern). The (3:7) ratio in 
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Figure 5.4 Patch-clamp measurements in primary cultures of neurons. 
(a-d) Firing pattern of spontaneously active patch-clamped neurons 1 min before and 7 min 
after the treatment with different Aβ ratios (2 h) as indicated. 
(e) Measurement in control conditions (only buffer) 
(f) Relative changes in spontaneous AP frequency expressed as % of initial (1 min) rate. 
Note the early increase in AP rate for Aβ40 (0:10)-treated neurons. The other ratios do not 
reach statistical significance as compared with control likely because of the comparatively 
short time of treatment. 
(g) Relative change in single EPSP. Note the significantly decreased EPSPs rate for 
Aβ42:Aβ40 ratio 3:7 (p<0.03 versus control, unpaired two-tailed t-test) after only 7 min of 
treatment. Values are % of initial firing rate±s.e.m. of at least three independent experiments. 
Statistical significance of the data is indicated by *p<0.035 or **p<0.01 in (f) and (g).
contrast showed no fibrils at this time point, and the first aggregates appeared 
only after ~9 h. These aggregates differed markedly in their morphologies as they 
interacted heavily with the uranyl acetate stain used to visualize the aggregates in 
TEM and also formed densely fibrous and fractured networks in which individual fibrils 
cannot be distinguished, which is similar to the later stages of Aβ42 aggregation (not 
shown). Interestingly, the fast nucleation and aggregation kinetics of the (3:7) ratio 
as observed  using thioT fluorescence assays (Figure 5.2) did not coincide with the 
early appearance of mature aggregates using EM (Figure 5.5a). This suggested that 
the (3:7) ratio rapidly generates small thioT-positive oligomers, but that these do not 
propagate towards assemblies that are sufficiently large to allow visualization with EM. 
Although EM experiments confirmed clearly the dramatic differences in the aggregation 
properties of the different mixtures, they did not allow visualizing the postulated toxic 
species responsible for the synaptic effects observed in the MEA experiments with the 
(3:7) ratio. We hence set out to further identify the presence of smaller oligomeric Aβ 
using the complementary technique of tapping mode atomic force microscopy (AFM). 
The various Aβ ratios under investigation were screened at 1.5 h incubation, which 
is a time point that yields strong synaptotoxicity for ratios (3:7) and (10:0), but not for 
ratios (1:9) and (0:10) (Figure 5.3e). Interestingly, we observed oligomer formation for all 
four ratios of Aβ42:Aβ40 (Figure 5.5b), even for the two non-synaptotoxic ratios (1:9) 
and (0:10). 
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Figure 5.5 Characterization of Aβ oligomers with transmission electron microscopy and 
atomic force microscopy. 
(a) Transmission electron microscopy images of Aβ ratios incubated for 0, 4, 6 and 9 
h. Images shown are representative for two experiments. Time of appearance and fibril 
morphology are affected by Aβ42:Aβ40 ratio and mature fibril formation is delayed for 
the synaptotoxic 3:7 ratio. The bars represent 0.2 μm size. The last column shows a 
magnification of the area indicated by squares in the panels of 9 h. The bars represent 
0.04 μm size. The arrows indicate a regular twist pattern observed in the 1:9 and 0:10 fibrils. 
(b) AFM height images of Aβ oligomers formed by incubation of 70 μM Aβ for 1.5 h at 25 
°C in 50mM Tris, 1mM EDTA. The buffer image is shown as a control. The bar represents 
250 μm size.
This finding implies that oligomer formation per se is not directly linked to the toxic 
effects of Aβ. We infer that the internal organization of the oligomers might make them 
toxic to neuronal cells. Native PAGE showed that (10:0) and (3:7) already display 
a wide range of oligomers and fibrillar material that did not enter the gel after 4 h 
incubation. SDS PAGE in contrast shows at the same time points only low-molecular 
weight oligomers (Figure 5.6). It, therefore, seems that SDS PAGE dissociates the 
larger native structures in the toxic mixtures. The smaller oligomeric SDS-resistant 
structures can only be considered ‘building blocks’ of larger structures. As no clear 
differences were observed in oligomerization state between the four different ratios 
that could explain the variation in cytotoxicity, we used in situ FTIR spectroscopy to 
obtain information on the conformation of the Aβ peptides and aggregates in solution. 
We found that the initial spectra of the different Aβ mixtures at t=0 h, when peptides
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Figure 5.6 Native PAGE and SDS PAGE of Aβ ratios show a range of different oligomeric 
sizes of Aβ present throughout the aggregation process. 
(a) Native PAGE and (b) SDS PAGE (10-20% tris-tricine) and subsequent staining by mAb 
6E10. Native PAGE shows large oligomers and fibrils (comparable with EM) especially 
upon longer incubation for synaptotoxic (3:7) and (10:0). SDS PAGE only shows primarily 
monomeric and some trimeric and tetrameric species indicating that the oligomers and 
fibrils detected by Native PAGE are constructed from similar building blocks and that the 
detection of these oligomeric species is dependent on the particular technology used.
are mainly monomeric, are characterized by a broad peak at 1654 cm-1 indicative 
of random coil structure [35]. This spectrum gradually converts into a defined and 
sharper peak at 1627 cm-1 (Figure 5.7). The intensity at 1627 cm-1 is indicative 
for β-sheet-organized aggregates [36] and the concomitant increases of the FTIR 
signal at 1627 cm-1 with a decreased signal at 1654 cm-1 suggested a transition 
from disordered monomeric structures to β-sheet enriched-oligomeric structures in all 
mixtures (Figure 5.7 a-d). Conformational changes are rapidly evolving for the three Aβ 
ratios that contain Aβ42, but the rate of this change does not seem to predict toxicity: 
Aβ42 is toxic at 1.5 h, whereas ratio (1:9) is not. For Aβ40 alone (Figure 5.7a) and 
for Aβ (1:9) (Figure 5.7b), it appears that the loss of unordered structure (1654 cm-1) 
coincided with a prompt transition into amyloid fibrillar β-sheet structure (1627 cm-1), 
suggesting a two-state manner in the mixtures that develop at inverse rates. This is 
not observed for Aβ (3:7) and (10:0), suggesting that there is an intermediate, which 
seems to correlate with toxicity.
5.2.4 long-term cellulAr toxicity of Aβ mixtures 
Although the changes in synaptic activity are clearly an early effect of the toxic 
conformations in the Aβ preparations, it remained unclear whether these initial hits on 
the synapse could also evolve to full cellular neurotoxicity. This is an important question 
with regard to Alzheimer disease as it is characterized in essence by neuronal cell 
loss. We investigated, therefore, the effects of the different Aβ42:Aβ40 ratios over two 
distinct concentrations (1 μM, which appeared sub-lethal and 10 μM, which appeared 
lethal) on the staining pattern of primary hippocampal neurons with the synaptic 
marker synaptophysin or with the early apoptotic markers cleaved caspase-3 and 
annexinV/propidium iodide (PI). Treatment of cells with 1 μM concentration of Aβ ratios 
(the same as used for the MEA experiments) for 12 h clearly decreased synaptophysin 
staining for the Aβ (3:7, 2 h) and (10:0, 2h) ratios. At this concentration, no or little 
effect on appearance of apoptotic markers in the neuronal cells was observed (Figure 
5.8a; quantified in Figure 5.8c), further indicating that the initial effect of the Aβ toxic 
intermediates is at the synapses. However, 10-fold higher concentration of Aβ (3:7, 2h) 
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Figure 5.7 Conformational transitions observed using Fourier transform infrared (FTIR) 
spectroscopy. 
FTIR spectra were collected continuously upon incubation of Aβ ratios at 25 °C to investigate 
conformational changes over time. Aβ42:Aβ40 (a) (0:10), (b) (1:9), (c) (3:7), (d) (10:0). Intensity 
at 1654 cm-1 in grey characteristic for disordered structure and intensity at 1627 cm-1 in 
black characteristic for amyloid fibril structure. Intensities are averages of three independent 
experiments and normalized against buffer. Notice that the transition of ratio (3:7) and (10:0) 
cannot be explained by a two-state transition model (the two curves do not cross at the 
50% intersection), whereas (0:10) and (1:9) can completely be accounted for by the two 
states. Insets show typical spectra for the different Aβ ratios recorded at 0 h (black) and 
after incubation for 8 h (grey).
and (10:0, 2h) ratios resulted not only in the loss of synaptophysin staining, but was 
accompanied by a strong increase in the early apoptotic markers, annexin V/PI 
and cleaved caspase-3 staining (Figure 5.8b; quantified in Figure 5.8d). In contrast, 
synapses remained intact and no early apoptotic marker induction was caused by 
Aβ (0:10, 2 h) and (1:9, 2 h) ratios at both 1 and 10 μM concentrations after 12 h of 
treatment (Figure 5.8 c,d). This finding indicates that synaptotoxic and cytotoxic effects 
of Aβ intermediates are both ratio and concentration dependent.
We evaluated the time course of caspase-3 activation and its subcellular localization 
versus the synaptic marker synaptophysin in both sub-lethal (1 μM) and lethal (10 μM) 
concentrations of the (3:7, 2 h) ratio (Figure 5.8e). Cells treated with 1 μM (3:7, 2 h) 
showed that cleaved caspase-3 after 2 and 6 h was mostly observed in areas positive 
for synaptophysin staining. Further treatment up to 12 h resulted in loss of synapses 
as indicated by loss of staining for synaptophysin; however, the cleaved caspase-3 
immunostaining did not propagate to the soma and nucleus. Treatment with 10 μM (3:7, 
2 h) caused in contrast strong activation of caspase-3 at the synapses already after 2h 
(Figure 5.8e). In addition, immunostaining for activated caspase-3 was clearly detectable 
after 6 h in the soma of the cells. At 12 h, this concentration resulted in loss of synaptic 
staining with synaptophysin antibodies and strong staining of activated  caspase-3 in 
the soma and nucleus indicative of cell apoptosis (Figure 5.8e). These data indicate 
that the Aβ toxicity observed at the level of the synapses can spread towards the cell 
body depending on the type of Aβ species and concentration of toxic intermediates. In 
addition, the observation suggests that synapse toxicity and cellular toxicity are related.
To further confirm that the different Aβ preparations exerted cellular toxicity, we 
used a Cell-Titer Blue viability assay on neurons 48 h after they had been exposed to
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Figure 5.8 Mixed Aβ oligomers affect synapses at low concentration and induce cell 
death at higher concentrations. 
(a,b) Fluorescence microscopy images of hippocampal neurons stained for annexin V 
(green)/PI (red) (upper row), cleaved caspase-3 (middle row) and synaptophysin (green)/
DAPI (blue) (bottom row) after 12 h treatment with (a) 1 μM Aβ ratios and (b) 10 μM Aβ 
ratios incubated for 2 h before the addition to cells. Fluorescence intensity quantification for 
annexin V, cleaved caspase-3 and synaptophysin staining 
(c) 1 μM and (d) 10 μM of Aβ ratios. Values are intensity±s.e.m., **p<0.001 and *p<0.003, 
of five different areas from two independent experiments. 
(e) Time course of fluorescence microscopy study of hippocampal neurons stained for 
synaptophysin (red) and cleaved caspase-3 (green) after treatment with 1 and 10 μM 
(3:7) ratio Aβ oligomers incubated for 2 h prior the addition to cells (blue: DAPI) figure 
representative for two independent experiments. 
(f) Cell-Titer Blue viability assay of hippocampal neurons treated with 10 μM Aβ ratios 
incubated for different time periods before the addition to cells. The Cell-Titer Blue reagent 
conversion was determined 48 h after the treatment. Values are OD±s.e.m., **p<0.01, three 
independent experiments performed in triplicates.
10 μM of different Aβ ratios, taken at the start of the aggregation process (0 h in 
Figure 5.8f) and during the propagation reaction (1, 2, 4 and 12 h in Figure 5.8f). In 
agreement with the previous studies, monomers (Figure 5.8f, 0 h) and mature fibril 
preparations (Figure 5.8, 12h) are largely inert towards neurons [16,37]. In contrast, the 
Aβ42:Aβ40 (3:7, 1 and 2 h) and (10:0, 1 and 2 h) exhibited clear neurotoxicity (Figure 
5.8f). Both (1:9) and (0:10) did not exhibit neurotoxicity at any stage of the aggregation 
process (Figure 5.8f). Collectively, these data indicate that stabilized intermediates in 
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the Aβ (10:0) and (3:7) ratios bind to synapses and inhibit synaptic activity, and affect 
neuronal viability at higher concentrations.
5.2.5 Aβ rAtio Affects behAviour And leArning AlterAtion in mice 
We finally evaluated to what extent the different Aβ ratio mixtures affected memory 
formation in mice in vivo. We injected mice intraventricularly with 6 μl of 100 μM Aβ 
mixtures allowed to aggregate for 1.5 h before the injection. The effect of these Aβ 
preparations on memory formation was tested using passive avoidance and contextual/
auditory-cue fear conditioning as described previously [16]. In a light–dark step-through 
task (passive avoidance test), animals were trained to memorize an electrical shock 
that followed entrance to a dark compartment. When the test was repeated 24 h 
later, animals injected with (0:10, 1.5 h) or (1:9, 1.5 h) recalled the electroshock correctly 
and showed a latency to enter the dark room of 232±15 and 273±16s, respectively, 
which was not significantly different from control mice injected with buffer (256±20s)-
control group not shown. Injection of (10:0, 1.5 h) or (3:7, 1.5 h) before the shock, 
however, inhibited strongly the formation of new memory. These animals showed 
significantly faster entrance latencies of 134±12 and 165±19 s, respectively (p<0.002) 
(Figure 5.9a). Contextual and auditory-cue fear conditioning experiments confirmed 
these results. Injection of (10:0) and (3:7) 90 min before conditioning disturbed the 
typical freezing behaviour observed 24 h after the training when the animals were 
exposed again to the contextual stimulus (~50%, p<0.006) or the auditory-cue fear 
conditioning experiment (39%, p<0.004) (Figure 5.9b). These results show that also in 
the complex environment of a living animal clear differences can be observed between 
the different Aβ ratios similar to those observed in biophysical and cellular assays.
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Figure 5.9 Toxic Aβ affects behaviour and learning of mice. 
(a) Passive avoidance; 1.5 h after intraventricular injection with 6 μl of Aβ ratios incubated 
for 2 h before the injection, latency of entrance in the dark cage during the training (white) 
was tested. The latency of entrance during the testing was performed 24 h later (black) 
(values are latency mean±s.e.m., p<0.002, control (n=13), Aβ40 and ratio 1:9 (n=12), ratio 
3:7 and Aβ42 (n=11)). 
(b) Conditional fear response; 1 h after intraventricular injection with 6 μl of Aβ ratios, 
habituation was induced. Animals were exposed to the training after an additional 4 h. The 
freezing response was recorded 24 h later for context-dependent (white bars) and auditory 
cue-dependent (black bars) memory formation. Values are % freezing mean±s.e.m., Aβ 
ratios (0:10) and (1:9): n=13 for ratio (3:7) and (10:0): n=14.
5.3 discussion
One of the most challenging issues in Alzheimer disease research is the unresolved 
nature of the Aβ peptide conformation(s) that exert neurotoxicity. Our current work 
shows that Aβ-associated toxicity is a dynamic property and that a critical equilibrium 
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between the two major Aβ species, Aβ40 and Aβ42, exists, which determines the 
rate of appearance of these toxic properties as assessed in neuronal cell culture and 
in brains of animals in vivo. Our study design has taken this dynamic behaviour into 
account by indicating the time of aggregation of the peptides used in each experiment. 
We found that relative high concentrations of Aβ are needed to induce fibrillization 
and toxic-oligomer conformation. Although this might seem an artificial situation, one 
should realize that by increasing the Aβ concentrations, processes which otherwise 
take decades become accelerated to the extent that they can be studied in laboratory 
conditions. Most importantly, such high concentrations of Aβ might actually be even 
quite relevant for what happens in vivo. A recent publication suggested indeed that 
intracellular compartments accumulate Aβ at high μM concentrations, which could 
create the conditions for the local formation of the elusive toxic conformations of Aβ 
peptides [38].
It turns out that a small relative increase of Aβ42, comparable with those observed 
in patients with familial cases of Alzheimer disease [2,4,30,31], dramatically influenced 
the final effects on spontaneous synaptic activity and viability of neuronal cells and 
on memory formation in animals. This correlated with remarkable changes in the 
biophysical behaviour of the Aβ peptides as assessed in a variety of approaches. 
Thus, we find that shifting the ratio of Aβ42:Aβ40 from (1:9) to (3:7) shortened 
nucleation time strongly, whereas fibril elongation time remained similar as measured 
by thioT incorporation. In EM, the (3:7) ratio revealed only visible fibrillar structures 
after prolonged incubation compared with the other three ratios investigated. Both 
experiments together suggested that intermediary assemblies of Aβ peptides became 
stabilized in the (3:7) ratio, which were too small to be observed in EM, but which, 
as evaluated in MEA, exerted strong effects on synaptic activity. In SDSPAGE, these 
assemblies apparently fall apart in small multimeric Aβ oligomers as observed by others 
[17,19], but from non-denaturing PAGE analysis, we deduced that these ‘building 
blocks’ are part of larger structures present in the toxic mixtures on the neuronal 
cultures. Investigation by AFM further underlined that oligomeric Aβ was present in 
all Aβ ratio preparations, suggesting that the presence of oligomers per se are not 
directly linked with toxic effects. We suggest, therefore, that the toxic aggregates of Aβ 
in our assays were dynamic in nature and could assemble and disassemble when in 
solution in the culture medium of the cells. In addition, based on the results obtained by 
AFM, one can assume that not the size but the structure of the intermediate oligomers 
dictates their stability and synaptotoxic potential. Indeed, with FTIR spectroscopy, 
we found indications for particular conformational transitions in the peptides that are 
specific for this postulated toxic intermediate situation. Going from monomeric Aβ 
(disordered at 1654 cm-1) to fibrillar Aβ (parallel β-sheet at 1627cm-1) [35,36], we 
find in the Aβ40 (0:10) or Aβ42:Aβ40 (1:9) preparations that the unstructured state 
converted to the β-sheet conformation without intermediary structures. In contrast, the 
patterns of conversion in the Aβ42:Aβ40 (3:7) and the Aβ42 (10:0) ratios indicated the 
existence of an intermediate conformation (Figure 5.5d, Figure 5.7c). The current work 
also suggests the prolonged time window of existence of such intermediate states in 
the (3:7) ratio.
Aβ42 drives apparently this reaction, interactions of Aβ40 and Aβ42 occur random. 
Previously, it has been shown that Aβ42 induces indeed the aggregation of Aβ40 
[7,9,12,13,28]. We show here that the relative amount of Aβ42 is most crucial in 
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this regard as shown by the dramatic shift in properties from Aβ42:Aβ40 ratio (1:9) 
towards the FAD-like Aβ42:Aβ40 ratio (3:7). In fact, ratio (1:9) is nucleating very late 
(Figure 5.2), but once the nucleation occurs, this mixture rapidly forms mature and 
well-organized fibrils (Figure 5.5a), in which oligomer formation is observed by AFM 
(Figure 5.5b), but not by TEM. Collectively, the data suggest that the Aβ (1:9) and 
(0:10) ratios most probably bypassed the synaptotoxic stage and aggregated quite 
rapidly into non-toxic mature fibrils once nucleation had been induced (Figure 5.3 e,f, 
Figure 5.5a) and, therefore, did not bind and affect synapses. In contrary, Aβ (3:7) and 
(10:0) ratios were enriched with synaptotoxic intermediates that bind to synapses and 
inhibit spontaneous synaptic activity. It should be mentioned that it has been already 
suggested that neurotoxicity by Aβ is not exerted by a specific species, but that in 
contrast the polymerization reaction itself, which depends on monomer concentration 
and nucleation rate, drives toxicity [39]. Our data seem indeed more compatible with 
a dynamic interpretation of Aβ toxicity, and argue against a simple receptor-ligand 
mechanism mediated by a precise Aβ species as has been proposed by several 
others; e.g. [40].
A wide range of evidences indicate that Aβ oligomers and protofibrillar intermediates, 
regardless of their origin or preparation, attack synapses, block LTP and disrupt 
cognitive functions [16,19,23,25,41-43]. One of the questions in these assays is 
whether the species that exerts the toxicity as measured in the biological assay is the 
same as the one that is analysed in the biophysical assays. We developed, therefore, 
an acute cellular assay to measure synaptic effects very early after addition of the 
Aβ preparations. We observed changes in the spontaneous firing rate of neurons in 
culture already within 20 min incubation with Aβ ratio mixtures (Figure 5.3 d,e). We 
confirmed that the thioT tinctorial properties of the different Aβ preparations used 
were minimally changed over the time frame of 40 min. This assay was performed in 
neuronal culture medium and at the same dilution and temperature used in the cellular 
assays, further strengthening our assumption that the toxicity measured in the MEA 
cellular assay was indeed associated with the Aβ aggregation state characterized in 
the biophysical assays. This acute toxicity was further confirmed by measuring EPSPs 
of neurons in culture: as early as 7 min after addition of the Aβ mixtures toxicity, 
measured as decreased rate of EPSP, was detected.
We addressed the question of synaptotoxic versus cytotoxic effects of Aβ 
intermediates. We show that intermediates from the Aβ (3:7) ratio specifically bind 
synapses (Figure 5.3f) without major cytotoxicity as assessed by caspase-3 and 
annexin staining (Figure 5.8). Our data also provide some preliminary evidence that the 
initial synaptotoxicity is accompanied by some local synaptic activation of caspase-3 
(Figure 5.8) occurring in parallel to the functional inactivation of synapses (Figure 5.3), 
which needs further exploration. Interestingly, higher concentrations of the Aβ (3:7) ratio 
caused caspase-3 activation in the soma as well (Figure 5.8).
The findings in this chapter impact on our understanding of the function of the 
different Aβ species and their relative contribution to synapse toxicity and neuronal cell 
death in the brain of patients with Alzheimer disease. The paradox of loss of function of 
several presenilin mutations causing Alzheimer disease (reviewed in [6]) indicates that 
at least in these FAD cases, a lower generation of Aβ peptide can still be associated 
with disease and progressive amyloid accumulation. In vivo experiments are in line with 
this conclusion: more amyloid pathology was observed in transgenic mice expressing 
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a PS1 mutant allele over a PS1 null allele than over a PS1 wild-type allele [10]. Our work 
explains that it is indeed possible to come to very different, pathologically relevant, 
situations with the same quantitative Aβ load, but with a qualitatively different Aβ mix. 
This could potentially explain the early and aggressive neurodegeneration in the brain 
of presenilin FAD patients, even with a loss of function of γ-secretase [5]. If indeed 
the specific mix of the different Aβ peptides with specific conformation in the brain 
dictates the synapse and neuronal toxicity potential of the Aβ load in FAD and, by 
extrapolation, in SAD brain, these observations have obviously important implications 
for the development of anti-amyloid medication.
5.4 experimentAl procedures
5.4.1 prepArAtion of Aβ peptide rAtios 
Aβ peptide was dissolved as described in Chapter 2 and the peptide concentration 
was measured using Bradford assay. The samples were kept on ice until experiments 
started, with a maximum lag time of 20 min.
5.4.2 thiot fluorescence
Aβ protein concentrations were normalized to 50 μM by further dilution using 50mM 
Tris, 1mM EDTA containing buffer and a final concentration of 12 μM thioT was added. 
The fibrillation kinetics were followed in situ at excitation and emission wavelengths of 
440 and 480 nm resp. Readings were recorded in triplicate every 10 min during 6h.
5.4.3 time-resolved western blot And dotblot
Aggregation of Aβ40, Aβ42 and ratios (1:9) and (3:7) (Aβ42:Aβ40) was studied 
using Western blot analysis. Aggregates were prepared at 100 μM and incubated 
at 25 °C. At various time points, aliquots of Aβ were mixed 2x Novex Tricine SDS 
sample buffer (for SDS PAGE) or with 4x native PAGE sample buffer with G-250 
and loaded onto a 10% bis-tris gel (SDS-PAGE) or a 3-12% bis-tris gel (native PAGE). 
The SDS-gel was run at 125 V for 75 min and the native-gel at a fixed voltage of 
100 V for 120 min, Subsequently the peptides were transferred onto a nitrocellulose 
membrane (SDS PAGE) or to PVDF membrane (native PAGE) for 2 h at 25 V at 4 °C 
using Towbin blot buffer (25mM Tris, 192mM Glycine, 20% MeOH, 0.1% SDS) (SDS 
PAGE) or for 70 min at 0.09 A at 4 °C using NuPAGE transfer buffer (native PAGE). 
For dotblot, 5 μL sample was blotted onto nitrocellulose membrane followed by boiling 
of the membrane in PBST. Membranes were blocked and incubated with primary 
antibodies 6E10, and A11 for PAGE and anti-Aβ40 and anti-Aβ42 for dotblots. After 
blotting with HRP-tagged secondary antibodies the membranes were visualized using 
an electrochemical luminescence (ECL) system.
5.4.4 trAnsmission electron microscopy
Aliquots (5 μl) of the Aβ preparation were adsorbed to carboncoated FormVar film 
on 400-mesh copper grids for 1 min. The grids were blotted, washed twice in droplets 
of Milli-Q water and stained with 1% (wt/vol) uranyl acetate. Samples were studied with 
a JEOL JEM-2100 microscope at 200 kV.
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5.4.5 Atomic force microscopy
Atomic force microscopy imaging was performed on a custom built instrument 
using Si3N4 tips with a spring constant of 0.5 N/m and a nominal tip radius of 10 nm. 
The measurements were made in tapping mode in liquid, with a tapping amplitude of 
less than 4 nm. The AFM scan settings were optimized to minimum force interaction 
with the sample. All AFM images have 512x512 pixels. Aβ ratios were incubated at 
25 ºC at 70 μM for 1.5h. AFM samples were prepared by placing 4 μL of sample on 
freshly cleaved mica. After 4 min adsorption time, unbound Aβ was gently washed 
off with twice 100 μL buffer (filtered 10mM Tris, 1mM EDTA, pH 7.5). The sample was 
then mounted on the AFM stage with application of 300 μL extra buffer, a volume 
sufficient to keep the sample in buffer throughout the experiment. The images are 
represented in 3D after removal of height discontinuities between subsequent scan 
lines and compensation for piezo drift using SPIP software.
5.4.6 fourier trAnsform infrAred spectroscopy
Aβ solutions were applied to the FTIR sample holder and incubated for 8 h at 25 °C. 
InfraRed spectra were recorded on a Bruker Tensor 27 infrared spectrophotometer 
equipped with a Bio-ATR II accessory. The spectrophotometer was continuously 
purged with dried air. Spectra were recorded at a spectral resolution of 4 cm-1 and 
120 accumulations were performed per measurement. FTIR spectra were recorded 
every 5 min in situ at a wavelength range from 900 to 3500 cm-1. The obtained 
spectra were baseline subtracted and rescaled in the amide I area, which spans from 
~1600 to ~1700 cm-1.
5.4.7 primAry hippocAmpAl cultures
Hippocampal neuronal cultures were generated from trypsinized brains obtained 
from 17-days-old embryos and were maintained in Neurobasal medium supplemented 
with B27 and 12.5 μM L-glutamate After 3 days of culturing, the medium was changed 
to Neurobasal medium without glutamate. Cultures were maintained at 37 °C in a 
humidified 5% CO2 atmosphere for 8-10 days prior to further experiments.
5.4.8 spontAneous synAptic Activity recording by meA
Neurons were plated at 1000 cells mm–2 on an MEA substrate and grown 
for 8-10 days. The spontaneous firing rate of the neuronal network was recorded 
simultaneously from at least 10 successful electrodes (out of 60 available). During the 
recording experiment, a temperature controller was used to maintain the MEA platform 
temperature at 37 °C. The basal firing rate was recorded during 5 min. Upon treatment 
with Aβ, the spontaneous synaptic activity was continuously recorded during 40 min. 
Raw signals from MEA electrodes were amplified with a gain of 1200 and digitized at a 
sampling rate of 25 kHz; MC_Rack 3.5.10 software was used for data recording and 
processing. The raw data stream was high-pass filtered at 200 Hz, and the threshold 
for spike detection was set to 5 SD of the average noise amplitude computed during 
the first 1000 ms of recording. A number of spikes detected by every electrode per 
time bin of 60 s was normalized to baseline (firing rate in the absence of treatment). 
After data analysis, the firing rates at 10, 20 and 40 min of treatment were extracted 
and presented as percentage of initial rate.
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5.4.9 immunocytochemistry
Slides were washed with PBS, fixed with 4% paraformaldehyde/PBS and 
immunostained with anti-cleaved caspase 3 antibody (1:100) or anti-synaptophysin 
(1:200) followed by staining with Alexa-Fluor 488-conjugated GaM secondary antibody 
(1:200). For double staining anti-oligomer A11 antibody (1:200) and anti-synaptophysin 
(1:200) were used and subsequently stained with Alexa-Fluor 564-conjugated GaR 
and Alexa-Fluor 488-conjugated GaM secondary antibodies (1:200), respectively. 
Microscopic analysis was performed on a Confocal microscope. 
5.4.10 cell-titer-blue cell viAbility AssAy
Ten μL of Cell-Titer-Blue dye was added directly to the growth medium on the cells. 
After 3 h incubation the fluorescence intensity of the samples was measured at an 
excitation wavelength of 560 nm and an emission wavelength of 590 nm.
5.4.11 Annexin v/propidium iodide (pi) stAining
Hippocampal cultures on slides were incubated with annexin V/PI dye mixture from 
the ApoAlert apoptosis kit for 15 min according to manufacture recommendations. 
Microscopic analysis was performed using confocal microscope as described above.
5.4.12 pAtch-clAmp experiments
Two-week-old neurons from at least five independent hippocampal cultures were 
patch clamped, and spontaneous electrical activity comprising APs and EPSPs was 
recorded. Quartz glass pipettes with an inner diameter of 1mm were pulled using a 
P-2000 Laser Puller to obtain pipettes with series resistance of 2-4MΩ. The pipette 
solution consisted of 140mM KCl, 5mM EGTA, 5mM NaCl, 5mM Na2ATP, 10mM 
HEPES, 1mM MgCl2, pH 7.2. After the formation of a gigaseal, the cell membrane 
was ruptured using ZAP pulses to obtain the whole-cell configuration. Then, APs and 
EPSPs were recorded in current clamp mode. Neurons were kept in neurobasal cell 
medium supplemented with 10% HEPES. Different ratios of Aβ were added to the 
measurement chamber by manual pipetting. The number of EPSPs before and after 
the treatment were analysed in 1 min segments by means of the Clampfit software. 
5.4.13 mouse cAre
Female 3 month old mice of comparable weight were maintained in a specific 
pathogen-free facility that meets Belgian and European Union requirements for animal 
care. Mice were group housed in a climate-controlled animal colony with a 12 h light/
dark cycle (light on 6:00 A.M.) with access to food and water ad libitum, except during 
some of the behavioral testing. Adequate measures were taken to minimize pain or 
discomfort.
5.4.14 brAin intrAventriculAr injections
Animals were locally anesthetized by subcutaneous injection of 5 μL of 2% 
Xylocaine. The needle was inserted unilaterally 1 mm to the right of the midline point 
equidistant from each eye, at an equal distance between the eyes and the ears and 
perpendicular to the plane of the skull and 6 μg Aβ from an aged (2 h) solution was 
injected using a Hamilton syringe. The surgery was completed within 8 min. Animals 
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were followed-up for their post-surgery recovery and normally showed unimpaired 
behavior and motility. 1-1.5 h after the injections the animals were exposed to behavior 
tests. Different experimental groups of transiently injected animals were used for each 
behavioral test.
5.4.15 leArning And memory tests
Passive avoidance learning was tested in a step-through box. During training, 
dark-adapted mice were placed in the small illuminated compartment of the box. 
After 5 s, a sliding door to the larger dark compartment was opened, and entry 
latency was recorded. The door was closed as soon as all four feet were on the grid 
floor, and a slight foot shock (0.3 mA, 2 s) was delivered using a constant current 
shocker. Retention was tested 24 h later using the same procedure, and entry was 
recorded up to 300 s cutoff. The results are expressed as latency to enter the dark 
compartment before and after the foot shock. In cue- and context-dependent fear 
conditioning the unconditioned stimulus (US) (an electric shock) is paired with a CS 
(the tone) to elicit a freezing response, a reliable measure of fear in rodents. On 
the first day, the animals were placed in the testing chamber (22.5x32.5x33.3 cm; 
Plexiglas cage with a grid floor) and were allowed to acclimatize for 5 min. On day 
2, they were first allowed to explore the testing chamber for 2 min (pre-US score). A 
30-s tone (conditioned stimulus (CS)) was delivered (frequency, 2150±200 Hz), which 
coterminated with a 2 s, 0.35mA foot shock (the US). Two minutes later, a second 
pairing of the CS and US was presented, followed by another 30 s exploration (post-
US score). Twenty-four hours later, the animals were returned to the testing chamber 
for 5 min exploration in the same context as the previous day (context score). Ninety 
minutes later, the animals were returned to the test chamber, but now the grid floor 
was hidden with a Plexiglas plate and odourized sawdust to alter the context of the 
testing chamber. The animals were observed for 6 min. During the first 3 min, no 
stimulus was delivered (pre-CS score). During the next 3 min phase, the auditory cue 
was delivered (CS score). Freezings were automatically recorded. A freezing score 
was expressed as the percentage of freezing, when the threshold was defined equally 
through all experiments in each of the five trial blocks. 
5.4.16 stAtistics
Differences between groups were examined using unpaired two-tailed t-tests, 
and one-way or two-way repeated measurements ANOVA procedures with 
Fisher’s method. Significance levels for each experiment are indicated in the figure 
legends. Significance in Cell-Titer Blue viability assay, MEA assay, ThioT assays and 
immunofluorescence intensity assay was established using two-tailed t-tests.
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Aβ is directly related to neurotoxicity in Alzheimer disease. The two most abundant 
alloforms of the peptide co-exist under normal physiological conditions in the brain in 
an Aβ42:Aβ40 ratio of ~ 1:9. This ratio is often shifted to a higher percentage of Aβ42 
in brains of patients with familial Alzheimer disease and this has recently been shown 
to lead to increased synaptotoxicity. The molecular basis for this phenomenon remains 
unclear. Although the aggregation characteristics of Aβ40 and Aβ42 individually are 
well established, little is known about the properties of mixtures. We have explored 
the biophysical and structural properties of physiologically relevant Aβ42:Aβ40 ratios 
by several techniques. We show that Aβ40 and Aβ42 directly interact as well as 
modify the behavior of the other. The structures of monomeric and fibrillar assemblies 
formed from Aβ40 and Aβ42 mixtures do not differ from those formed from either 
of these peptides alone. Instead, the co-assembly of Aβ40 and Aβ42 influences the 
aggregation kinetics by altering the pattern of oligomer formation as evidenced by 
a unique combination of solution nuclear magnetic resonance spectroscopy, high 
molecular weight mass spectrometry, and cross-seeding experiments. We relate 
these observations to the observed enhanced toxicity of relevant ratios of Aβ42:Aβ40 
in synaptotoxicity assays and in Alzheimer disease patients.
struCturAl bAsis for inCreAsed toxiCity 
of pAthologiCAl Aβ42:Aβ40 rAtios in 
Alzheimer diseAse.
The results described in this chapter have been published in:
Pauwels K, Williams T, Morris K, Jonckheere W, Vandersteen A, Kelly G, Schymkowitz J, 
Rousseau F, Pastore A, Serpell L, and Broersen K (2012). J. Biol. Chem., 287:5650-5660.
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6.1 introduction
Alzheimer disease is a multifactorial neurodegenerative disease that mainly affects 
the growing population of the elderly. The primary agents of Alzheimer disease, the Aβ 
peptides, are released from the amyloid precursor protein by sequential endoproteolytic 
cleavages. The severity of dementia correlates with soluble assemblies of Aβ peptides 
rather than with the final fibrillar Aβ deposits observed in the brain [1] and a plethora of 
different toxic oligomers have been identified [2-5].
Imprecise cleavage of the amyloid precursor protein substrate by γ-secretase 
or altered catabolism of the Aβ peptides affect the relative amounts of Aβ40 and 
Aβ42, the two main Aβ fragments [6-8]. An increased Aβ42:Aβ40 ratio seems to 
coincide with more aggressive forms of the disease compared with cases of sporadic 
Alzheimer disease [9] and affects synaptic activity, viability of neuronal cells, and 
memory formation in animals [7,8,10-12]. Minor shifts in the Aβ42:Aβ40 ratio have been 
reported to drastically influence the formation of neurotoxic oligomers [13,14]. Despite 
the very similar chemical nature of the two peptides, they seem to have quite different 
structural and biophysical properties. Aβ42 is known to be highly fibrillogenic and more 
prone than Aβ40 to form neurotoxic assemblies [13,15-17]. Different architectures of in 
vitro generated amyloid fibrils from pure Aβ40 and Aβ42 peptides have been revealed 
by nuclear magnetic resonance (NMR) [18], electron microscopy (EM) [19], and x-ray 
fiber diffraction methods [20-22]. A limited number of studies have demonstrated that 
Aβ40 and Aβ42 each affect the aggregation rates of the other, and it is generally 
reported that Aβ40 inhibits the aggregation of Aβ42 [12,14,23-27].
To date, most structural and biophysical studies have been performed using Aβ40 or 
Aβ42 in isolation. However, the aberrant behavior of neurotoxic Aβ peptides directed by 
the Aβ42:Aβ40 ratio requires the need to simultaneously investigate Aβ40 and Aβ42. In 
this chapter, we address how Aβ40 and Aβ42 influence and modulate assembly and 
consider how structural aspects of intermediates along the aggregation pathway can 
direct the cytotoxic response of Aβ42:Aβ40 ratios. By combining transmission electron 
microscopy (TEM), x-ray fiber diffraction, surface plasmon resonance (SPR), solution 
NMR, and high molecular weight mass spectrometry, we have characterized the start 
and end states of different relevant Aβ42:Aβ40 ratios. Using the unique combination 
of 15N-edited and 15N-filtered NMR experiments, we have been able to isolate the 
specific behavior of either Aβ40 or Aβ42 in mixtures. We show that Aβ40 and Aβ42 
can interact and that they mutually influence their aggregation behavior. Interestingly, 
cross-seeding and mass spectrometry experiments reveal differences in the prefibrillar 
stage of aggregation, which are reflected by different aggregation kinetics.
6.2 results
6.2.1 direct interActions between Aβ40 And Aβ42
SPR was used to explore whether Aβ40 and Aβ42 are able to directly associate. 
Either biotinylated Aβ40 or Aβ42 were tethered to a chip and measurements of 
interactions between Aβ40-Aβ40 and Aβ42-Aβ42 adsorption resulted in initial fast 
adsorption of the Aβ peptides, followed by a slower kinetics phase of peptide binding, 
characteristic for high affinity binding (Figure 6.1). A similar binding profile has been 
reported for the aggregation and fibrillization of isolated Aβ42, where a high incidence 
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of specific binding is observed between 11-mercaptoundecanoic acid tethered Aβ42 
and monomeric Aβ42 in bulk solution [28]. The interaction between tethered Aβ42 with 
Aβ40 monomers showed a similar binding profile but slightly weaker binding. Binding 
between the same Aβ alloform resulted in greater mass adsorption to the sensor 
surface compared with mixed Aβ oligomeric interactions. These data show that the 
strongest binding occurs between the same alloform such as Aβ40-Aβ40 or Aβ42-
Aβ42. However, strong specific binding was also observed between Aβ42-Aβ40.
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Figure 6.1 Aβ40 and Aβ42 interact directly. 
10 μM covalently tethered biotinylated Aβ40 or Aβ42 to streptavidin-coated SA chips show 
binding between 10 μM Aβ variants. The sensorgram presents the interaction between 
Aβ40-Aβ42, Aβ42-Aβ42, Aβ40-Aβ40, and the negative control nonspecific binding between 
Aβ42-KAAEAAAKKFFE. 
6.2.2 different molAr Aβ42:Aβ40 rAtios Are structurAlly similAr At beginning of 
AggregAtion process
Because Aβ42 and Aβ40 were found to interact directly, we used NMR to explore 
whether the interactions could influence the conformation of Aβ at different Aβ42:Aβ40 
ratios immediately following their preparation. The peptides were treated according 
to a new protocol designed to yield completely solubilized samples without solvent 
contamination [13]. 15N-labeling of one Aβ alloform at a time allowed us to monitor 
the individual structural behavior of each alloform within the context of different molar 
ratios. The structural fingerprints of pure Aβ40 and Aβ42 peptides by the 15N-1HN 
HSQC spectra are in excellent agreement with data shown in the literature (Figure 
6.2) [27,29]. The spectra of 15N-labeled Aβ42 at different molar ratios do not present 
chemical shift variations, not even for the resonances of the C terminus, which should 
be the most sensitive to even a small change of environment (Figure 6.2b). This 
indicates that the co-presence of the two alloforms has no influence on the structure 
at an atomic level, as expected for the monomeric state. The same is observed for 
Aβ40 (Figure 6.2a). We conclude that samples with different Aβ ratios are structurally 
equivalent to samples of pure individual peptides prior to aggregation. 
6.2.3 fibers formed by different Aβ rAtios hAve similAr morphology And cross-β structure 
Negative stain TEM was used for a morphological characterization of the end states 
of the Aβ aggregation reactions. Upon long term incubation, all Aβ ratios display a similar 
morphology with long, unbranched amyloid fibrils with detectable helicity and uniform 
diameters of 5.4, 10.2, and 16 nm, depending on the number of laterally associated 
protofilaments (Figure 6.3a). At a qualitative level, the fibrillar structure of the (3:7) ratio of 
Aβ42:Aβ40 appeared to be slightly more polymorphic compared with the other ratios.
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Figure 6.2 The monomeric structures of Aβ42:Aβ40 ratios are identical at atomic level. 
Shown is the overlay of the 1H-15N HSQC spectra immediately after sample preparation of 
(a) 15N-labeled Aβ40 in pure Aβ40 sample (black), ratio 1:9(15N) (green) and ratio 3:7(15N) 
(red). (b) 15N-labeled Aβ42 in pure Aβ42 sample (black), ratio 1(15N):9 (red), and ratio 
3(15N):7 (green). For representation purposes and clarity, we have artificially introduced a 
systematic shift of the spectra of the 1:9 and 3:7 Aβ42:Aβ40 ratios.
X-ray fiber diffraction showed that the samples of pure Aβ and mixed ratios all 
exhibit the classic cross-β fiber diffraction patterns described in the literature [30,31], 
showing a strong meridional reflection at 4.7 Å and a major equatorial reflection at 
~10 Å consistent with a cross-β architecture (Figure 6.3b). The patterns arising from 
Aβ40 and Aβ42 fibrils both share the same 9.7-9.8 Å major equatorial reflection, 
which we attribute to the β-sheet spacing perpendicular to the fiber axis. The fiber 
diffraction pattern obtained from Aβ42 fibrils was distinguishable from Aβ40 fibrils 
only by the sharper signals likely to arise from a higher degree of order in the Aβ42 
fibers, whereas the mixtures of the two peptides give rise to patterns that are virtually 
indistinguishable from that of Aβ40. This could be due to the large amount of Aβ40 
relative to Aβ42 such that the signal from Aβ40 dominates the pattern. Although subtle 
differences in the fiber diffraction patterns likely arise from differing degrees of order 
and composition of the samples, the equatorial signal positions and relative intensities 
of signals are largely comparable for all samples (Figure 6.3c).
To confirm structural similarity of fiber architecture of various Aβ ratios at a higher 
resolution, we measured the protection factors of the Aβ peptides by acquiring 15N-1HN 
HSQC spectra for monomeric Aβ40 and Aβ42 after resolubilizing amyloid fibers that 
were subjected to hydrogen-deuterium exchange (HDX) (Figure 6.4). Amide protection 
factors were measured by comparing the amide peak intensities obtained for the 
sample in H2O and the sample in D2O after the exchange period. The backbone 
amide chemical shift data are consistent with those previously reported in acidified 
DMSO-d6 [32], although we observed (partial) overlaps in the cross-peaks of residues 
11/23, 12/18, 13/27, 19/40, and 32/41 for Aβ42. Only residues 11/23 and 13/27 have 
overlapping cross-peaks in the Aβ40 spectrum.
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Figure 6.3 Morphology and detailed structure analysis of fibrils of Aβ42:Aβ40 ratios 
reveals similar structural characteristics. 
(a) TEM images of Aβ ratios obtained upon aggregation for 2 weeks at 25 °C without 
agitation. Top left panel, pure Aβ40; top right panel, ratio 1:9; bottom left panel, ratio 3:7; 
bottom right panel, pure Aβ42. Bar, 200 nm. 
(b) fiber diffraction patterns of Aβ ratios obtained upon aggregation for 4 weeks at 25 °C 
without agitation. Top left panel, pure Aβ40; top right panel, ratio 1:9; bottom left panel, ratio 
3:7; bottom right panel, pure Aβ42. 
(c) overlay showing the normalized x-ray scattering intensity function of D-spacing plotted 
from b.
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Figure 6.4 HSQC spectra obtained after redissolving Aβ fibrils in perdeuterated 
dimethylsulfoxide containing 0.01% deuterated trifluoroacetic acid. 
(a) HSQC spectrum of 15N-labeled monomeric Aβ40 obtained from resolubilized fully protonated 
amyloid fibrils. The cross-peaks of residues 11/23 and 13/27 overlap in the Aβ40 spectrum. 
(b) HSQC spectrum of 15N-labeled monomeric Aβ42 obtained from fully protonated fibrils. 
For Aβ42, there are (partial) overlaps in the cross-peaks of residues 11/23, 12/18, 13/27, 
19/40 and 32/41. The sequence-specific assignment of the peptide backbone amides 
is indicated next to each cross-peak. The presence of the unlabeled Aβ alloform in the 
mixtures does not influence the spectra as expected for monomeric peptides, since the 
cross-peaks of labeled peptides in the 1:9 and 3:7 ratios display identical chemical shifts. 
For the HDX interpretation, the intensities of the peaks are determined by the height of the 
spectral signals.
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The HDX pattern of 15N-labeled Aβ40 for the (1:915N) and (3:715N) ratios and 
for pure Aβ40 fibers shows that the stretches comprising residues 18-22 and 30-
34 are more protected from solvent exchange than the N terminus (Figure 6.5). The 
C-terminal residues 37-40 also appear more accessible to solvent exchange. This 
agrees with earlier observations and proposed models for Aβ40 fibrils [18,33-35]. 
The HDX patterns of 15N-labeled Aβ40, Aβ42, and the ratios showed only small 
differences. Extensive exchange times (up to 672h) (Figure 6.5) of Aβ42 showed no 
noticeable effects in agreement with the suggestion that Aβ42 fibrils are highly resistant 
to solvent exchange [32,36]. The pattern for pure Aβ42 and the (315N:7) and (115N:9) 
ratios is less distinct but indicates a clear distinction between the N- and the C-terminal 
halves with higher protection of the C-terminal half. 
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Figure 6.5 Atomic resolution HDX using NMR reveals that small differences at atomic level 
may be present between fibrillar Aβ ratios. 
The protection factor of each residue is derived from comparing the corresponding peak 
intensities observed under fully protonated conditions to the signal intensities after exchange 
with D2O. The results are shown as bar plots. In these plots no data is available for 
residues 11, 12, 13, 18, 19, 23, 27, 32, 40 and 41 for Aβ42, and 11, 13, 23 and 27 for Aβ40 
due to (partial) overlapping peaks (and therefore ambiguous N-H cross-peak assignments). 
(a) signals for the 15N-labeled Aβ40 alloform in the ratios; 
(b) signals for the 15N-labeled Aβ42 alloform.
We conclude that the architecture of Aβ fibers in pure or mixed form is overall 
indistinguishable both at a macromolecular and high resolution level, although small 
differences at atomic level may be present. As these mature fibrils have been shown 
to have weak toxicity, we will focus on differences in the oligomeric regime.
6.2.4 Aβ40 And Aβ42 Affect AggregAtion Kinetics of the other
To address whether aggregation kinetics are affected by different ratios, we 
monitored the intensity of NMR spectra as a function of time, exploiting the disappearance 
of the resonances due to the increased molecular weight, typical of events in a 
slow exchange regime. We exploited again the possibility of 15N-isotope labeling only 
one of the Aβ alloforms, in combination with 15N-edited filter experiments to monitor 
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the aggregation of both the 15N-labeled and unlabeled peptides simultaneously. This 
experimental setup offers the advantage that the individual Aβ alloforms are selectively 
observed in parallel and within the same sample preparation, thereby circumventing 
any uncertainty that might arise from different sample preparations or peptide batches. 
In all cases, we observed the concomitant disappearance of all peaks according 
to a cooperative behavior along the whole peptide or at least the region of it visible 
in the NMR spectrum. No sufficiently populated lower molecular weight assemblies 
were observed, indicating that Aβ aggregates directly into NMR invisible assemblies 
under these experimental conditions. Due to the long apparent lag phase, we did not 
detect a sigmoidal transition for Aβ40 and the (1:9) ratio over a time scale of 180 h 
(Figure 6.6 a,e,f). In contrast, pure Aβ42 aggregates very rapidly with a sigmoidal 
signal disappearance (Figure 6.6b). Interestingly, the Aβ42 component of the (1:9) ratio 
remains in solution significantly longer in the presence of Aβ40. The kinetics recorded 
for Aβ40 and Aβ42 within the (3:7) ratios with either 15N-labeled Aβ42 or 15N-labeled 
Aβ40 (named (315N:7) and (3:715N), respectively) indicate that Aβ40 remains longer 
in solution compared with Aβ42, which aggregates more rapidly (Figure 6.6 c,d). 
However, the complete loss of signal for Aβ42 in the presence of Aβ40 is delayed 
in comparison with pure Aβ42, suggesting that the shorter Aβ40 alloform reduces 
the aggregation propensity of the longer Aβ42 alloform. To make sure that these 
observations could not be explained as the average of populations containing only 
the same alloforms, we analyzed a (5:5) ratio where 15N-labeled Aβ42 or Aβ40 are 
present in equimolar amounts of the unlabeled alloform (Figure 6.6 g,h). We observed 
a nearly simultaneous disappearance of the signals of Aβ42 and Aβ40, which strongly 
suggests co-aggregation of both peptides into mixed fibers. We conclude that Aβ40 
and Aβ42 mutually influence the aggregation kinetics of the other.
6.2.5 Aβ40 And Aβ42 rAtios both form complex but different ensembles of oligomers
To investigate whether the observed alloform influence on the aggregation arises 
from an impact on the formation of intermediates along the aggregation pathway, 
we followed aggregation of the Aβ mixtures using high molecular weight mass 
spectrometry, a technique that uses high voltages to enable detection of high molecular 
weight species. Because non-covalent complexes disassemble at these voltages, we 
incubated our samples prior to analysis with glutaraldehyde as cross-linking agent. 
The resulting masses reveal various interesting features (Figure 6.7). First, the masses 
of Aβ42 and of the two mixtures are consistently larger than those of Aβ40, in support 
of the hypothesis that there are appreciable populations of oligomers that contain both 
alloforms. Second, early aggregation proceeds through a monomer addition process 
during which oligomers gradually grow by the addition of one monomer at a time. 
Third, in all cases we observed that assemblies accumulate during aggregation, the 
maximum size of which depends on the Aβ42:Aβ40 ratio. At an incubation time of 1 
h, Aβ40 samples contain oligomers with a range of sizes from dimers up to 13-mers. 
As the process continues, larger oligomers are formed and after 6 h of incubation, 
25-mer assemblies are detected together with larger oligomers at apparent molecular 
weights of 186 up to 852 kDa. For (1:9) ratios, we observe formation of much smaller 
oligomers with a maximum of 8-mers and accumulation of larger sized oligomers at 
apparent molecular masses of 171 up to 515 kDa. The (3:7) ratios aggregate in a 
similar manner but share features closer to the pattern observed for Aβ42. No very 
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Figure 6.6 Aβ40 and Aβ42 show different aggregation behavior in different Aβ42:Aβ40 
ratios. 
(a) pure Aβ40 at a concentration of 180 μM does not aggregate within the timeframe 
of data collection. (b) pure Aβ42 at a concentration of 20 μM displays a lag phase 
and a sigmoidal transition from monomeric species into NMR invisible aggregates. (c) 
3:7(15N) ratio, whereby the Aβ sample is composed of 70% 15N-labeled Aβ40, which is 
monitored via HSQC (140 μM Aβ40 monomer concentration) and 30% unlabeled Aβ42 
(at a monomer concentration of 60 μM), which is simultaneously monitored via the amide 
region 15N-filtered one-dimensional NMR spectrum. (d) the 3(15N):7 ratio whereby the Aβ 
sample is composed of 30% 15N-labeled Aβ42 and 70% unlabeled Aβ40. (e), the 1:9(15N) 
ratio with 10% unlabeled Aβ42 (20 μM) and 90% 15N-labeled Aβ40 (180 μM). (f) the 1(15N):9 
ratio with 10% 15N-labeled Aβ42 and 90% unlabeled Aβ40. (g) the 5(15N):5 ratio whereby 
the 15N-labeled Aβ42 and unlabeled Aβ40 are present in equimolar amounts (60 μM of 
each alloform). (h) the 5:5(15N) ratio whereby equimolar amounts (60 μM) of unlabeled 
Aβ42 and 15N-labeled Aβ40 are present. The grey symbols represent Aβ40, and the black 
symbols correspond to Aβ42.
large molecular weight oligomers are observed after 6 h of incubation, presumably 
because they become so large that either they cannot become mobile or are not 
efficiently cross-linked. These results reveal clear differences in the pattern of small 
oligomeric species formed under different ratio conditions, indicating a potential basis 
for the difference in toxic effect [13].
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Figure 6.7 Oligomer formation by Aβ42:Aβ40 ratios shows a monomer addition process 
and a dynamic distribution of oligomeric species. 
Mass spectra of the different ratios with the high molecular weight detection spectra as 
insets whereby the blue trace is t = 1 h, the black trace is t = 3 h, and the red trace is t = 
6 h. (a) pure Aβ40; (b) 1:9 ratio; (c) 3:7 ratio; (d) pure Aβ42. 
6.2.6 differences between Aβ42:Aβ40 rAtios reside Along the AggregAtion pAthwAy
The influence of the Aβ40 and Aβ42 ratios on aggregation kinetics is also evident 
from cross-seeding experiments where sonicated protofibrils were added to monomeric 
solutions of different Aβ42:Aβ40 ratios. Seed preparations were verified by TEM (Figure 
6.8a) and added to freshly prepared monomeric Aβ solutions. The aggregation kinetics 
were followed by in situ thioT fluorescence (Figure 6.8 b-e). Aβ40 aggregation was 
efficiently seeded by Aβ40 seeds and the (1:9) ratio seeds leading to elimination of the 
lag phase (Figure 6.8b). The initial parts of the two curves overlap, indicating that the 
properties of Aβ40 are predominant, also in the (1:9) mixture. Addition of (3:7) seeds 
also induces aggregation, but some lag phase is retained. Addition of pure Aβ42 not 
only does not seed aggregation, but even lengthens the lag phase. Seeding of Aβ40 
therefore appears to proceed in a highly specific manner with preference for the same 
alloform seeds. The (1:9) ratio is seeded by any seed but, as for pure Aβ40, Aβ40 and 
(1:9) seeds have a similar strong seeding effect, whereas Aβ42 and (3:7) seeds have 
a milder effect, which, however, still preferentially selects the same alloform (Figure 
6.8c). In contrast, pure Aβ42 and the (3:7) ratio were equally effectively seeded by any 
Aβ seed, regardless of whether they were formed from Aβ40 or Aβ42 or a mixture 
(Figure 6.8 d,e). Therefore, it appears that Aβ42 monomers have a higher degree of 
plasticity so that they may use a less specific surface as a template, whereas Aβ40 
oligomers have higher selectivity.
The effect of cross-seeding on the disappearance of the NMR signals of the 
different Aβ alloforms was also studied. In these experiments, we limited ourselves 
to the addition of seeds of pure Aβ40 or pure Aβ42 to the preincubated samples 
of which the NMR signals were monitored. In all cases, adding seeds resulted in 
appreciable aggregation irrespectively of the time point at which the addition was 
made. The control experiments were performed without any addition and this ensured 
that the effect is the direct consequence of the addition. Pure Aβ42 monomers could 
be easily seeded by both peptides (Figure 6.9 c,d). Induction of aggregation of Aβ40 
with Aβ40 seeds was also highly efficient (Figure 6.9b), whereas Aβ42 seeds induced 
some initial signal disappearance but with a delayed aggregation (Figure 6.9a). 
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Figure 6.8 Cross-seeding reveals that Aβ42 oligomers show plasticity, whereas Aβ40 
oligomers display a higher selectivity. 
(a) TEM of seed preparations. Seeds were prepared by incubation of 50 μM Aβ ratios 
for 24 h followed by sonication at maximum power for 10 min. From left to right: pure 
Aβ40, ratio 1:9; ratio 3:7, pure Aβ42. Bar, 0.2 μm. Freshly prepared seeds were added 
to monomeric solutions of Aβ42:Aβ40 ratios at final concentrations of 0.5 μM and 25 μM, 
respectively. (b) thioT of Aβ40 monomers seeded with pure Aβ40 seeds; with seeds from 
ratio 1:9, with seeds from ratio 3:7, and with seeds from pure Aβ42. The dashed line 
represents the unseeded Aβ40 control. (c) thioT of ratio 1:9 monomers seeded with Aβ 
ratios as compared with the non-seeded aggregation curve. (d) thioT of ratio 3:7 monomers 
seeded with Aβ ratios as compared with the non-seeded aggregation curve (dashed line). 
(e) thioT of Aβ42 monomers seeded with Aβ ratios in comparison with the non-seeded 
sample (dashed line). 
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Figure 6.9 Cross-seeding was monitored by NMR by recording one-dimensional proton 
spectra as a function of time
(a,b) with unlabeled pure Aβ40 and (c,d) pure Aβ42 monomers using preformed Aβ40 seeds 
(b,d) and Aβ42 seeds (a,c). Pure Aβ40 samples (grey) were prepared at a concentration 
of 180 μM, whereas pure Aβ42 samples (black) were at a concentration of 20 μM. The 
addition of 10% (v/v) of a 50 μM (monomeric equivalent) seed preparation was added at 
the time points indicated by the arrow.
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In the (1:9) and (3:7) ratios, Aβ40 seeds could efficiently induce aggregation of the 
two Aβ alloforms in the mixtures, while the Aβ42 seeds efficiently seeded the Aβ42 
alloform, whereas the Aβ40 alloform lags behind in the aggregation. This implies that 
the presence of Aβ42 monomers in the ratios influences the behavior of the Aβ40 
alloform. Overall, it is observed that the Aβ40 seeds can efficiently induce aggregation 
of Aβ samples, whereas the Aβ40 alloform responds less efficiently to the Aβ42 
seeds (Figure 6.10 and Table 6.1). These data show a genuine difference between 
the two peptides at the level of the oligomeric state. They reveal that even a relatively 
small increase in Aβ42 in the mixture confers aggregation properties to Aβ40 that are 
markedly more similar to pure Aβ42.
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Figure 6.10 Cross-seeding was monitored by 15N-filtered and 15N-edited NMR experiments.
with Aβ samples composed of the (a,b) Aβ42:Aβ40 ratio 1(15N):9, whereby 20 μM 
15N-labeled Aβ42 is present with 180 μM unlabeled Aβ40 and the (c,d) Aβ42:Aβ40 ratio 
3(15N):7 with 60 μM 15N-labeled Aβ42 and 140 μM unlabeled Aβ40. The addition of 10% 
(v/v) of a 50 μM (monomeric equivalent) preparation of preformed Aβ40 seeds (b,d) and 
Aβ42 seeds (a,c) is indicated by the arrows.
seeds Aβ42 Aβ40Monomeric sample
Efficiency of seeding monitored by NMR
+++ NA
+++ NA
+++ +++
+++ +
Aβ42:Aβ40 3:7
pure Aβ42
Aβ42:Aβ40 1:9
pure Aβ40
+++ +++
+++ +
NA +++
NA +
Aβ42
Aβ40
Aβ42
Aβ40
Aβ42
Aβ40
Aβ42
Aβ40
Table 6.1 Efficiency of cross-seeding on Aβ alloforms as monitored by isotope-labeled 
NMR
NA not applicable, + seeding induces aggregation, +++ seeding induces aggregation very 
efficiently.
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6.3 discussion
Although previous structural studies have mostly focused on pure Aβ alloforms and 
the identification of a single oligomeric species, the present work aims to understand 
the determinants of the toxicity of different Aβ42:Aβ40 ratios. We demonstrate by 
independent evidence from mass spec, NMR, and SPR that the two peptides interact, 
although recognition between the same alloforms is preferred over interactions between 
different ones. We therefore expect that the populations of the two peptides in the 
aggregates will be mixed. This explains and expands previous data [23,25,27] that 
indicate that Aβ40 and Aβ42 influence their respective aggregation properties.
To understand which step along the aggregation pathway is responsible for this 
effect, we compared the structures and morphologies of all the species formed. We 
show that the initial monomeric and final fibrillar states do not differ to a large extent. 
NMR analysis of freshly prepared samples at different Aβ42:Aβ40 ratios conclusively 
reveals the presence of predominant monomeric species that lack a regular and well 
defined structure. Therefore, at this stage, the peptides are not affected by the presence 
of the other alloform. Likewise, we do not observe appreciable differences between 
the mature fibrillar states by TEM, HDX, and fiber diffraction: fibers formed during long 
incubation times are virtually identical. The absence of significant differences in the 
start and end points of Aβ fibrillation directed our focus to the formation of transient 
oligomeric intermediates. Previous data had indicated differences in the protofibrillar 
morphologies and FTIR data following short term incubation, which, together with 
the present data, underline the importance of the aggregation pathway and of the 
dynamics of the oligomeric state [13,37,38].
We observed subtle but clear differences between the different Aβ ratios along 
the aggregation pathway. NMR experiments visualizing the spontaneous aggregation 
(Figure 6.6) showed that the presence of monomeric Aβ40 slows down the aggregation 
kinetics of Aβ42, increasing the time frame that soluble forms are found in solution 
for any peptide ratio. Vice versa Aβ42 stimulates Aβ40 aggregation as revealed 
by comparing the (3:7) and (1:9) ratios with pure Aβ40. This is compatible with the 
view that Aβ42 drives aggregation and acts as a template by lowering the kinetic 
barriers that prevent Aβ40 from aggregating [15,25,39]. Aβ40 potentially delays Aβ42 
aggregation through “non-productive” interactions. Although these conclusions are in 
agreement with previous reports [25,27,39], our cross-seeding data suggest that 
Aβ40 monomers specifically require Aβ40 oligomers to induce growth of mature fibrils, 
whereas Aβ42 monomers are less selective and are stimulated by all types of seeds.
It might be argued that there is an apparent discrepancy between the progressive 
Aβ aggregation as monitored by NMR (Figure 6.6) and the cross-seeding data (Figure 
6.8, 6.7, 6.8). By NMR, we observe that Aβ42 stimulates Aβ40 to aggregate while 
Aβ40 simultaneously delays Aβ42 aggregation. Vice versa, the cross-seeding data 
reveal that monomeric Aβ40 is not efficiently seeded by sonicated Aβ42 protofibrils. 
It is reasonable to explain this discrepancy by assuming that the oligomers formed 
during the aggregation process have features that are distinct from the sonicated 
protofibrillar species (seeds) that may have undergone advanced structural maturation. 
For pure Aβ42, these seeds would not be the optimal templates to directly incorporate 
Aβ40 monomers and perhaps even entail a conformational restructuring to lead to 
productive aggregation. We cannot rule out the possibility that monomeric Aβ40 
105
Structural basis of Aβ40:Aβ42 ratios
could be able to resolubilize Aβ42 seeds, thereby bringing Aβ42 into solution and 
promoting in this way productive aggregation, as hinted by Yan and Wang [27]. 
Because our observations with high molecular weight mass spectrometry underline 
that the aggregation process proceeds through a monomer addition mechanism, 
the dynamic interplay (productive and non-productive) of monomeric Aβ with soluble 
Aβ assemblies seems appropriate to explain toxicity of the Aβ42:Aβ40 ratios. This 
relevance of monomer addition processes for neurotoxicity was recently described by 
Jan and colleagues for pure Aβ42 aggregation [37]. Thus, the modulation of the Aβ 
oligomer formation by the Aβ42:Aβ40 ratio adds to the cause of neurotoxicity and the 
Alzheimer disease pathology.
In conclusion, our work indicates that the Aβ42:Aβ40 ratio behavior cannot be 
simply interpreted by stating that Aβ42 can induce Aβ40 aggregation while at the 
same time, Aβ40 can prevent or delay Aβ42 aggregation. Rather than the morphology 
of the amyloid fibrils, the Aβ42:Aβ40 ratio modulates the Aβ oligomer formation. Our 
data indicate that neurotoxicity is more likely to be explained by the dynamic nature 
of the ongoing Aβ aggregation rather than by the prevailing view that Aβ toxicity 
is associated with a distinct assembly. A change in the Aβ42:Aβ40 ratio induces 
differences in conformational plasticity of the oligomeric peptide mixtures and the 
pattern of detectable oligomeric species. That the oligomer formation along the amyloid 
assembly pathway is affected by the different Aβ ratios emphasizes the necessity to 
further expand our understanding of the exact compositional, temporal, and structural 
properties of the homo- and hetero-oligomers. The implications of this finding for 
Alzheimer disease therapy are fundamental: the results imply that it is less important 
to focus on lowering the total amyloid burden in patients, although it appears crucial 
to affect the relative ratios of the peptides.
6.4 experimentAl procedures
6.4.1 prepArAtion of Aβ peptide rAtios
The Aβ40 and Aβ42 peptides and their uniformly 15N-labeled variants were 
purchased from rPeptide. The Aβ40 and Aβ42 peptides were combined in monomeric 
form in the desired ratios as described in detail in chapter 2. In brief, Aβ peptides were 
dissolved in HFIP, Aβ42 and Aβ40 were then mixed in molar ratios of 1:9 and 3:7 
together with pure Aβ42 and Aβ40 samples, and after evaporation of HFIP, they were 
redissolved in DMSO. The peptide was passed through a desalting column and eluted 
in a 50mM Tris, 1mM EDTA buffer, pH 7.5. Peptide concentrations were measured 
by the Bradford assay or by UV absorbance at 280 nm (ε280=1490 M-1cm-1). The 
samples were kept on ice until required, with a maximum lag time of 30 min.
6.4.2 spr AnAlysis
N-terminally labeled biotin-linker chain Aβ40 (biotin-Aβ40) and biotin-Aβ42 and 
Aβ40, Aβ42, and a non-assembling peptide with the sequence KAAEAAAKKFFE 
[40] were treated as described above except using a 10mM HEPES, 100mM NaCl, 
1mM EDTA, and 0.05mM NaN3, pH7.4 buffer, and the peptide was eluted using 
a 2-ml Zeba spin column for buffer exchange. SPR measurements were carried 
out on a Biacore® 2000 system using carboxymethylated dextran preimmobilized 
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with streptavidin sensor chips. A volume of 150 μl of biotin-Aβ40 or biotin-Aβ42 was 
immobilized to the sensor surface at a concentration of 10 μM at a flow rate of 30 
μl min-1. Concentrations of 10 μM of Aβ40, Aβ42 or KAAEAAAKKFFE were injected 
at 3 μl min-1. Measurements were done in triplicate and analyzed with the built-in 
BIAevaluation software. Curve fitting relied on the Marquardt-Levenberg algorithm, 
and the change in response was fitted to the binding isotherm Req = Rmax[A]/
((koff/kon)+[A]), where Req is the equilibrium response, Rmax is the maximum signal 
response, [A] is the analyte concentration, koff is the dissociation rate constant, and 
kon is the association rate constant. 
6.4.3 fiber diffrAction
Samples of mature fibers were aligned by suspending a droplet of solution at 4 
mg/ml between two waxtipped capillaries positioned end-to-end. Fibers were mounted 
on a goniometer head, and x-ray diffraction data were collected using a Rigaku CuKα 
rotating anode with a wavelength of 1.5419 Å and RAxis IV++ detector. Specimen to 
detector distances were 160 and 250 mm with an exposure time of 10 min. Diffraction 
patterns were examined in CLEARER [41]. For additional inspection, meridional, and 
equatorial axes signals were sampled through an angular search width of 60°, 
exported as a function of distance (pixels), and plotted using Braggs Law. 
6.4.4 tem AnAlysis
Aliquots of 4 μl Aβ were adsorbed for 30 s onto freshly prepared carbon-coated 
and glow-discharged copper grids, washed briefly with milli-Q water, and subsequently 
stained with 1% (w/v) uranyl acetate for 30 s. Samples were examined with a JEOL 
1200 transmission electron microscope operating at 100 KV. 
6.4.5 cross-seeding monitored with thiot
Aliquots (100 μl) of each Aβ ratio at 50 μM were incubated at 25 °C in 50mM Tris, 
1 mM EDTA, pH 7.5. After 24 h incubation these samples were sonicated at 4 °C 
for 10 min at maximum power and mixed with freshly and simultaneously prepared 
Aβ ratios to induce (cross)-seeding of Aβ aggregation. Final concentrations in these 
mixtures were 0.5 μM of sonicated Aβ and 25 μM of monomeric Aβ. The seed 
preparations were examined by TEM. 
6.4.6 thiot fluorescence
A peptide samples of 25 μM were incubated with 12 μM thioflavin T (thioT) in a 
total volume of 150 μl. Fibrillization kinetics were followed using a Fluostar OPTIMA 
fluorescence plate reader using 440 nm excitation wavelength and an emission 
wavelength of 480 nm. Readings were recorded in triplicate every 10 min for a period 
of 24 h. 
6.4.7 high moleculAr weight ms
High mass measurements were performed at CovalX AG using an ABI 4800 
MALDI TOF mass spectrometer retrofitted with CovalX HM2 TUVO high mass system. 
A phosphate-buffered saline buffer was used to prepare the Aβ ratios, which were 
subjected to cross-linking with gluteraldehyde at specific time points. Each sample was 
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mixed with sinapinic acid matrix (10 mg ml-1) in acetonitrile/water (1:1, v/v), TFA 0.1% 
and spotted on the MALDI plate. High-mass MALDI TOF MS analysis was performed 
using standard nitrogen laser and focusing on different mass ranges from 8 to 1000 
kDa in linear and positive mode and at a gain voltage of 3.14 kV and an acceleration 
voltage of 20 kV for HM2 High-Mass detection. The instrument was calibrated using 
insulin, BSA, and IgG. The analysis was repeated in triplicate.
6.4.8 solution nmr
Aβ samples for NMR studies varied between 20 and 200 μM (monomer 
concentration) in 50mM Tris-HCl, 1mM EDTA at pH 7.5, supplemented with 10% (v/v) 
D2O. The experiments were performed at 25 °C either on a Bruker Avance (equipped 
with cryoprobe) or on a Varian Inova spectrometer both operating at 14.1 Tesla (600 
MHz). 15N sofast heteronuclear single quantum coherence (HSQC) spectra were each 
collected over 30 min to monitor aggregation. 15N NOESY-HSQC and 1H,1H TOCSY 
experiments were recorded at 5 °C to obtain sequence specific 1HN,15N assignments 
to identify the HSQC peaks. A combination of 15N-edited and 15N-filtered experiments 
[42] acquired on samples containing uniformly 15N-labeled and unlabeled Aβ peptides 
at different ratios was used to selectively monitor Aβ42 and Aβ40 in solution. Protection 
factors of mature Aβ fibers were measured by comparing the amide peak intensities 
obtained for Aβ samples incubated in H2O or in D2O after for a period of 672 h 
to allow amide exchange. The fibers were collected by centrifugation, washed, and 
incubated in D2O at 25 °C for 48 h, flash-frozen to quench the hydrogen-deuterium 
exchange (HDX), lyophilized, and redissolved in 100% DMSO-d6 acidified with 0.1% 
(v/v) trifluoroacetic acid for 30 s, followed by a 10-fold dilution with perdeuterated 
DMSO [32]. Amide exchange was measured by collecting two-dimensional 15N-1H 
HSQC spectra in comparison to control samples that were incubated in H2O. The 
15N-1H HSQC cross-peak assignment was confirmed with a 15N-resolved NOESY 
experiment.
6.4.9 cross-seeding monitored viA nmr
Seeds were prepared of pure Aβ40 or pure Aβ42 as described above. An aliquot 
of 30 μl seeds (50 μM equivalent monomeric concentration) was mixed with 330 μl of 
the corresponding Aβ samples that were preincubated in an NMR tube, whereas the 
non-seeded signals were monitored. 15N-edited and 15N-filtered spectra [42] were 
acquired as a function of time to simultaneously monitor both Aβ alloforms in the 1:9 
and 3:7 ratios, whereby Aβ42 was 15N-labeled and Aβ40 was unlabeled. Only one-
dimensional proton spectra were recorded as a function of time for the pure Aβ40 or 
pure Aβ42 unlabeled samples.
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The mechanisms by which mutations in the presenilins or the amyloid precursor 
protein genes cause familial Alzheimer disease are controversial. Those mutations 
increase the release of Aβ42 relative to Aβ40 by an unknown, possibly gain-of-toxic- 
function, mechanism. However, many PS mutations paradoxically impair γ-secretase 
and ‘loss-of-function’ mechanisms have also been postulated. Here, we use kinetic 
studies to demonstrate that mutations related to familial Alzheimer disease affect Aβ 
generation via three different mechanisms, resulting in qualitative changes in the Aβ 
profiles, which are not limited to Aβ42. Loss of ε-cleavage function is not generally 
observed among the mutations related to familial Alzheimer disease. On the other hand, 
γ-secretase inhibitors used in the clinic appear to block the initial ε-cleavage step, but 
unexpectedly affect more selectively Notch than APP processing, while modulators 
act as activators of the carboxypeptidase-like (γ) activity. Overall, this chapter provides 
a coherent explanation for the effect of different FAD mutations, demonstrating the 
importance of qualitative rather than quantitative changes in the Aβ products, and 
suggest fundamental improvements for current drug development efforts.
the meChAnism of γ-seCretAse dysfunCtion in 
fAmiliAl Alzheimer diseAse.
The results described in this chapter have been published in:
Chávez-Gutiérrez L, Bammens L, Benilova I, Vandersteen A, Benurwar M, Borgers M, Lismont 
S, Zhou L, Van Cleynenbruegel S, Esselmann H, Wiltfang J, Serneels L, Karran E, Gijsen H, 
Schymkowitz J, Rousseau F, Broersen K, and De Strooper B (2012). EMBO J., 31:2261-2274.
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7.1 introduction
A central and still unresolved debate with important therapeutic implications in the 
field of Alzheimer disease research revolves around the question of how mutations in 
presenilin (PS), the catalytic core of the γ-secretases [1], cause disease. More than 
150 familial Alzheimer disease mutations have been mapped to the genes encoding 
PS1 or PS2 (http://www.molgen.ua.ac.be/ADMutations), pointing to a crucial role of 
the γ-secretase complexes in the disease. As a rule, PS mutations leading to familial 
Alzheimer disease increase the relative amount of Aβ42 versus Aβ40 in in vivo and 
in vitro paradigms [2-5], which led to propose that PS mutations act via a toxic gain-
of-function mechanism. However, more refined analyses have made clear that the 
change in Aβ ratio does not necessarily reflect an increase in Aβ42 production, but 
can also be the consequence of a decrease in Aβ40 levels. Actually, many mutations 
reduce one or both products of the γ-secretase in steady-state conditions [6-10]. 
These observations have led to an opposite hypothesis in which those mutations in 
PS cause dementia through a loss-of-function of γ-secretase, resulting in decreased 
proteolytic processing of different substrates and compromising intracellular signalling 
pathways [8,11]. In fact, the current model for γ-secretase successive proteolysis 
[12] may link a loss of function to misprocessing of APP and abnormal generation 
of Aβ [13,14]. However, the fact that less efficient proteolytic processing of APP may 
lead to alterations in the Aβ profile and Alzheimer disease is contraintuitive in the light 
of the classical amyloid hypothesis, which stresses the importance of quantitative 
accumulation of either total Aβ or Aβ42 [15]. Moreover, a recent report has shown 
that reduced γ-secretase activity does not increase the production (accumulation) of 
longer Aβ peptides [16].
Importantly, the biophysical and biochemical properties of Aβ vary strongly with its 
length. Whereas Aβ40 appears to act protectively in various toxicity assays [17,18], 
longer Aβ peptides promote aggregation and neurotoxicity [19]. In fact, it has been 
suggested that the ratio (Aβ42:Aβ40) is more important than the absolute amounts of 
Aβ42 [20]. Similar to Aβ42, Aβ43 is potently amyloidogenic and neurotoxic [21]. Thus, 
qualitative changes in Aβ [13,14] are at least as important as the quantitative alterations 
proposed by the original amyloid hypothesis [15].
In contrast, the ‘simple’ loss-of-function hypothesis proposes that Aβ alterations 
are only an epiphenomenon of the PS mutations, and that inefficient cleavage of 
membrane proteins by γ-secretase complexes is the fundamental upstream cause of 
the neurodegenerative process [8,11]. 
On the other hand, recent observations in patients suffering from familial acne 
inversa in China [22] and independently in Great Britain [23] raise doubts about the 
validity of the ‘simple’ γ-secretase loss-of-function hypothesis. This condition appears 
to be associated with the haploinsufficiency of γ-secretase subunit genes (Nicastrin, 
Pen2) and most likely involves a deficiency in Notch cell signalling. However, none of 
the acne-affected individuals had Alzheimer disease symptoms. These observations 
indicate that reduced γ-secretase activity is not sufficient to cause Alzheimer disease, 
although further follow-up studies in these families are needed. Alternative mechanisms 
for the loss-of-function hypothesis have been proposed over the years (for an 
overview, see [24]). For instance, several reports indicate alterations in subcellular 
trafficking or turnover of selected membrane proteins [25,26], defective acidification of 
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phagolysosomal compartments [27] or disturbances in cellular Ca2+ homeostasis [28]
(reviewed in [29]) associated to PS loss of function. However, these hypotheses do 
not provide an explanation for the mutations in APP and also do not take into account 
that all tested mutations related to familial Alzheimer disease affect the prime function 
of PS, which is proteolysis.
From this brief overview it is clear that further in-depth investigation of the effects 
of clinical mutations on the function and structure of γ-secretase is required, especially 
given the relevance of such analysis for further drug development.
Addressing this important question implies multidisciplinary approaches, in which 
deep structural and functional studies dissect the mechanisms of the mutations linked 
to hereditary Alzheimer disease. On the other hand, dissecting γ-secretase activity 
by kinetic analysis can yield important mechanistic insights into how those mutations 
regulate enzyme function. In vitro reconstitution of γ-secretase activity has provided 
initial insights into the enzymatic mechanism. Ihara and co-workers have provided 
compelling evidence for sequential processing of substrates by γ-secretase [30-33]. 
Their model proposes that APP can be sequentially cut along two production lines: 
Aβ49>Aβ46>Aβ43>Aβ40 and Aβ48>Aβ45>Aβ42>Aβ38 (Figure 7.1a) In agreement, it 
has been shown that the endoproteolytic cleavage site determines the product line 
preference of the γ-secretase in vivo [34], and therefore the series of Aβ products. 
In the current study, we used a cell-free assay to analyse how clinical mutations 
in PS1, PS2 and APP affect the activity of the γ-secretase complex. Dissection of 
the different activities of the γ-secretase complex allowed us to reach a coherent 
explanation for the effects of the tested mutations linked to familial Alzheimer disease. 
We coupled kinetic studies of the endopeptidase activity to the analysis of the 
carboxypeptidase-like cleavage to show that these mutations have widely variable 
effects on the efficiency of the first cleavage, which releases the intracellular signalling 
domains of substrates. This observation rules out an impairment in the endopeptidase 
(ε) mechanism as necessary for the pathological effect of these mutations. In contrast, 
all mutations in PS and APP linked to hereditary Alzheimer disease alter the processing 
of APP, regulating the generation of Aβ by three different mechanisms.
7.2 results
7.2.1 ps1 mutAtions do not consistently impAir the endopeptidAse Activity of the γ-secretAse 
We analysed the effects of mutations PS1-Y115H, - M139V, -L166P, -I213T, -G384A 
and delta-exon9 (DE9) on the kinetic constants of the ε-cleavage of APP, Notch, ErB4 
and N-cadherin substrates. The selected mutations are spread throughout the PS1 
primary sequence (Figure 7.1b). Importantly, blockage by the transition state analogue 
L-685,458 (TSA, InhX) demonstrated the specificity of the assays (Figure 7.2). To 
determine the kinetic constants of wt and mutated γ-secretase complexes, we used 
CHAPSO-extracted membranes from Ps1/2-/-, rescued with wt or mutant PS1 as 
source of enzyme (Figure 7.1c) and purified APP C99-3XFlag, Notch-3XFlag, Erb4-
3XFlag or N-Cadherin-3XFlag as substrates. The kinetic data fit the Michaelis-Menten 
reaction curves (Figure 7.1 d,f), and Km (affinity constant) as well as Vmax (maximal 
velocity) were determined (Table 7.1). Since γ-secretase activities are normalized to 
enzyme levels, Vmax can be taken as kcat and enzymatic efficiencies calculated as 
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kcat/Km. The results reveal diverse effects of the PS1 mutations on this important kinetic 
parameter. Y115H, L166P and G384A mutants decrease γ-secretase efficiencies by 
75% for both APP and Notch, while I213T and DE9 only affect APP, and M139V does 
not show any effect on the ε-cleavage (Figure 7.1e). Moreover, PS1 mutations that do 
not affect Notch endoproteolysis do not impair ErB4 cleavage either, while only the 
M139V significantly increases the processing of N-cadherin (Figure 7.1g). Thus, the 
tested FAD-PS1 mutations have no consistent inhibitory effect on the endoproteolytic 
cleavage of γ-secretase substrates, indicating that reduced release of intracellular 
domains and signalling cannot explain their Alzheimer disease-causing effects.
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Figure 7.1 FAD–PS1 mutations do not consistently decrease the enzymatic efficiency of 
the endopeptidase cleavage. 
(a,b) Schematic overviews of APP processing and location of FAD–PS1 mutations used 
in the current study. (c) Expression levels of Nct, PS1–NTF, PS1–CTF and Pen-2 in Ps1/2/ 
mEFs transduced with human wt or FAD–PS1 mutants using a replication-defective 
recombinant retroviral expression system and selected with puromycin (5 μg ml-1). Western 
blotting and densitometric analysis of the CHAPSO-solubilized membrane proteins from 
the different PS1 cell lines indicate that wt and mutant PS1 rescued γ-secretase complex 
to similar extents. In order to determine specific activities for the wt or FAD complexes, 
γ-secretase activities were normalized to PS CTF fragment levels or full-length PS1 levels for 
the DE9 mutant. (d) Kinetic curves for wt and PS1–FAD mutants using purified APP-C99-
3XFLAG or Notch- 3XFLAG substrates (mean±s.e.) or (f) ErB4-3XFLAG and N-Cadherin-
3XFLAG substrates (mean±s.d.). Detergent-extracted membranes were incubated in 0.25% 
CHAPSO reaction buffer with varying concentrations of purified substrate for 4 h at 37 
°C. In vitro generated ICD-3XFLAG were analysed by quantitative western blot analysis. 
(e) FAD–PS1 ε-enzymatic efficiencies for APP-C99 and Notch substrates (mean±s.e.). 
Enzymatic efficiencies unequivocally demonstrate that loss of function at the ε-cleavage 
is not a constant among PS1 mutations. (g) FAD–PS1 mutations that did not affect the 
generation of NICD did not change significantly the processing of ErB4 (mean±s.d.) 
either. In contrast, N-Cadherin processing was significantly upregulated by the M139V 
(mean±s.d.). (e,g) Experiments were repeated 3–5 times. Statistical significance of the data 
was tested with one-way analysis of variance (ANOVA) and Dunnett’s post test, taking the 
corresponding WT efficiency as control group, *p<0.05.
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Figure 7.2 In vitro generation of ICD products from APPC99, Notch, ErB4 and N-Cadherin 
is γ-secretase dependent. 
In vitro activity assays using CHAPSO extracted membranes from (a) Ps1/2-/- mEFs stably 
transduced with human wt or FAD PS1 mutants and purified substrates-3XFlag. Substrate 
concentrations: 1,125 μM APP-C99 or 2 μM for the other substrates. (b) Ps1/2-/- mEFs 
stably transduced with human wt PS1 and purified wt- or FAD-APP-C99-3XFlag. Addition 
of the transition state analog inhibitor L-685,458 demonstrates that ICD products are 
generated in a γ-secretase dependent manner.
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Table 7.1 Kinetic parameters for human PS1 γ-secretase complexes using APP-C99, 
Notch, ErB4 or N-Cadherin as substrates
Kinetic values are derived from the curves displayed in Figure 7.1 and were determined by 
nonlinear curve-fitting using GraphPad Prism4 software. * Significant changes according 
to the 95% CI (p<0.05). In vitro activity assays were performed using CHAPSO-extracted 
membranes from PS1/2-/- mEFS stably transduced with human wt or FAD PS1 mutants 
and purified substrates-3XFlag, n≥3.
7.2.2 ps mutAtions impAir the fourth γ-secretAse cleAvAge in both product lines 
Next, we asked whether PS1 mutations lead to APP misprocessing at the γ-cleavage 
sites. We use Ihara’s model (see Introduction) for further description of our work since 
it explains very well our observations. Kinetic analysis of the carboxypeptidase-like 
activity is challenging to perform since controlling substrate concentrations, that is, 
the intermediary Aβ products, is experimentally not possible yet. Nevertheless, we 
measured two γ-products in each production line: Aβ43, Aβ42, Aβ40 and Aβ38 
(Figure 7.1a) at saturating APP-substrate concentration. Thus, substrates (Aβ43 and 
Aβ42) and products (Aβ40 and Aβ38) of the fourth γ-secretase cleavage in both 
pathways are analysed and provide a relative number for the γ-cleavage efficiency. 
Importantly, as some of the clinical mutants affect the ε-cleavage, we normalized the 
Aβ product levels (Aβ38, Aβ40, Aβ42 or Aβ43) towards total AICD (Figure 7.3 a,b). 
AICD reflects the total initial Aβ substrate (Aβ49 + Aβ48) produced and processed in 
each reaction. Low Aβ40 and Aβ38 levels and high, long Aβ levels (>Aβ42) are found 
in all the mutations linked to familial Alzheimer disease tested, including the M139V, 
which does not affect the ε-efficiency. Interestingly, the M139V mutation affects the 
processing of APP only at the level of Aβ, indicating that endo- and carboxypeptidase-
like activities of the γ-secretase can be dissociated.
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Total ‘secreted’ Aβ, defined as the sum of Aβ38, Aβ40, Aβ42 and Aβ43, decreases 
significantly in the Y115H, L166P, DE9 and G384A mutations (Figure 7.3b), implying 
the concomitant accumulation of longer Aβ precursors generated in cycles 2 and 
3. Qualitative analysis of the Aβ profiles in urea-based SDS PAGE confirmed this 
observation (Figure 7.3c). We finally determine product:substrate ratios for the fourth 
enzymatic turnover (Aβ38:Aβ42 and Aβ40:Aβ43) (Figure 7.3d), which demonstrates 
that the PS1 mutations investigated here dramatically impair the fourth γ-secretase 
cleavage in both product lines. Our data imply that PS1 mutations cause Alzheimer 
disease by qualitative shifts in Aβ profiles and not by general loss of function of the 
enzyme complex [8,14]. The dysfunction at the carboxypeptidase-like activity of the 
complex not only explains the widely documented increase of the Aβ42:Aβ40 ratio, 
but also suggests a pathological relevance of an increase in Aβ43, which has been 
reported recently in vivo with the PS-R278I [21].
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Figure 7.3 FAD–PS1 mutations impair the fourth enzymatic turnover. AICD levels (moles 
per min) generated by the wt or FAD mutant complexes 
(a) were used to normalize Aβ products (moles per min) in order to determine accurately Aβ 
generation relative to C99 substrate. Aβ profiles (b) thus represent Aβ products corrected for 
the initial endoprotease activities, plotted as percentage of the wt Aβ products (mean±s.e.). 
Soluble Aβ (sum of Aβ38, Aβ40, Aβ42 and Aβ43 peptides) gives information about the 
efficiency of the γ-cleavages: lower levels (<100%, grey box) suggest that longer peptides 
(>Aβ43) accumulate in the reactions. (c) In agreement with the ELISA quantifications, total 
Aβ analysed in urea-based gels show increments in Aβ42 and Aβ43, and reductions in 
Aβ40 and Aβ38 in FAD–PS1 mutations, relative to wt. (*) Indicates a non product band that 
is present in the C99 substrate. (d) Aβ product:substrate ratios determined in vitro for the 
FAD–PS1 mutations show an impairment at the fourth γ-secretase turnover (mean±s.e.). 
Experiments in (b) and (d) were repeated 4-6 times. Statistical significance of the data 
tested with one-way ANOVA and Dunnett’s post test taking the corresponding WT as 
control group; *p<0.05, **p<0.01. (e) Aβ product:substrate ratios determined in vivo confirm 
impairment at the fourth enzymatic cycle: wt or FAD–PS1 mEF cell lines were transiently 
transduced with APPswe, extracellular media collected at 24 h after infection and sAβ 
measured by ELISA (mean±s.e.). Statistical significance: n=4, ANOVA and Dunnett’s post 
test, **p<0.01.
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In order to confirm our in vitro data, mouse embryonic fibroblasts (MEFs) derived 
from Ps1/2-/- mice [35] rescued with human WT- or mutant-PS1 were transiently 
transduced with APPsw. Secreted Aβ levels (sAβ) were quantified by ELISA. Figure 
7.3e shows drastic reductions in the Aβ38:Aβ42 and Aβ40:Aβ43 ratios for all PS1 
mutations, confirming that the fourth enzymatic turnover of the γ-secretase is actually 
impaired in cells (native γ-secretase conditions). To investigate whether PS2 mutations 
also affect the fourth enzymatic turn-over of the γ-secretase, we performed kinetic 
analyses with human WT-PS2 or FAD N141I-PS2 mutant. The effect of the mutation 
on the endopeptidase efficiency of the γ-secretase complex does not reach statistical 
significance (Figure 7.4a) (mean±s.e.: 100±39.9, n=4 or 46.6±3.9, n=3 for WT- or 
FAD N141I-PS2, respectively, two-tailed t-test, p=0.3). Although we cannot discard 
that this difference is biologically meaningful, the effect on the fourth catalytic cycle 
is unequivocal. In particular, the Aβ40 product was decreased to undetectable levels 
(Figure 7.4b). Similar to the mutations in PS1, the N141I–PS2 reduces the Aβ38:Aβ42 
and Aβ40:Aβ43 ratios (Figure 7.4c), confirming an impairment in the carboxypeptidase-
like activity.
Since high Aβ42 and Aβ43 (substrates in this cycle) accumulate in vitro or are 
released in vivo, we speculate that FAD-PS mutations promote a premature release 
of the Aβ43:Aβ42 peptides.
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Figure 7.4 FAD–PS2 N141I impairs the fourth enzymatic turnover. 
(a) Kinetic curves for wt and PS2–FAD N141I mutant using purified APP-C99-3XFLAG 
as substrate (mean±s.e.). (b) Aβ profiles represent Aβ products corrected for the initial 
endoprotease activities, plotted as % of the wt Aβ products (mean±s.e.). Soluble Aβ (sum of 
Aβ38, Aβ40, Aβ42 and Aβ43 peptides) suggests accumulation of longer peptides (>Aβ43) 
in the mutant reactions. (c) Aβ product/substrate ratios determined in vitro for the FAD– PS2 
mutation show an impairment at the fourth γ-secretase turnover (mean±s.e.). In (b) and (c) 
statistical significance (two tailed t-test) is indicated by **p<0.005 and ***p<0.001. Note that 
N141I abolishes Aβ40 generation.
7.2.3 App mutAtions chAnge the product line preference of the γ-secretAse
We then asked whether similar mechanisms could explain the effect of mutations in 
the APP substrate. The tested mutations are located close to the γ-secretase cleavage 
site, that is, T43I, V44A, I45T, V46F and V46I (Figure 7.5a) and all produce wild-type 
Aβ38, Aβ40, Aβ42 and Aβ43 peptides, except for the T43I mutation. Kinetic analyses 
of the ε-cleavage show that APP-T43I, V44A and I45T mutants produce less AICD per 
mol mutant APP compared to wt substrate, while the other mutations do not affect the 
ε-enzymatic efficiency (Figure 7.5 b,c). In order to analyse accurately the Aβ profiles 
from wt and disease-related substrates, Aβ levels were normalized to the amount 
of AICD generated in the reaction. FAD Aβ levels, corrected for the initial amounts 
of substrates, were then plotted as a percentage of the wt enzyme (Figure 7.5d). 
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Figure 7.5 FAD substrate mutations shift APP processing towards the Aβ38 product line. 
(a) Kinetic curves for the ε-processing of APP. Detergent-extracted membranes from Ps1/2-
/- mEFs rescued with human wt PS1 were incubated in 0.25% CHAPSO reaction buffer, 
with varying concentrations of purified wt or FAD–APP substrates. AICD-3XFLAG levels 
were analysed by quantitative western blot analysis. (b) Enzymatic efficiencies for FAD–
APP-C99 substrates (mean±s.e.) prove that AICD generation is affected in three out of 
five FAD-mutant substrates. (c) FAD Aβ product profiles suggest consistent increments in 
Aβ42 and Aβ38. Soluble Aβ levels (sum of Aβ38, Aβ40, Aβ42 and Aβ43 peptides) suggest 
accumulations of longer Aβ peptides in the γ-processing of the V44A and I45T mutants. The 
T43I mutation disrupts the epitope for the anti-Aβ43-specific antibody, thus neither Aβ43 
nor soluble Aβ levels could be determined (ND). (d) Aβ product:substrate ratios reveal that 
APP mutations do not consistently affect the fourth γ-secretase turnover, but change the 
product-line preference as indicated by the Aβ40:Aβ38 ratio (e). (f) sAβ in the conditioned 
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media of HEK293 cells transiently transfected with wt or FAD-C99 mutants were quantified 
by ELISA. sAβ ratios indicate that APP–FAD substrate mutants change the product-line 
preference towards the Aβ48>Aβ38 (Aβ40/Aβ38) in living cells, but do not affect the fourth 
catalytic turnover of the γ-secretase (Aβ38/Aβ42) (mean±s.e., n=5). (g) Primary cultured 
neurons were transduced with SFV expressing WT APP or the indicated mutant substrates 
(mean±s.d., n=3). (b-g) Statistical significance tested with one-way ANOVA and Dunnett’s 
post-test, taking the corresponding WT as control group; *p<0.05,**p<0.01.
Importantly, and in contrast to mutated PS, none of  the tested APP mutations affect 
Aβ38:Aβ42 or Aβ40:Aβ43 ratios (Figure 7.5e). The I45T mutant is the exception, 
showing increased Aβ38:Aβ42 ratio, which would be consistent with an impairment 
in the processing of Aβ45 (mutant peptide) to Aβ42. However, APP mutations result 
in high Aβ40:Aβ38 compared to wt APP (Figure 7.5f). Thus, all investigated mutations 
change the product line preference by shifting APP processing towards the Aβ38 
production line. The APP-V44A and I45T substrates in particular show an additional 
accumulation of longer Aβ precursors (generated in cycles 2 and 3), as deduced from 
soluble Aβ in Figure 7.5d. The change in the product line can be explained if these APP 
mutations shift the position of the ε-cleavage to generate more Aβ48, the initial substrate 
in the Aβ38 production line. A neo-epitope antibody against AICD50–99 (Figure 7.6) 
was generated, and allowed us to confirm the product line preference (Figure 7.7 a,b).
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Figure 7.6 AICD50-99 neo-antibody specificity. 
AICD50 neo-antibody was tested against 10 or 100 ng AICD50-62 and AICD49-62 
synthetic peptides in Western blot analysis. The neo-epitope antibody is able to interact with 
the AICD50-62 but not with the AICD49-62 peptide (lanes 1-2 vs. 3-4). Neo-epitope and 
FLAG antibodies were detected with secondary antibodies coupled to different fluorophores. 
Signals in red and green for the neo and anti-Flag antibodies; respectively. As expected, the 
neo-epitope antibody does not recognize C99-FLAG substrate (lane 5). Arrow indicates the 
neo-antibody specific signals. * Dye front.
Figure 7.7c shows that the APP mutations consistently shift the position of the 
ε-cleavage towards AICD49–99, promoting the Aβ38 product line, and therefore 
causing increments in the Aβ42 and Aβ38 products. Importantly, HEK cells transiently 
transfected with FAD-mutant C99 substrates increase the Aβ42 and Aβ38 levels in 
the extracellular medium while decreasing Aβ40, compared to control (wt C99) (Figure 
7.8). Figure 7.5g actually shows that APP mutations change the product line preference 
(Aβ40:Aβ38 ratio), but do not alter the fourth enzymatic turnover (Aβ38:Aβ42 ratio). 
Similar results were obtained from primary neuronal cultures transiently expressing wt, 
I45T or V46F-APP (Figure 7.5h). These results indicate that our observations in the 
cell-free assay can be extrapolated to the in vivo situation. The APP data imply that 
promoting the Aβ38 production line is pathogenic.
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Figure 7.7 Shift in the ε-cleavage position contributes to the FAD-associated phenotype. 
(a) Detection of AICD50–99 and total AICD using a neoepitope antibody and the FLAG-M2 
antibody, respectively. (b) SDS PAGE/western blot analysis of AICD products from either 
wt and FAD substrates (left panel) or wt and FAD–PS1 mutants (right panel). Signals for 
the AICD50–99 neo-epitope antibody or the FLAG-M2 antibody are shown in red and 
green, respectively. Overlapping neo-epitope and FLAG antibody signals are displayed 
in yellow. (c) AICD50–99/total AICD ratios indicate that FAD–APP mutations promote the 
Aβ38 product line by shifting the ε-cleavage position. The I45T could not be included in the 
analysis because of extremely low AICD signals (ND, not determined). (d) This pathogenic 
mechanism is also observed in some FAD–PS1 mutations. Statistical significance of the 
data (n=5) tested with ANOVA and Dunnett’s post test, taking AICD generated in WT 
conditions as control group; *p<0.05,**p<0.01.
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Figure 7.8 Aβ products in the conditioned media of HEK293 cells transfected with wt or 
C99 mutants. 
HEK293 cells transiently transfected with human wt C99 or mutants were maintained in 
DMEM supplemented with 2% serum. Media were collected at 48 h post-transfection and 
Aβ levels determined by ELISA. Secreted Aβ43 was at undetectable levels in the media. 
Plot shows mean ± s.d. Notice the same shifts in profiles (increase of the Aβ38 pathway, 
decrease of the Aβ40 pathway) as measured with the cell free assays.
We therefore investigated the effects of different Aβ peptides on spontaneous 
synaptic transmission in the primary mouse hippocampal neurons. Our results show 
that Aβ38, similar to Aβ42 and Aβ43, but to a lesser extent, elicits acute synaptotoxicity. 
Although further work is needed to investigate the effects of Aβ38 in vivo, these data 
confirm that individual Aβ peptides have widely divergent biophysical and biochemical 
properties (Figure 7.9).
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Figure 7.9 Aβ38 elicits acute synaptotoxicity. 
Aβ synaptotoxicity on primary neurons. Primary mouse hippocampal neurons were cultured 
on MicroElectrode Array (MEA) substrate for 7-10 days. Synaptic activity was recorded as a 
function of increasing Aβ concentration. Aβ42 (dark grey) and Aβ43 (black) are significantly 
synaptotoxic at a concentration of 0.5 μM. At a concentration of 1 μM Aβ38 (white) inhibits 
activity with 15%. Values are percent of initial firing rate ± SEM; culture response was first 
normalized to the initial basal firing rate. Recorded values were averaged over all active 
electrodes from different chips. Different buffer treatments were each normalized to 100%. 
Statistical significance (unpaired 2-tailed t-test) is indicated by ***p<0.0001 or **p<0.0005. 
(5 independent cultures, n=3 MEA substrates for Aβ38 and Aβ42, n=4 MEA substrates 
for Aβ40 and Aβ43).
7.2.4 effects of inhibitors And modulAtors on the γ-secretAse Activity 
Our data indicate that the various mechanisms affecting the Aβ spectrum generated 
by γ-secretase are responsible for the pathogenic effects of the FAD mutations. 
Therefore, we asked to what extent γ-secretase inhibitors (GSI) and modulators (GSM) 
that were tested in clinical trial or are under development [37] affected the different 
parameters discussed above. To evaluate γ-secretase inhibition under equal kinetic 
conditions, we took advantage of the in vitro system and performed activity assays 
at 1x Km substrate concentrations for APP C99 or Notch substrates (0.4 and 1.1 μM, 
respectively). Under these conditions, the GSI semagacestat (LY-450139), begacestat 
(Notch sparing GSI) and avagecestat (Notch sparing GSI) efficiently inhibit Aβ generation 
in the two production lines (Figure 7.10).
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Figure 7.10 Dose-response inhibitory assays for semagacestat, begacestat and 
avagacestat. 
IC50 curves for GSI using CHAPSO extracted membranes from Ps1/2-/- MEFs 
stably expressing human wt PS1 mutants and 400 nM mutant-C99 substrate (1x Km 
concentration). All GSI inhibit Aβ38, Aβ40, Aβ42 and Aβ43 production to similar extents. Aβ 
products are plotted as percentage of control reaction (DMSO). Error bars indicate S.D. 
(n=3); except for semagacestat plot (S.E., n=5).
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Figure 7.11 Analysis of GSI and GSM. Dose-response inhibitory assays for 
(a) the transition state analogue (TSA) L-685,458 (InhX), (b) semagacestat, and the Notch-
sparing compounds (c) begacestat and (d) avagacestat were performed using CHAPSO-
extracted membranes from dKO PS1/2 MEFs stably expressing human wt PS1 as source 
of γ-secretase and 1x Km substrate concentrations (400 nM APP-C99-3XFLAG or 1 mM 
Notch-3XFLAG). Structures of the different compounds are displayed. In vitro generated 
AICD (in black) or NICD (in grey) are plotted as percentage of control reaction (DMSO). Error 
bars indicate s.d. (n=3); except for semagacestat plot (s.e., n=5). (e) Top panel: structures 
of the GSM tested. Low panel: increasing concentrations of GSM 1–3 did not change in 
vitro AICD generation, neither at 0.4 μM APP-C99 substrate (1x Km) nor at saturating 
conditions (1.75 μM C99-3XFLAG). (f) Effect of increasing concentrations of GSM 1–3 on 
Aβ production at 1x Km APP-C99 substrate (0.4 μM): Aβ product:substrate ratios show 
that GSM 1–3 specifically activate the fourth cycle of the γ-secretase complex. In particular, 
GSM activate the Aβ38 product line. Panel shows mean±s.e.; statistical significance of the 
data (n=4) tested with ANOVA and Dunnett’s post test, vehicle (DMSO) as control group; 
*p<0.05,**p<0.01.
 However, semagacestat, which failed in phase III trial (https://www.investor.lilly.
com/releasedetail2.cfm?releaseid=592438) because of cognition and skin problems, 
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is more selective for Notch than for APP (AICD IC50=257.8 nM and Notch intracellular 
domain (NICD) IC50=24.62 nM (95% confidence interval (CI): 190.2-349.5 nM for APP 
and 15.74-38.51 nM for Notch, n=5), whereas the transition state inhibitor L-685,458 
affects both substrates to an equal extent (Figure 7.11 a,b). Surprisingly, and in contrast 
to previous claims [38,39], the selectivity of both of the ‘Notch sparing’ GSI is not 
significantly different for APP and Notch substrates (Begacestat: AICD  IC50=61.71 
nM and NICD IC50=138.4 nM (95% CI: 24.77-153.7 nM for AICD and 73.29-261.3 for 
NICD, n=3) and BMS708163: AICD IC50=6.82 nM and NICD IC50=20.03 nM (95% 
CI: 4.06-11.46 nM for AICD and 7.76–51.7 nM for NICD, n=3)) (Figure 7.11 c,d).
Recently, γ-secretase modulators (GSM) have been evaluated as an alternative 
to GSI [40]. GSM lower Aβ42 and increase Aβ38, but the precise mechanism of 
action has not been elucidated. One NSAID and two arylimidazole-derived GSM [41] 
(E-2012 and a close analogue) did not affect the endopeptidase activity (Figure 7.11e, 
Figure 7.12a) but, as expected, reduced Aβ42 and increased Aβ38. Analysis of the 
product:substrate ratios for the fourth enzymatic turnover shows that these drugs 
increase specifically this cycle (Figure 7.11f, Figure 7.12b) and act, therefore, in the 
opposite way to the clinical FAD-PS mutations. The Aβ ratios indicated that the GSM 
evaluated in this study act mainly on the fourth cycle of the Aβ38 production line. In 
fact, our data show them as activators of the γ-secretase (GSA). Taking into account 
the changes in the mutant APP Aβ profiles and the possibility that Aβ38 may be part 
of the pathogenic mechanism, it is crucial to evaluate to what extent the differential 
effects of the GSA on the Aβ production lines are problematic.
A
IC
D
 a
s 
%
 o
f c
on
tr
ol
0
20
40
60
80
100
D
M
SO
10
e-
7
10
e-
6
10
e-
5
10
e-
7
10
e-
6
10
e-
5
10
e-
7
10
e-
6
10
e-
5
GSM1 GSM2 GSM3
1.75 μM C990.4 μM C99
a
A
β 
ra
tio
s 
as
 %
 o
f c
on
tr
ol
300
200
100
0
1.75 μM C99-3X FLAG
Aβ38/Aβ42 Aβ40/Aβ43
D
M
SO
10
e-
7
59
55
, 1
0e
-6
10
e-
5
D
M
SO
10
e-
7
84
13
, 1
0e
-6
10
e-
5
10
e-
7
43
80
, 1
0e
-6
10
e-
5
10
e-
7
59
55
, 1
0e
-6
10
e-
5
10
e-
7
84
13
, 1
0e
-6
10
e-
5
10
e-
7
43
80
, 1
0e
-6
10
e-
5
b
Figure 7.12 Effects of increasing concentrations of GSM 1-3 on γ-secretase activity. 
(a) In vitro activity assays using CHAPSO extracted membranes from Ps1/2-/- mEFs stably 
expressing human wt PS1 and 0.4 or 1.75 μM APP-C99 substrate (1x Km or saturating 
concentrations, respectively). The three GSM (at 1x10-5, 1x10-6, 1x10-7 M) do not affect the 
endopeptidese activity of the γ-secretase (no effect on AICD production). AICD production is 
plotted as percentage of control reaction (DMSO). (b) Increasing concentrations of GSM 1-3 
on Aβ38:Aβ42 and Aβ40:Aβ43 ratios show that GSM 1-3 activate the 4th catalytic cycle 
of the γ-secretase; in particular, the Aβ48>Aβ38 product line. Panels a,b show mean±s.d.; 
statistical significance of the data (n=3) tested with ANOVA and Dunnett’s post test, vehicle 
(DMSO) as control group; *p<0.05.
7.3 discussion
This study settles several issues that have been heavily debated in the literature. 
Dissection of the different activities of the γ-secretase complex allowed us to characterize 
the mechanisms that are regulated in a consistent fashion by FAD mutations in PS 
and APP. Previous reports have employed steady-state analyses to evaluate the 
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effect of these mutations on the γ-secretase. In general, these studies have employed 
transfected cells to measure, in culture or in vitro, changes in secreted product levels 
or follow the intracellular generation of ICD products by coupling it to reporter systems. 
Although these approaches are informative, they do not truly reflect the kinetic features 
of the mutated γ-secretase complexes or APP substrates. For instance, substrate 
concentration and accessibility is not controlled in such assays.
By analysing the catalytic efficiency of the γ-secretase complex (wt or mutated) in an 
in vitro assay, with both enzyme and substrate in solution, we find here that mutations 
in PS1 and PS2 affect γ-secretase at three levels. We see (i) a variable inhibitory effect 
at the initial endoproteolytic ε-cleavage step, which releases the intracellular domains 
of substrates such as APP, Notch, Erb4 and N-cadherin. (ii) A consistent effect on 
the consecutive carboxypeptidase-like γ-cleavage with all PS mutations causing a 
‘premature’ release of (intermediary) substrates/products, explaining why longer Aβ is 
generated by these mutants. Interestingly, our data suggest that both Aβ42:Aβ38 and 
Aβ43:Aβ40 ratio increments are pathologically relevant. (iii) Additionally, some of the 
mutations in PS and all mutations investigated here in the APP sequence (selected for 
their close position to the γ-cleavage site in APP) affect the initial position of the ε-site, 
that is, whether γ-secretase cleaves preferentially at position 49-50 or 51-50 in the 
APP sequence. While these three mechanisms explain for the first time the abundantly 
documented increase in Aβ42:Aβ40 ratio associated with all mutations leading to 
familial Alzheimer disease, they also provide a set of entirely novel insights, as we 
discuss in the following paragraphs.
Our study gives definite numbers on the catalytic efficiency of the γ-secretase 
complex at the ε-site and unequivocally shows that ‘loss of function’ - lower catalytic 
efficiency - is not consistent across the hereditary mutations tested. In this regard, 
we wish to draw attention to the fact that point mutations in PS might affect protein 
stability, and therefore solubilization of ‘less stable’ mutated γ-secretase complexes 
might result in an accentuated ‘loss of function’. Thus, we cannot exclude that the 
enzymatic efficiencies of particular mutated complexes (less stable) are underestimated 
in the conditions used in the current work, which would even strengthen our conclusion 
that ‘loss of function’ is not necessary for the pathogenic mechanism. Taking all 
into consideration, our results indeed rule out the possibility that loss of intracellular 
signalling is necessary and sufficient to cause Alzheimer disease, as postulated by 
the ‘simple’ loss-of- function hypothesis. Interestingly, the effects at the ε-cleavage 
site are also variable for different substrates tested (Km values for APP, Notch, Erb4 
and N-cadherin, Table 7.1), suggesting that some of the clinical mutations affect the 
substrate specificity mechanism. This is in particular clear for the M139V and DE9 
mutations. DE9 removes part of the hydrophobic domain VII (HDVII) of PS1, which is 
located in the active site of the γ-secretase [42], while the M139 residue is located 
in the second transmembrane domain of PS, which contributes to the formation 
of the initial substrate-binding site [43]. On the contrary, our results show that the 
L166P mutation affects the catalytic rate of the enzyme but does not change the 
substrate specificity of the complex, explaining why steady-state levels of NICD and 
AICD products in vivo are equally affected by different amino-acid substitutions in the 
position 166 [44].
We analysed in considerable detail the effects of PS1 and PS2 mutations on the 
γ-secretase (carboxypeptidase-like) mechanism that follows the initial ε-endoproteolytic 
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cleavage of the APP substrate. We find that PS mutations impair dramatically the fourth 
turnover in both Aβ49>Aβ40 and Aβ48>Aβ38 product lines, resulting in decreased 
Aβ40:Aβ43 and Aβ38:Aβ42 ratios. Our data therefore give a mechanistic explanation 
for the decrease in short Aβs (<40) reported in the cerebrospinal fluid of carriers of 
PS-A431E10 [45] or the alterations in the lengths of Aβ peptides produced in vitro 
by mutated PS-containing complexes [46]. Moreover, biophysical observations have 
shown that PS mutations alter the conformation of the γ-secretase complex [47]. 
Based on our biochemical data we propose that changes in the active site of PS 
mutations promote the premature release of the Aβ43 or the Aβ42 peptides from the 
γ-secretase complexes.
A third mechanism by which APP mutations act in particular is the shift in the initial 
ε-cleavage site resulting in an increased Aβ48>Aβ38. Likely, the product preference 
results from differential docking modes of the APP substrate into the active site. We 
confirmed the shift towards Aβ48>Aβ38 in living cells expressing wt or mutant APP 
substrates. This result corroborates our claim that the product line preference is an 
intrinsic property of the γ-secretase complex that remains unaltered in our cell-free 
assay. Interestingly, this shift in initial docking and production lines is also observed 
in four of the six PS1 mutants (Figure 7.7 c,d). The fact that some PS1 mutations 
combine these two mechanisms (impaired fourth cycle and change in the product line 
preference) explains the direct and indirect correlations between Aβ38 and Aβ42 levels 
reported in the past [48,49].
Our study thus demonstrates that mutations linked to familial Alzheimer disease 
cause qualitative changes in the Aβ profiles by various mechanisms [7,13], and that 
decreased release of intracellular domains [11] is not an essential part of the Alzheimer 
disease pathogenic mechanism. Nevertheless, as indicated above, the most aggressive 
PS1 mutations, for example, the L166P, negatively impact the endopeptidase activity 
as well, and therefore it is not unlikely that ‘partial loss’ of γ-secretase function at Notch 
or other γ-secretase substrates acts as an aggravating factor in familial Alzheimer 
disease.
Moreover, our Aβ product profiles evidence the generation of longer Aβ peptides 
(>Aβ43) by the most aggressive mutated complexes. However, whether particular 
changes in the Aβ profiles can be correlated to the age of onset is an interesting but 
unaddressed question.
In a final series of experiments, we have also assessed to what extent different 
γ-secretase-directed drugs such as GSI and GSM affect the three mechanisms identified 
in the current work. When investigating the transition state analogue L-685,458 (InhX), 
semagacestat, and the Notch-sparing begacestat and avagacestat, we found that the 
four compounds lowered all γ-cleavages to a similar extent and did not change the Aβ 
ratios. However, when we assayed the effects of these GSI on Notch processing, which 
is considered to be the major liability of GSI, we surprisingly found that semagacestat 
was more effective in inhibiting Notch than APP. This is particularly significant when 
considering that a phase III clinical trial with semagacestat was interrupted last year 
because of severe side effects including worsened cognition and increased incidence 
of skin cancer. Similarly, the Notch-sparing compounds begacestat and avagacestat 
did not show significant higher selectivity for APP compared to the Notch substrate 
in our assay. These data raise serious concerns about the interpretation of inhibitory 
studies that relied on cellular or in vivo data, which in general do not allow direct 
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quantitative comparisons as done with our assay. Importantly, our data do not discard 
the selective inhibition of APP at the ε-cleavage as a plausible strategy for drug 
development, but basically indicates that the approaches that have been used to 
reach this aim need to be revisited.
We also tested GSMs and found that all three candidates keep full functionality 
at the endopeptidase cleavage and regulate the carboxypeptidase-like activity by 
activating the fourth cycle of the γ-secretase, resulting in an increased processing of 
the aggregation-prone Aβs towards shorter Aβ peptides. Our data, however, suggest 
some caution with this strategy as the tested compounds differentially affect the 
Aβ48>Aβ38 versus the Aβ49>Aβ40 pathway. The relative increase of Aβ38 observed 
with all compounds needs further scrutiny, as APP clinical mutations also promote this 
production line.
In conclusion, our work provides an important step forward towards the 
understanding of the mechanisms by which early-onset familial mutations in PS and 
APP cause Alzheimer disease. Our findings support strongly the hypothesis that 
although these mutations affect γ-secretase in various ways, they all lead to qualitative 
shifts in the Aβ profiles, which provides a common denominator for the pathogenic 
effect of all mutations leading to hereditary Alzheimer disease.
7.4 experimentAl procedures
7.4.1 cell culture
Ps1/Ps2-deficient (-/-) MEF (Ps1/2-/- mEF) [35] were cultured in Dulbecco’s modified 
Eagle’s medium/ F-12 containing 10% fetal bovine serum. Ps1/2-/- mEF rescued with 
wt (human) PS1 or L166P, G384A and DE9 as well as wt (human) PS2 or N141I were 
reported before [7]. The Y115H, M139V and I213T FAD–PS1 cell lines were generated 
accordingly. mEF–PS1 cell lines were transduced with a recombinant adenovirus 
Ad5/CMV-APP bearing human APP-swe, as previously described [50]. Neuronal 
cultures derived from E14 embryos and Semiliki Forest virus transfection procedures 
have been described previously and Semliki Forest viruses (SFV) were produced as 
described [51]. Briefly, brains from E14 embryos were trypsinized and plated on 6-cm 
dishes precoated with poly-L-lysine. Cultures were maintained in neurobasal medium 
supplemented with B27 and 5mM cytosine arabinoside to prevent glial cell prolification. 
After 3 days, neurons were transduced with SFV expressing wt or FAD mutant APP. 
After 1 and 3 h, post-infection media were refreshed. After 24 h, sAβ were analysed 
by ELISA.
7.4.2 expression And purificAtion of substrAtes-3xflAg
Substrate purification was performed as previously described [50]. Notch-, ErB4- 
and N-Cadherinbased substrates were designed to be similar in size to the APP 
substrate (C99–3XFLAG). Purity was assessed by SDS PAGE and Coomassie 
staining. 
7.4.3 In vItro Activity AssAys using solubilized γ-secretAse 
In vitro activity assays were done as previously described [50], with minor 
modifications. MEF’s microsomal fractions were prepared in 50mM citric acid, pH 6.7, 
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0.25M sucrose, 1 mM EGTA, complete protease inhibitor and 1% CHAPSO. In vitro 
reactions were carried out in 50mM citric acid, pH 6.7, 0.25M sucrose, 1 mM EGTA, 1 
EDTA-free complete proteinase inhibitor, 2.5% DMSO and 0.05% phosphatidylcholine. 
Reactions were incubated for 4 h at 37 °C unless otherwise mentioned. Lipids and 
substrates were extracted by adding 1 volume chloroform:methanol (2:1, v/v). Then, 
the aqueous fraction (ICD products) was taken and subjected to SDS PAGE and 
quantitative western immunoblot. Known amounts of C99-3XFLAG were included as 
standards for absolute quantifications. ICD-3XFLAG and standards were determined 
with the anti-FLAG M2 and goat anti-mouse IR800 antibodies, whereas the AICD50–
99 product was determined with a neo-epitope mAb and a goat anti-rabbit Alexa680 
secondary antibody. 
7.4.4 cAlculAtion of Kinetics constAnts
Kinetic constants were estimated by nonlinear curve-fitting using GraphPad Prism 
4 software. The equation V=(Vmax [S])/(Km+[S]) was used to calculate apparent Km 
and Vmax values for the different enzymes, where V was experimentally determined 
using a range of substrate concentrations [S]. γ-Secretase activities were normalized 
to PS–CTF fragment levels or full-length PS1 levels for the DE9 mutant.
7.4.5 quAntificAtion of soluble Aβ using sAndwich elisA
Ninety-six-well plates were coated with 1.5 μg ml-1 Aβ capture antibody, excepting 
Aβ43-ab coated at 7.5 μg ml-1, in a final volume of 50 μl buffer (10mM Tris HCl, 
10mM NaCl, 10 mM NaN3, pH 8.5). After overnight incubation at 4 °C, the plates were 
rinsed with PBS+0.05% Tween20 and blocked with 100 μl per well of casein buffer 
(1g casein in 1L 1xPBS, pH7.4) for 4 h at room temperature. Samples and standards 
(synthetic human Aβ38, Aβ40, Aβ42 or Aβ43 peptides) were diluted in casein buffer. 
After overnight incubation at 4 °C, plates were rinsed and developed using 50 μl per 
well of 100mM NaAC pH 4.9/TMB/H2O2. Reactions were stopped with 50 μl per well 
of 2N H2SO4 and read on a Perkin Elmer Envision 2103 multilabel reader at 450 nm.
7.4.6 ureA gels
Aβ-peptides were analysed by a modified version of the urea-based SDS 
PAGE [52]. Western immunoblot was done using 1E8, amplifying the signal with 
biotinylated anti-mouse IgG and streptavidin-HRP. Signals were detected using ECL 
chemiluminescence with an Intas Imager.
7.4.7 synAptotoxicity on primAry neurons
Trypsinized brain from 17-days-old FVB mice embryos was used to generate 
hippocampal neurons. Cultures were plated at 1,000 cells/mm2 on a MEA substrate 
and maintained in neurobasal medium supplemented with B27 for 3 days at 37 °C 
in a humidified 5% CO2 atmosphere. Then, medium was changed to neurobasal 
medium supplemented with B27, without L-glutamate and cells were cultured for 8-10 
days prior to further experiments. During the recording experiment, a temperature 
controller was used to maintain the MEA platform temperature at 37 °C. The basal 
firing rate was recorded during 500 sec. Subsequently, cultures were titrated with 
pre-aggregated Aβ (1.5 h, 25 °C) at final concentrations of 0.5 and 1 μM at 500 sec 
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intervals. The spontaneous synaptic activity was continuously recorded during these 
500 sec. Raw signals from MEA electrodes were amplified (gain 1200) and digitized 
at a sampling rate of 25 kHz. The raw data stream was high-pass filtered at 200 
Hz, and the threshold for spike detection was set to 5 SD of the average noise 
amplitude computed during the first 1000 ms of recording. The firing rates recorded 
by all electrodes were averaged over the 500-sec time bins and were normalized 
to buffer treatment. Experiments were performed using 5 independent cultures, n=3 
MEA-chips for Aβ38 and Aβ42, and n=4 MEA-chips for Aβ40 and Aβ43. Results were 
analyzed using two-tailed unpaired t-test for significance. Significance is indicated by 
***p<0.0001 and **p<0.0005.
7.4.8 quAntificAtion of totAl Aβ using sAndwich elisA
Sandwich ELISA were done using 4G8 as capture antibody at final concentrations 
of 1.5 μg/mL in a final volume of 50 μL coating buffer (10mM Tris HCl, 10mM NaCl, 
10mM NaN3, pH8.5). Synthetic human Aβ40 peptide was used for the preparation of 
the standard curve.
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Current therapeutic approaches under development for Alzheimer disease, including 
γ-secretase modulating therapy, aim at increasing the production of Aβ38 and Aβ40 
at the cost of longer Aβ peptides. Here, we consider the aggregation of Aβ38 and 
Aβ43 in addition to Aβ40 and Aβ42; in particular their behavior in mixtures representing 
the complex in vivo Aβ pool. We demonstrate that Aβ38 and Aβ43 aggregate similar 
to Aβ40 and Aβ42, respectively, but display variation in kinetics of assembly and 
toxicity due to differences in short timescale conformational plasticity. In biologically 
relevant mixtures of Aβ, Aβ38 and Aβ43 significantly affect the behaviors of Aβ40 
and Aβ42. The short timescale conformational flexibility of Aβ38 is suggested to be 
responsible for enhancing toxicity of Aβ40 whilst exerting a cyto-protective effect on 
Aβ42. Our results indicate that the complex in vivo Aβ peptide array, and variations 
thereof, is critical in Alzheimer disease, which can influence the selection of current and 
new therapeutic strategies.
moleCulAr plAstiCity regulAtes 
oligomerizAtion And CytotoxiCity of the 
multipeptide length Aβ pool.
The results described in this chapter have been published in:
Vandersteen A, Masman M, De Baets G, Jonckheere W, van der Werf K, Marrink SJ, Rozenski 
J, Benilova I, De Strooper B, Subramaniam V, Schymkowitz J, Rousseau F, and Broersen K 
(2012). J. Biol. Chem., 287:36732-36743.
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8.1 introduction
Extracellular deposits containing Aβ represent one of the hallmarks of Alzheimer 
disease [1]. Processing of the transmembrane amyloid precursor protein (APP) primarily 
generates the 40-amino acid Aβ40 peptide and smaller amounts of the 42-amino acid 
Aβ42 peptide, in addition to minute quantities of other Aβ peptides ranging in length 
from 27 to 43 amino acids [2,3]. The observed variation at the Aβ carboxy terminus 
is a consequence of the heterogeneous γ-secretase processing pattern [4] and the 
array of Aβ peptides that is produced in this way can be affected by clinical mutations 
in APP [5,6] or in presenilin-1 (PS1) [5-7]. Mutations of PS1 potently shift the ε-cleavage 
site on APP towards the Aβ38 production pathway [8].
Generally, longer Aβ peptides are more hydrophobic as the carboxy-termini 
progressively form part of the transmembrane domain of APP and are therefore 
considered more aggregation prone [9-11]. Recently, γ-secretase modulators (GSMs) 
have been developed. These fine-tune the action of γ-secretase to shift the production 
of Aβ peptides towards shorter variants while leaving the total Aβ peptide production 
and activity of γ-secretase unchanged [12,13]. Given the finding that specifically 
aggregated Aβ peptide can lead to a neurotoxic response, GSMs offered in this way 
a promising perspective as a potential agent to slow down the progress of senile 
plaque deposition in Alzheimer disease by decreasing the production of Aβ42 whilst 
increasing that of Aβ38. The first generation of GSMs were classified as non-steroidal 
anti-inflammatory drugs (NSAIDs) and derivatives thereof. Administration of these drugs 
to healthy individuals showed positive effects on cognitive function which could be 
entirely attributed to the cyclo-oxygenase (COX) inhibitory action of the compound 
without displaying GSM action [14,15]. Clinical trials with non-COX inhibitory NSAIDs 
did not display protective effects on Alzheimer disease progress possibly as a result 
of the low potency and poor brain penetrance of the compounds, inhibition of Notch 
processing or accumulation of APP C-terminal fragments [16]. A next generation of 
Notch sparing GSMs and non-NSAID derived compounds with improved potency and 
brain penetration are currently being developed but yet await clinical trials [15]. 
The reported neurotoxicity of Aβ43 [7] as well as the observed increasing [17] and 
decreasing Aβ38 [18] levels in CSF upon Alzheimer disease progress, indicate that the 
contributions of Aβ38 and Aβ43 to disease progression require further elucidation. By 
comparing their pathogenicity, aggregation profiles and biophysical properties with that 
of well-studied Aβ40 and Aβ42 we show that Aβ38 and Aβ43 both form aggregates 
which differ in cytotoxic potential. We further show that inclusion of Aβ38 and Aβ43 
into complex mixtures containing Aβ40 and Aβ42 substantially affects the behavior 
of total Aβ and that Aβ38 and Aβ40, previously considered non-amyloidogenic, can 
unexpectedly become toxic in these mixtures. These findings have been related to 
conformational plasticity of the respective peptides and highlight the relevance of 
understanding the role of carboxy-terminal variation of Aβ peptides and their potential 
as therapeutic targets.
8.2 results
8.2.1 Aβ peptide length determines AggregAtion, oligomerizAtion And toxicity
It has been reported before that Aβ40 and Aβ42 display different aggregation 
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kinetics [9,19]. Consistent with these data, we also observed substantial differences 
in aggregation kinetics as a function of peptide length (Figure 8.1a) when comparing 
Aβ38, Aβ40, Aβ42 and Aβ43 using thioT fluorescence. While Aβ38 and Aβ40 showed 
a delayed onset of aggregation, Aβ42 and Aβ43 rapidly aggregated as suggested by 
the immediate rise in thioT fluorescence signal. Even though the aggregation regimes 
of Aβ38 and Aβ40 are generally alike with a distinct lag phase and significant and 
sigmoidal development of thioT signal after 10 h of incubation, Aβ38 showed a more 
rapid onset of aggregation compared to Aβ40. The final (10h) thioT fluorescence 
intensity of both Aβ42 and Aβ43 aggregates was very low compared to Aβ38 and 
Aβ40 (Figure 8.1b) and has been reported to correlate with the weight concentration 
and the morphology of the formed fibrils [20]. Transmission electron microscopy (TEM) 
showed that 0.5 h of incubation of Aβ42 and Aβ43 resulted in networks of intertwined 
fibrils while for Aβ38 and Aβ40 aggregates were absent (Figure 8.1c). Upon incubation 
for 4 h the fibrillar network observed for Aβ43 had progressed into polymorphous 
clusters interconnected by mature fibrils. Aβ42 showed a similar organization yet 
short and aligned fibrils seemed more prevalent compared to Aβ43. In contrast, Aβ38 
and Aβ40 both formed long, negatively stained and regularly twisted fibrils with a 
diameter of 8-12 nm which is typically observed for amyloid-like fibrils [21]. All Aβ 
peptides formed extensive fibrillar networks upon incubation for 24 h. To establish 
by which mechanism carboxy-terminal variation affected the observed aggregation 
characteristics of Aβ, the statistical thermodynamics algorithm TANGO was used 
to predict aggregating stretches in the various Aβ peptides tested. TANGO scores 
further showed that, in general, increasing aggregation propensity could be observed 
with increasing peptide length with the exception of Aβ varying in length from 37 
to 40 amino acids (Fig. 1d). A per-residue analysis of the aggregation propensity 
showed that all Aβ sequences contain a common aggregating stretch ranging from 
residue 16 to residue 22 [22] (Figure 8.1e). A second aggregating region starts at 
residue 28 and spans the remaining carboxy-terminal part of the sequence and 
showed strong variation with Aβ length, owing predominantly to the presence of two 
subsequent glycine residues, which disfavor aggregation but which are compensated 
by additional aggregation promoting residues in the longer forms. Our analysis shows 
that differences in aggregation propensity directly stem from C-terminal variation. In 
line with our observation that Aβ38 aggregates faster than Aβ40 (Figure 8.1a), TANGO 
predicted a slightly higher aggregation propensity for Aβ38 than for Aβ40 (Figure 8.1 
d,e).
ThioT does not interact strongly with oligomeric Aβ [23] while soluble oligomeric Aβ is 
generally considered to represent the toxic species [24-26]. We used complementary 
oligomer-sensitive techniques such as the A11 oligomer-specific antibody [27] and 
atomic force microscopy (AFM) to obtain information on the lifetime of oligomeric Aβ 
as a function of C-terminal variation. Aβ peptides were allowed to aggregate and 
were tested for A11-reactivity at various time points of incubation (Figure 8.2a). Aβ42 
and Aβ43 formed A11-positive oligomers already after 0.5 h of incubation while Aβ38 
and Aβ40 only interacted with the A11-antibody after an incubation time of 5 and 6 
h, respectively, with Aβ38 exhibiting substantially stronger staining with the antibody 
than Aβ40. Complementary to A11 reactivity, AFM imaging of samples upon 1.5 h of 
incubation showed the presence of small oligomeric species for all Aβ peptides tested, 
including Aβ38 and Aβ40 (Figure 8.2b). Even though oligomers were present for all
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Figure 8.1 Carboxy-terminal heterogeneity affects aggregation kinetics of the Aβ peptide. 
(a) ThioT fluorescence was recorded in situ every 5 min at 25 °C. Aβ38 (black line) and 
Aβ40 (grey line) display a lag phase while Aβ42 (dotted black line) and Aβ43 (dotted 
grey line) induce ThioT fluorescence almost immediately. The values represent the means 
of three experiments. (b) Final (10 h) thioT fluorescence intensities derived from panel A. 
Statistical significance (unpaired 2-tailed t-test) compared to the Aβ38 value is indicated by 
***p<0.0001, **p<0.0005 or *p<0.005. (c) After 0.5 h incubation Aβ42 and Aβ43 formed 
networks while Aβ38 and Aβ40 did not show visible aggregates. After 4h incubation Aβ38 
and Aβ40 formed 8-12 nm wide, extended, negatively stained fibrils. Aβ42 organized into 
a network of rigid 14-16 nm wide fibrils. For Aβ43 a mixture of protofibrils and fibrils was 
observed. After 24h all Aβ formed similar fibrillar networks. Scalebar: 200 nm. (d) Total 
TANGO scores indicated an increasing overall aggregation propensity of Aβ with increasing 
peptide length except for 37 to 40 amino acids long peptides. (e) Sequence based prediction 
of aggregation prone stretches by TANGO suggests a common aggregating region in the 
core of the peptide and a second aggregating region at the C-terminus. Differences in total 
TANGO score (d) are exclusively due to the C-terminal aggregating region. Aβ38 (black line) 
and Aβ40 (grey line) display similar predicted aggregation propensity while that of Aβ42 
(dotted black line) and Aβ43 (dotted grey line) were higher.
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Aβ peptides tested, Aβ38 and Aβ40 oligomers only developed into A11-positive 
oligomers at a later stage compared to Aβ42 and Aβ43. Cytotoxicity of oligomeric Aβ 
upon carboxy-terminal variation was assessed using neuroblastoma cell line SH-SY5Y 
(Figure 8.2c). A11-positive oligomers derived from Aβ42 and Aβ43 induced loss of cell 
viability at a concentration of 5 μM while those derived of Aβ38 and Aβ40 affected cell 
viability only at a significantly higher concentration of 20 μM.
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Figure 8.2 Differences in aggregation kinetics due to C-terminal heterogeneity are 
reflected at toxic oligomer level. 
Aβ at 50 μM was allowed to aggregate at 25 °C under quiescent conditions. (a) Analysis 
with the A11 oligomer-specific antibody detected oligomeric Aβ42 and Aβ43 after as little as 
0.5 h incubation whereas Aβ38 and Aβ40 became A11-positive after 5 to 6 h of incubation. 
(b) Imaging using AFM indicated the presence of oligomers for all Aβ samples incubated for 
1.5 h. The length of the bar represents 500 nm. (c) Pre-incubated (1.5 h) Aβ was added 
to cultured SH-SY5Y cells and incubated for 24 h before probing cytotoxicity using Cell 
Titer Blue viability assay. Aβ38 (black) and Aβ40 (dark grey) only cause cytotoxicity at a 
concentration of 20 μM while Aβ42 (light grey) and Aβ43 (white) are significantly cytotoxic at 
a concentration of 5 μM. Values are expressed as percent of cell viability ± SD (n=4), buffer 
signal was normalized to 100%. Statistical significance (unpaired 2-tailed t-test) compared 
to buffer control values (normalized to 100%) is indicated by p-value analysis similar to 
Figure 8.1b.
8.2.2 Aβ lengths displAy conformAtionAl differences
Circular dichroism (CD) and Fourier transform infrared (FTIR) spectroscopy were 
used to evaluate Aβ structure after 1.5 h of incubation. The spectra recorded for 
Aβ38 and Aβ40 using CD were very similar, and displayed typical characteristics of a 
largely unstructured protein while the spectra of Aβ42 and Aβ43 showed pronounced 
β-sheet formation with a minimum intensity at a wavelength of 218 nm (Figure 8.3a). 
As FTIR is more sensitive to β-sheet formation than CD and can distinguish between 
parallel and anti-parallel β-sheet arrangements, FTIR measurements were performed 
complementary to CD. Figure 8.3b shows difference spectra obtained by subtraction 
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of the spectrum of non-aggregated Aβ (time 0) from the spectrum recorded after 1.5 
h of incubation. The strong increase of absorbance at a wavelength of 1627 cm-1 
concurrent with a loss of signal between 1650-1655 cm-1 and 1680 cm-1 for all four 
peptides tested, indicated that β-sheet formation took place during the 1.5 h incubation 
time at the cost of random coil and β-turn structure. The more narrow peak for 
Aβ38 suggests the formation of a more stable β-sheet as a result of more extensive 
H-bonding, compared to the other peptide lengths investigated although Aβ40 was 
found to form most β-sheet judging from a higher signal intensity at a wavelength of 
1627 cm-1. The small increase at 1695 cm-1 seen here for Aβ38 and Aβ43 in addition 
to the increase at a wavelength of 1627 cm-1 reveals the formation of an antiparallel 
oriented β-sheet which has been typically used as a fingerprint for oligomer formation 
[28]. Variation in evolution of these regions is observed between the Aβ isoforms. This 
observation suggests that the various Aβ isoforms display small structural differences 
during aggregation. Even though CD and FTIR provide useful structural information 
in terms of an average of the entire protein sequence, they do not provide insight 
into the behavior of individual residues in the sequence, and, hence, are not able to 
address the question why the addition of two valines in Aβ40 rendered this peptide 
less aggregation prone than Aβ38. Also CD and FTIR spectroscopy were unable to 
report on short-time scale conformational flexibility of peptides potentially required to 
trigger the onset of aggregation. 
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Figure 8.3 Aggregating Aβ peptides show differences on a secondary structural level. 
(a) CD measurements were performed with pre-incubated (1.5 h) Aβ at 15 μM. Spectra 
recorded for Aβ38 (continuous black line) and Aβ40 (continuous grey line) were 
characteristic of peptides with a large degree of disorder whereas Aβ42 (dotted black line) 
and Aβ43 (dotted grey line) displayed curves with a single minimum at 217 nm, suggesting 
β-sheet formation. High buffer interference was observed at wavelengths < 207 nm (b) FTIR 
absorbance was measured of monomeric and pre-incubated (1.5 h) Aβ at 200 μM and the 
difference between both spectra was plotted. The difference spectra showed an intensity 
increase at a wavelength of 1627 cm-1 indicating that all four peptides were converted 
into a β-sheet conformation. For Aβ38 (continuous black line), and Aβ43 (dotted grey line) 
an additional increase in intensity around 1695 cm-1 was observed implying an antiparallel 
oriented β-sheet. Aβ40 (continuous grey line) and Aβ42 (dotted black line) data were both 
characterized by a loss of β-turn as observed by the decrease in intensity at 1680 cm-1.
We used molecular dynamics (MD) simulations to establish whether individual 
residues contributed to changes in peptide conformation which could explain the 
observed results. We focused our observations on definition of secondary structure of 
proteins (DSSP) analysis [29]. Here, we report the DSSP results as: coil (unstructured 
conformation), extended conformation (β-bridge plus β-sheet structures), loop (bend 
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plus turns), and helical conformation (β-helix plus 310-helix plus π-helix). All peptides 
presented a general trend to possess a mixture of a collapsed coil structure and 
helical conformation for residues 1-20. N-terminal helical structure was partially retained 
over time, whereas C-terminal helicity, if any, was rapidly lost (Figure 8.4). 
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Figure 8.4 At short time scales extended conformations only occur at the C-termini of Aβ, 
while N-termini retain their helical conformation.
Secondary structure composition per residue in function of time for selected representative 
MD simulations: (a) Aβ38, (b) Aβ40, (c) Aβ42, Aβ42 (d) Aβ43. Secondary structure was 
determined using DSSP criteria. Reported conformations are coil, extended, loop and helical 
conformation. Snapshots of peptide conformations are shown for 0, 25, 50, 75, and 100 
ns of simulation time.
Also as a general observation, all extended conformations occurred between residues 
21-28 and residues 32 to the C-terminal amino acid. A loop section comprising residues 
29-31 formed flexible links between these extended portions. Contrary to what was 
expected, Aβ38 conformation behavior most closely resembled that of Aβ42, rather 
than Aβ40 (Figure 8.4)(Figure 8.5 a,b). Over the 100 ns time scale of the simulations, 
Aβ38 showed a marked tendency to form extended conformations (Figure 8.5 a,b), 
comparable to Aβ42 and Aβ43 (Figure 8.5 b,b1). Aβ40, on the other hand, exhibited 
low tendency to form extended conformations (Figure 8.5a). Interestingly, during the 
first tens of nanoseconds the behavior of Aβ38 was erratic and fluctuated between 
resembling Aβ40 and Aβ42/Aβ43. Only after 50 ns of simulation the content of 
extended conformation invariably increased (Figure 8.5 a,d). Aβ42 and Aβ43 seemed 
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to accumulate and stabilize better their extended conformations, from earlier simulation 
times onwards (Figure 8.5 b,b1)(Figure 8.6). The same behavior was reflected in the 
overall helicity of the peptides (Figure 8.5c) revealing a slight, yet statistically significant, 
higher tendency to retain its helical conformation for Aβ38 in comparison to Aβ42 
and Aβ43. A marked increase in the helicity of residues 20-23 and 28 was uniquely 
observed for Aβ40 (Figure 8.5 c,d). Collectively, these data showed that the behaviors 
of Aβ42 and Aβ43 were remarkably similar in terms of their high tendency to form 
an extended β-sheet conformation while Aβ40 retained helicity longer. The Aβ38 
peptide showed very interesting behavior in terms of its highly fluctuating tendency to 
form extended β-sheet conformation. Over time Aβ38 conformation alternated rapidly 
between Aβ42/Aβ43-like conformation and Aβ40-like conformation before forming 
stable, extended β-sheet.
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Figure 8.5 Aβ peptides show conformational fluctuations at short time-scales, which vary 
upon C-terminal elongation.
Secondary structure composition determined by DSSP method: extended conformation 
(β-bridge plus β-sheet structures), and helical conformation (α-helix plus 310-helix plus π-helix). 
Results were averaged over ten independent simulations. The extended conformation 
content in function of time for Aβ38 (continuous black line) is compared to: (a) Aβ40 
(continuous grey line); and (b) Aβ42 (dotted black line); inset plot (b1) Aβ43 (dotted grey 
line), which reveals a similar profile compared to Aβ42. Statistically significant differences 
(SEM) are denoted with a caped-line (##p<0.005). (c) The helical content in function of 
time is shown for all peptides. Regions of the simulation time wherein there are statistically 
significant differences are denoted with a caped-line (##p<0.005) compared to Aβ42. Inset 
plot (c1) shows helicity per residue for all Aβ peptides (##p<0.005, compared to all Aβ 
peptides). Helicity is reported as the percentage of simulation time that a given amino acid 
residue presented α-helix conformation. (d) Snapshots for all Aβ peptides at 0, 25, 50, 75 
and 100 ns of simulation time. C-termini positions are denoted with an asterisk (*).
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Figure 8.6 Secondary structure composition of Aβ38 correlates better to Aβ42 than to 
Aβ40.
Overall appearance of secondary structure composition (% of total amount of residues) 
in function of time for (a) Aβ38, (b) Aβ40, (c) Aβ42 (d) Aβ43. Secondary structure was 
determined using DSSP criteria, and reported as average of 10 simulations per peptide. 
Reported conformations correspond to: coil, extended, loop and helical conformation.
8.2.3 mixtures of Aβ show complex AggregAtion behAvior
To evaluate the influence of the observed differences between Aβ isoforms in a 
more biologically relevant setting, we mimicked the complex pool of various Aβ peptide 
lengths as observed in vivo by preparing Aβ peptide mixtures containing Aβ40, or 
Aβ42 and Aβ38, or Aβ43. Increased levels of Aβ38 in the CSF of Alzheimer disease 
patients are reported [17], as well as an increased generation of this peptide due to 
PS1 mutations [30]. Some forms of FAD display increased generation of Aβ43 [30], a 
peptide length frequently present in amyloid plaques [31]. Aβ40 and Aβ43 were shown 
to directly interact using ESI-MS although these dimeric species only accumulated at 
a population of ~1% (see appendix B). Effective but low accumulation of mixed dimers 
was also observed upon mixing Aβ38 and Aβ42 (see appendix B). Mixed dimeric 
complex formation was further detected for Aβ38:Aβ40 and Aβ42:Aβ43. Along the 
lines of the earlier identified processing pathways of APP toward the formation of either 
Aβ40 and Aβ38 with Aβ43 and Aβ42 as intermediates, respectively [8], we mapped 
dose-response curves of the presence of Aβ43 and Aβ38 on the aggregation kinetics 
of Aβ40 and Aβ42, respectively, using thioT fluorescence (Figure 8.7). We reported 
earlier that Aβ42:Aβ40 mixtures behave differently according to their proportional 
presence (Chapter 5). Titration of Aβ40 with increasing concentrations of Aβ43 
substantially reduced the lag phase of aggregation to become similar to that of Aβ43 
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alone while final fluorescence intensities were not affected (Figure 8.7 a,c). These 
observations suggest that Aβ43 dominantly influences the nucleation process of Aβ40 
while aggregate morphology or mass were presumably determined by Aβ40 (Figure 
8.7c). Titration of Aβ38 with Aβ42 similarly lead to a decreased nucleation rate but, in 
addition, gradually increased the elongation rate and final thioT fluorescence intensity 
(Figure 8.7 b,d). The complex aggregation characteristics compared to each of these 
peptides in isolation are highly suggestive of interaction of the Aβ peptides in mixtures.
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Figure 8.7 Little prevalent Aβ peptides strongly affect the behavior of predominant Aβ. 
ThioT fluorescence was recorded in situ every 5 min at 25 °C with 50 μM Aβ and 12 μM 
ThioT. Values represent means of two experiments. (a,c) Irrespective of its concentration, 
Aβ43 (dotted grey line) reduced the lag-phase for aggregation (c1) of Aβ40 (continuous 
grey line) without affecting elongation rates (c2). Aβ40:Aβ43 mixtures displayed higher 
fluorescence intensity after 8 h incubation (c3) than Aβ40 and Aβ43 alone. Greyscale code 
as in Fig. 5a. (b,d) Titration of Aβ42 (dotted black line) with Aβ38 (continuous black line) 
reduced lag phase (d1), and elongation rate (d2) but increased fluorescence intensity at 
plateau (d3). Greyscale code as in Fig. 5b.
Aβ40 is the most predominant species recovered from CSF [3,32]. Aβ38 has 
been reported to be present in CSF at concentrations of 1.26 to 2.78 ng/ml, while 
concentrations of Aβ42 were 0.46 to 2.07 ng ml-1 [3,32,33]. Quantitative detection 
of Aβ43 has only been performed in brain plaques and, as suitable antibodies are 
not available, can generally not be distinguished from that of Aβ42. While quantitative 
information on the released amounts of the four Aβ isoforms of interest from APP 
is only available for mutations related to familial Alzheimer disease based on in 
vitro observations [6,30,34,35], we performed titration assays (Figure 8.7). Results 
indicated that 30% of Aβ38 or Aβ43 already caused significant alteration of the 
aggregation profile of Aβ42 and of the lag phase of Aβ40. Many disease-related 
mutations accumulate Aβ42 while it can be assumed that in sporadic Alzheimer 
disease Aβ40 is predominantly produced [36]. We therefore decided to evaluate the 
effect of small concentrations (10%) of Aβ38 and Aβ43 on predominantly present 
(90%) Aβ40 and Aβ42 to monitor more subtle influences of the presence of peptides 
in mixtures. In summary, we evaluated oligomerization, cytotoxicity and aggregation of 
9:1 mixtures of Aβ40:Aβ38, Aβ40:Aβ43, Aβ42:Aβ38, and Aβ42:Aβ43. At these low 
concentrations the effect of the addition of Aβ38 and Aβ43 to either Aβ40 or Aβ42 
was limited to a significant decrease in final fluorescence intensity while leaving the 
nucleation phase unchanged (Figure 8.8 a,b). Visualization of aggregate morphology 
by TEM further rationalized the observed change in final fluorescence intensity (Figure 
8.1c and Figure 8.8c). Even though aggregate formation could not be established 
at early time points for Aβ38 and Aβ40 in isolation, a 9:1 mixture of these peptides 
showed the formation of extensive ThioT-negative but A11-positive aggregates that 
were present for extended periods of time (Figure 8.8 a,c,d). Also at early time points 
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of incubation the morphologies of both Aβ40 and Aβ42 in mixtures (Figure 8.8c) 
appear different from these peptides in isolation (compare with Figure 8.1c). Upon 
extended incubation all mixtures aggregated into morphologically similar networks of 
long, interacting fibrils, similar to those observed for peptides in isolation (Figure 8.8c). 
The observed differences in A11-interaction and aggregate morphology further led us 
to investigate the cytotoxic response of Aβ mixtures using cultured SH-SY5Y cells. 
Interestingly, even though Aβ38 or Aβ40 in isolation induced no cytotoxic response 
below a concentration of 20 μM, the addition of Aβ38 to Aβ40 resulted in a pronounced 
and significant loss of cell viability at a total peptide concentration of 10 μM, consistent 
with the A11-positive response for this mixture (Figure 8.8 d,e). Strikingly, the addition of 
Aβ38 to Aβ42 instead exerted a cytoprotective effect, despite showing the formation 
of A11-positive oligomers, preventing loss of cell viability up to a total Aβ concentration 
of 10 μM. In addition to this, even though both Aβ42 and Aβ43 are similarly cytotoxic 
at a concentration of 10 μM, the mixture of these two peptides alleviates the cytotoxic 
response while Aβ43 induces cytotoxicity in the presence of Aβ40. 
Collectively, our data suggest that, apart from distinct propensities to form cytotoxic 
oligomers and aggregates for individual Aβ peptides, mixtures of various Aβ peptides 
do not behave in a predictable manner according to a simple additive effect but can 
actively modulate the behavior of other isoforms present in the mixture to either induce 
or prevent toxicity or modify their aggregation propensities.
8.3 discussion
Aβ aggregation is a complex process during which a monomeric population 
progressively self-assembles first into oligomers and finally into mature fibrils. We 
show that biologically relevant mixtures of Aβ peptides, containing Aβ38, Aβ40, Aβ42, 
and Aβ43, behave in a more complex manner than can be anticipated from their 
behaviors in isolation with direct consequences for their oligomerization, aggregation 
and cytotoxic behavior. We also report that co-occurring Aβ peptides can affect 
each other by conformational modulation of the C-terminal region which, in turn, is a 
function of C-terminal flexibility to adopt various conformations. For example, Aβ38 in 
isolation exhibited little cytotoxic potential, similar to Aβ40. At the same time, cytotoxic 
oligomers accumulated rapidly for Aβ42, and Aβ43. Nevertheless, mixtures of Aβ38 
and Aβ40 were highly toxic while the addition of Aβ38 to Aβ42 surprisingly induced 
a cytoprotective effect. The A11 reactivity of the individual Aβ peptides in isolation 
correlated with the observed cytotoxicity although all isoforms were found to form 
oligomers. This observation suggests a conformational difference between oligomers 
of different isoforms. The presence of both toxic, A11-positive and non-toxic, A11-
negative oligomers has been reported recently for Aβ as well as for the yeast-sup35 
protein [37,38]. The cytotoxicity - A11 reactivity correlation for peptides in isolation 
could not be extended to mixtures of Aβ isoforms. This lack of correlation can be 
explained by the polyclonal nature of the antibody to recognize non-toxic oligomers in 
addition to toxic species. Another possibility is that non-toxic and toxic oligomers are 
both formed and that the variation in signal intensities, and cytotoxicity, arises from 
the variation in the distribution between these oligomers. At high concentrations when 
the level of toxic oligomers is sufficiently high, the shorter Aβ isoforms become similar 
cytotoxic to the longer Aβ isoforms. While not being able to reveal distinct accumulation 
of specific conformations using CD, FTIR revealed small structural differences during
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Figure 8.8 Aβ peptides in mixtures display complex aggregation behavior and toxicity. 
(a,b) Addition of 10% (=5 μM) Aβ38 (continuous black line) or Aβ43 (dotted grey line) to 
90% (=45 μM) Aβ40 (continuous grey line) or Aβ42 (dotted black line) decreased final (10 
h) ThioT fluorescence compared to Aβ40 or Aβ42 alone. Values represent means of three 
experiments (c) After 1.5 h of incubation mixtures containing Aβ38 formed amorphous 
aggregates while mixtures containing Aβ43 formed short fibrillar structures. Longer 
incubation for 6 h resulted in fibrillar networks for all mixtures which extended into dense, 
highly intertwined, stained networks after 24 h of incubation. Length of scale bar is 200 
nm. (d) All Aβ mixtures intensively reacted with A11 oligomer-specific antibody after 0.5 h of 
incubation which gradually decreased upon longer incubation dependent on the Aβ mixture. 
(e) Aβ was added to cultured SH-SY5Y cells and incubated for 24 h before probing 
cytotoxicity using the Cell Titer Blue viability assay. Note that non-toxic Aβ40 (left, grey) 
became highly toxic upon mixing with non-toxic Aβ38 (left, black) and Aβ43 (left, white) at 
a concentration of 10 μM. Toxicity of Aβ42 (right, grey) is reduced upon addition of Aβ38 
(right, black) or Aβ43 (right, white). Values are percent of cell viability ± SD (N=4), buffer 
signal was normalized to 100%. Statistical significance (unpaired 2-tailed t-test) compared 
to buffer control is indicated by ***p<0.0001, **p<0.0005, and *p<0.005.
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a 1.5 h incubation time. Even though all tested Aβ peptides showed substantial β-sheet 
formation over time, only for Aβ38 and Aβ43 anti-parallel β-sheet formation could be 
identified which has been interpreted previously as typical for oligomer formation [28]. As 
both FTIR and CD are only informative on an ensemble level, we used MD to elucidate 
the short-time scale dynamic behavior of the peptides. MD simulations revealed that 
both Aβ38 and Aβ42 gained extended β-sheet conformation rapidly while helicity in 
Aβ40 was retained for longer which is in good agreement with earlier reports [39]. In 
line with our findings, it has previously been reported that stabilization of the central 
α-helical region of Aβ by ligands or mutations results in significant delay of aggregation 
[40-42], and that inhibition of unfolding of the central α-helical region increases longevity 
in a Drosophila model of Alzheimer disease [41]. At the same time, rapid induction 
of extended β-sheet formation has been found to have strong predictive power in 
terms of toxic potential rationalizing the development of so-called β-sheet breakers as 
therapeutic approach (reviewed in [43]). Interestingly, Aβ38 showed behavior that could 
be explained by rapid gain and loss of extended β-sheet conformation, fluctuating in 
behavior between Aβ40 and Aβ42/Aβ43, respectively. Rapid conformational switching 
between distinct conformations has been observed before for synaptically confined 
proteins SNAP-25 and synaptobrevin and was proposed to characterize a specific 
class of intrinsically disordered proteins [44]. Conformational flexibility was suggested 
to allow for fast ligand interaction and conformational selection which potentially has 
functional implications for the findings we report on Aβ38 but which warrant further 
investigation. The presence of other peptides with higher preference of one over 
another conformation may drive Aβ38 to rapidly recognize these as a potential ligand 
and template for conformational selection, which, in turn, either induces or inhibits 
aggregation. However, this may be an oversimplification of the actual situation since 
Aβ42 in the presence of Aβ38 is in fact less toxic which does not comply with this 
suggestion. Further research is required to precisely underpin the molecular mechanism 
of this observation. It has been previously reported that Glu22, Asp23 and Lys28 play 
a critical role in the aggregation process [45-48]. Presumably, Asp23 (and Lys28), 
while residing in a helical conformation, may not be able to trigger the formation of 
extended conformations, at least at early time points, thus retarding the aggregation of 
Aβ40. Therefore, not only the unfolding rate of the C-terminus, as has been previously 
suggested, can dictate the potential event to trigger aggregation and toxicity of Aβ 
[47], but also the capability of a given Aβ peptide to retain its helical conformation 
may be considered to induce such events. Based on the outcome of our molecular 
dynamics simulations we suggest that the plastic behavior of Aβ38, inducing toxicity 
for Aβ40 while eliminating response to Aβ42, plays a key role to these observations. 
Hence, the presence of other peptides may direct the self-assembly process toward 
at least two possible pathways, one leading to toxic oligomers and the second leading 
to non-toxic intermediates. Aβ43 does not display fluctuating secondary structures, 
and rapidly forms extended β-sheets. The self-assembly process in presence of other 
peptides is therefore probably more dependent on the flexibility of the structure of the 
second peptide. Indeed, it has been shown for the N-terminal domain of the HypF 
protein from Escherichia coli that both toxic and non-toxic oligomers can be formed 
[49]. 
Overall, our results can be of major importance for the further development of 
therapeutic strategies. The current approach of modulating β-secretase activity to 
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decrease Aβ42 generation results in increased Aβ38 levels at the same time. This 
approach is based on the observation that longer Aβ isoforms are more aggregation-
prone. Hence, establishing an increased Aβ38 level is considered a suitable and 
non-toxic approach to inhibit Alzheimer disease progress without compromising the 
important multi-substrate processing by γ-secretase. However, clinical studies still 
have to confirm their disease-modulating capacity. Whether this is due to the low 
brain-barrier penetrating potency of the compounds being tested requires further 
investigation. Together with previously published data [30], our results possibly indicate 
that another explanation for the lack of clinical evidence to place GSMs firmly on the 
map as Alzheimer disease therapy may be the induction of adverse, unexpected 
events as a result of the increased Aβ38 levels in combination with other Aβ peptides. 
In this view, Golde and colleagues [50] recently argued that the efficiency of different 
GSMs to shift Aβ release towards shorter isoforms could determine their therapeutic 
potential. We propose that peptide conformational flexibility may confer toxic properties 
to its oligomers and underline the importance of understanding the interplay between 
various Aβ isoforms.
8.4 experimentAl procedures
8.4.1 prepArAtion of Aβ peptides And peptide rAtios
Aβ peptides (rPeptide) were dissolved, and mixed as described in Chapter 2. 
Briefly, Aβ was dissolved into HFIP, evaporated with a N2 stream and redissolved 
in DMSO. Solvents were removed by elution over a 5 mL HiTrap desalting column 
into a 50mM Tris buffer pH 7.4 containing 1mM EDTA. Peptide concentrations were 
measured using the Coomassie (Bradford) Protein Assay kit against a bovine serum 
albumin standard. Aβ peptide concentrations were diluted to a concentration of 50 
μM in 50mM Tris buffer pH 7.4 containing 1mM EDTA and incubated at 25 °C under 
quiescent conditions for further experiments. 
8.4.2 thioflAvin t fluorescence
Fibrillation kinetics of Aβ in the presence of 12 μM thioT were followed in situ at 25 
°C using a Fluostar OPTIMA fluorescence plate reader at an excitation wavelength 
of 440 nm and an emission wavelength of 480 nm. Readings were recorded in 
triplicate every 5 min for a period of 10 h and corrected by subtracting the intensity 
obtained for buffer containing 12 μM ThioT. The end of the lag phase was determined 
manually. Elongation rate was fitted to the central region of the exponential phase. Final 
fluorescence was determined at 10 h of incubation.
8.4.3 dot blot
At various time points a volume of 5 μL sample was spotted onto Protran BA85 
nitrocellulose blotting membrane. The membranes were blocked at 25 °C in phosphate-
buffered saline containing 0.2% Tween20 (PBST XL) for 1 h and incubated for 1 h 
at 25 °C with primary rabbit polyclonal anti-oligomer antibody (A11), diluted 1:4000 in 
100 mM Hepes pH 7.0 [27]. After incubation with secondary anti-rabbit-HRP-tagged 
antibody, diluted 1:5000 in phosphate-buffered saline containing 0.05% Tween20 
(PBST) for 0.5 h at 25 °C, the membranes were visualized using the ImmobilonTM 
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Western chemiluminescent HRP substrate system.
8.4.4 trAnsmission electron microscopy (tem)
A volume of 5 μL of Aβ was adsorbed to carbon-coated on 400-mesh copper 
grids for 1 min. The grids were washed in ultrapure water and stained with 1% (wt/
vol) uranyl acetate. Samples were studied using a JEOL JEM-2100 microscope at an 
accelerating voltage of 200 kV or a JEOL JEM-1400 microscope at an accelerating 
voltage of 80 kV.
8.4.5 Atomic force microscopy (Afm)
AFM imaging was performed on a custom built instrument using Si3N4 tips with 
a spring constant of 0.5 N/m and a nominal tip radius of 10 nm. The measurements 
were made in tapping mode in air, with a tapping amplitude of less than 4 nm. The 
AFM scan settings were optimized to minimum force interaction with the sample. AFM 
samples were prepared by placing 5 μL of sample on freshly cleaved mica. After 4 
min adsorption time, unbound Aβ was washed off with twice 100 μL ultrapure water 
and dried using a gentle N2 stream. The images are represented in 3D after removal 
of height discontinuities between subsequent scan lines and compensation for piezo 
drift using SPIP software.
8.4.6 fAr-uv circulAr dichroism (cd)
After 1.5 h incubation Aβ was diluted to 15 μM and placed in a quartz cuvette with 
an optical path of 3 mm and far-UV circular dichroism spectra were recorded in a 
Jasco J-715 spectrometer. The wavelength range was set from 260 to 190 nm with 
0.2 nm resolution, 2.0 s response time, 2.0 nm bandwidth at a scanning speed of 50 
nm min-1. Data were collected as averages of eight scans. The spectra obtained were 
corrected by subtracting the spectrum obtained for buffer only. 
8.4.7 AttenuAted totAl reflection fourier-trAnsform infrAred spectroscopy (Atr ftir)
Using a Bruker Tensor 27 infrared spectrophotometer equipped with a Bio-ATR II 
accessory, infrared spectra of aggregating Aβ (220 μM, 25 °C, in 50mM Tris buffer 
pH 7.4 containing 1mM EDTA) were recorded. The samples were applied to the FTIR 
sample holder and incubated for 1.5 h. Spectra were recorded in the range of 900 
to 3500 cm-1 at a spectral resolution of 4 cm-1 at the beginning (time 0) and the end 
(time 1.5 h) of the experiment. Each measurement consisted of 120 accumulations. The 
spectrophotometer was continuously purged with dried air. The obtained spectra were 
corrected for atmospheric interference, baseline-subtracted and rescaled in the amide 
I area (1700 to 1600 cm-1). Changes of secondary structure over 1.5 h incubation 
were analyzed by subtraction of the spectrum recorded at time 0. 
8.4.8 in sIlIco predictions
The statistical mechanics algorithm TANGO [51] was used to predict aggregation-
prone regions in the Aβ peptide sequence [52]. TANGO provides an aggregation 
propensity (0-100%) per residue as output. An aggregating region is defined as a 
continuous stretch of residues with an individual TANGO score higher than 5% and a 
total score for the region higher than 50%. Total TANGO scores are calculated as the 
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sum of the individual residual TANGO scores for a given sequence. TANGO calculations 
were performed using http://tango.switchlab.org/ at a pH of 7.0, a temperature of 
298.15 K and 0.02 M ionic strength without N- or C- terminal protection. 
8.4.9 moleculAr dynAmics (md) simulAtions
The NMR structure (protein data bank entry 1IYT) was used as starting structure 
of Aβ42 and as a template to generate the other Aβ species studied here. All MD 
simulations were performed with GROMACS 4.5.3, using the OPLS/AA force field [53]. 
The LINCS algorithm [54] was used for bond-length constraining. The non-bonded pair 
list was updated every 10 fs. The simulation of each system was repeated at least 
10 times, and then individually analyzed and their averaged properties here reported. 
Programs included in the GROMACS package, as well as some in-house scripts 
were used to perform the analysis of the trajectories. Molecular graphics images were 
produced using the UCSF Chimera package from the Resource for Biocomputing, 
Visualization, and Informatics at the University of California, San Francisco (supported 
by NIH P41 RR001081) [55].
8.4.10 neuroblAstomA cells And cytotoxicity
The human neuroblastoma cell line SH-SY5Y (ATCC number CRL-2266) was 
cultured in D-MEM:F-12 supplemented with 10% fetal bovine serum. The cells were 
incubated at 37 °C in a humidified 5% CO2 atmosphere. Cytotoxicity assays were 
performed in 96-well plates after plating 25 000 cells per well in serum-deprived 
D-MEM:F-12. After pre-aggregation for 1.5 h Aβ was diluted in D-MEM:F-12 and added 
to the cells. After 24 h treatment, cell viability was analyzed using the Cell Titer 
Blue Cell Viability assay. After 4 h, color conversion was analyzed by measuring the 
fluorescence intensity of the samples at an excitation wavelength of 544 nm and an 
emission wavelength of 590 nm using a Fluostar OPTIMA fluorescence plate reader. 
Values are percent of cell viability ± SD, buffer signal was normalized to 100%. 
8.4.11 stAtisticAl AnAlysis 
Results from thioT fluorescence and cytotoxicity experiments were analyzed using 
two-tailed unpaired t-test for significance. Significance is indicated by ***p<0.0001, 
**p<0.0005, and *p<0.005. MD results were analyzed using two-way ANOVA with 
repeated measures to determine whether each group differs significantly from each 
other, and multivariate analysis to determine at which specific point the groups 
significantly differed. Bonferroni post-hoc analysis was applied. Significance is indicated 
by ##p<0.005. All properties determined by MD techniques are reported as the 
average property of 10 simulations ± SEM. 
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The increasing number of Alzheimer disease patients as a result of the aging 
population, their need for care and the related economical consequences are one 
motive in the search for medication that stops disease progress, reverses symptoms 
and, ultimately, that leads to prevention of disease onset. The human burden, both 
for patients and for caregivers, and the social consequences are a second reason 
to fight Alzheimer disease. This thesis has focused on the complexicity of the total Aβ 
pool as insight thereof allows for better understanding of disease mechanisms and 
for the identification of potential drug targets or of crucial processes to intervene with. 
Aβ peptides are the main component of brain amyloid plaques and their release, as 
well as their aggregation behavior can be affected by mutations leading to early-onset 
Alzheimer disease. These observations led to the hypothesis that Aβ is the prime actor 
underlying Alzheimer disease. The results in this thesis describe how variability of the 
Aβ sequence can be generated and how it affects aggregation and toxicity.
ConCluding remArKs on the worK desCribed 
And on the Alzheimer diseAse field.
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9.1 considerAtions when prepAring Aβ for In vItro And cell experiments.
In the last decade a wide variety of transient Aβ species have been reported to be 
crucial in the aggregation pathway of Aβ while exerting different degrees of toxicity. 
Aggregation is a complex and highly dynamic process which is to a great extent 
influenced by environmental conditions such as ionic strength or pH as well as intrinsic 
Aβ peptide parameters including peptide length, sequence variations and truncations, 
as is underlined by the results reported in this thesis. However, reports describing 
the aggregation properties of these peptide variations vary greatly. As Aβ has been 
proven notoriously difficult to solubilize, resulting in large variations of the reported 
experimental conditions to investigate its aggregation, it is not inconceivable that a 
significant portion of the observed variation between the reported key Aβ species is 
the result of differences in the solubilization procedures or in environmental conditions 
used [1-5]. These variations deviate the attention from the ‘real‘ problem.
We found that a variety of factors are critically important when preparing Aβ in 
solution for in vitro studies and we describe how to practically address these factors. 
For example, the preparation of a solution of predominantly monomeric Aβ virtually free 
of seeding species according to a standardized procedure serves as an important 
basis for understanding aggregation events. A seed is a nucleated species that, 
when added to a monomeric peptide solution, leads to a very rapid aggregation of 
that solution as it bypasses the rate-limiting nucleation step in the nucleation pathway 
[6],[7]. Non-standardized or uncontrolled seeding of solutions therefore may mask the 
aggregation properties of a monomeric peptide solution. Moreover the composition of 
Aβ samples needs to be compatible not only with the major biophysical techniques, but 
also with the more sensitive cell cultures and experiments involving primary neurons. 
We describe and validate a method yielding monomeric Aβ without seeds in a buffer 
containing none of the chemicals used to achieve seed-free sample preparation. The 
presence of these chemicals, HFIP and DMSO, were found to influence aggregation 
events and are found to be toxic in a biological context. Moreover, our protocol allows 
for the study of co-aggregation of different Aβ variants which which allows for the 
study of more complex mixtures of Aβ variants. Crucial to mimick and understand 
the coexistence of Aβ in the brain. Further experimental parameters such as choice 
of buffer, Aβ concentration and temperature remain variable, and also play a role in 
determining the aggregation characteristics of Aβ. 
The buffer in which Aβ is dissolved is crucial in determining aggregation and toxicity 
characteristics of the peptide. Most commonly used biological buffers such as Tris, 
phosphate buffered saline and Hepes are suitable for many applications, both in 
vitro as well as in cell culture experiments. Alternatively, Aβ peptides may be directly 
solubilized into cell culture medium. High ionic strength and a pH close to the isoelectric 
point of the peptide (near pH 5.0) tend to increase the aggregation rate of Aβ [8],[9] 
as a result of charge screening. The choice of buffer is mainly determined by the 
limitations of the experimental set-up or the requirements of other biomolecules used 
in the experiment. For example, buffers may need to be free of compounds toxic for 
cells and compatible with most commonly used biophysical assays including NMR, CD 
or mass spectrometry [10]-[12]. 
Once Aβ is solubilized in the desired buffer, the concentration of Aβ needs to be 
carefully controlled as aggregation is a strongly concentration-dependent process [13]. 
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Both the degree and rate of association are influenced by the protein concentration. 
Moreover, according to the monomer-addition aggregation model, formation of a nucleus 
only occurs above a critical concentration [14]. Further, the peptide concentration 
used for in vitro experiments is a highly debated issue in the field. Concentrations in 
the micromolar range are widely used and are often required for in vitro aggregation 
studies [6,15]. The major critique however is that these ‘high’ concentrations are far 
above concentrations as observed in vivo which are in the nanomolar range [16]. 
The nanomolar range is however not experimentally accessible for most biophysical 
techniques, e.g. FTIR and NMR require peptide concentrations of 50 to 200 μM. 
However, a recent study described how local effective intracellular Aβ concentrations 
may be much higher reaching concentrations in the low μM range [17,18]. The ‘natural’ 
time scale to develop Alzheimer disease is considered to be in the order of magnitude 
of decades. This time scale is not very conveniently followed experimentally. Therefore, 
the extrapolation to higher concentration is assumed to accelerate the aggregation 
process so that it is still comparable with the in vivo situation but within a practical time 
scale for a single experiment.
A further requirement to match the in vivo situation is that aggregation experiments 
should ideally be conducted at a temperature of 37 °C. This temperature requirement 
can usually be accommodated for with incubation, in situ recordings in temperature-
controlled set-ups or cell culture experiments. Common on-the-bench preparation and 
further handling of the sample however cannot always be executed at 37 °C. A further 
problem when investigating the aggregation process of a fast aggregating peptide 
such as Aβ is that incubation at 37 °C results in rapid aggregation kinetics hindering 
the study of early aggregation intermediates [19]. Lowering the incubation temperature 
e.g. to 20 °C makes this study more manageable. Lowering temperature even further 
to 4 °C on the other hand resulted in delayed aggregation (data not published) which 
could be explained by the formation of off-pathway oligomeric intermediates that 
interfere with the study of aggregation processes.
Future research would greatly benefit from a consensus of solubilization procedures 
and experimental parameters to investigate Aβ aggregation and toxicity to allow for 
large-scale comparison of experimental data obtained in various laboratories to pinpoint 
important factors and as such simplify a greatly complicated field [20]. 
9.2 contribution of distinct Aβ peptide regions to AggregAtion.
The Aβ pool in the brain comprises various peptide lengths, N-terminally truncated 
forms and post-translationally modified peptides [21,22]. The consequence of a high 
degree of Aβ variability on aggregation has been described as one of the primary 
aims of this thesis. The aggregation profiles of the heterogenous APP processing 
products such as N-truncated Aβ and various disease-related mutants of Aβ42 were 
reported, while the possible contribution of Aβ peptide length to disease development 
was investigated in more detail.
A comprehensive study of various Aβ peptides allowed for an in-depth understanding 
of the aggregation determinants within the Aβ sequence. The Aβ sequence contains a 
first aggregation zone located in the central region (spanning residues 16 to 22) and a 
second zone located in the C-terminus (from residue 28 onwards) [23,24]. Based on our 
results using fluorescence spectroscopy, electron microscopy, immunohistochemistry 
and computational analysis using Aβ variants and mutants displaying stronger or 
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weaker aggregation propensities in these zones, we suggest that the zone located 
in the C-terminus of the Aβ peptide is the primary driving force for aggregation while 
the central region exerts a more ‘regulatory’ function in the aggregation process. While 
the C-terminus is responsible for rapid aggregation into randomly organized networks, 
as is the case for Aβ42 and Aβ43, the central region allows for a slower but more 
organized aggregation process, resulting in highly ordered fibrils upon shortening the 
peptide sequence from 42/43 to 40/38 residues. When the C-terminal aggregating 
zone is too strong and enforces very rapid aggregation, the regulating role of the 
central zone is overruled and less regular aggregates are formed.
Comparison of modified Aβ peptides with their unmodified counterparts allowed 
for the identification of the effects of the modification on the aggregation process. 
Modifications like biotinylation or fluorescent tagging are widely used in experimental 
approaches as they can be used for interaction studies or visualization of the Aβ 
peptides [25-27]. Our results indicate that the aggregation behavior of Aβ is almost 
certainly influenced by tagging the peptide. Following aggregation kinetics of the labeled 
peptide by thioT fluorescence, confirming fibril formation by TEM or AFM or performing 
structural analysis by FTIR can identify any discrepancy between the aggregation 
behavior of the unlabeled and labeled peptide. Even though rapid screening might 
not reveal significant differences in the behavior of the labeled peptide as compared 
to the unlabeled form, observations could still be influenced by the tag. Repeating 
the experiments with a different tag, or with the tag linked to another position of the 
peptide could serve as control experiments. Common mutations of APP are located 
in the central region of Aβ or near the secretase cleavage sites [28]. Many of these 
mutations affect the amount or the spectrum of released Aβ from APP while some - 
but not all - also influence the aggregating behavior of the resulting Aβ peptide. These 
Aβ mutants display an aggregating behavior that is very similar to that of the wild type 
peptide. This observation fits well with the previously described hypothesis that the 
aggregation of the peptides is driven by the C-terminal region, which is not affected 
in these mutants. The variance in elongation rate and fibril morphology observed 
for these mutants can be attributed to the alteration of the ‘regulatory’ capacities of 
the central region. Hence, it is likely that the early-onset FAD cases related to these 
mutations are primarily the result of altered APP processing, and are to a minor extent 
determined by the behavior of the resulting Aβ proteins. These observations are also 
important with regard to sporadic cases of Alzheimer disease: focussing on the release 
of Aβ peptides might be a more promising therapeutic approach than acting on the 
aggregation of Aβ. The role of the N-terminus (residues 1-15 approx.) in aggregation 
is less decisive than the rest of the sequence. The N-terminal region contributes to 
aggregation, but the exact determinants remain elusive [15]. Here, we investigated the 
role of the N-terminus by comparing the aggregation of the p3 peptides (residues 17-
40/42) with that of the full-length Aβ peptides. The p3 peptides are released through the 
non-amyloidogenic APP processing pathway by α- and γ-secretase and are generally 
considered as ‘safe’ [29,30] although the peptides showed significant oligomerization 
and fibrillization in the assays described in this thesis. 
9.3 in vItro Aβ AggregAtion studies should investigAte complexes.
Although the spectrum of Aβ peptides in the brain is heterogeneous, most studies 
focus on one or two of the more common variants of Aβ, usually Aβ40 or Aβ42. It has 
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been reported that Aβ40 can affect the behavior of Aβ42 and vice versa [8,31-36]. 
The influence of both isoforms on each other’s behavior has been used to emphasize 
the difference between both isoforms. However, little has been investigated on the 
extent of influence and on the mechanisms underlying it. Further, nothing is reported on 
a possible similar effect by other, less prevalent, Aβ isoforms. Evidence is accumulating 
that other Aβ isoforms are involved in Alzheimer disease progress [37,38]. It is thus of 
utmost importance for the understanding of disease mechanisms to study the behavior 
of Aβ in mixtures, so as to mimic the in vivo situation. Here, we used a multidisciplinary 
approach to unravel the degree and mechanisms of mutual influence of less studied 
Aβ isoforms. The results presented here emphasize that general detection of Aβ 
peptides other than Aβ40 and Aβ42 can provide useful insights in the mechanisms 
underlying Alzheimer disease.
Specific mutations in the γ-secretase complex or in APP result in an increased 
production of Aβ42 shifting the Aβ42:Aβ40 ratio roughly to 3:7, compared to 1:9 
for unaffected subjects [39,40]. Our results indicate that a small concentration of 
Aβ42 in an otherwise Aβ40 dominated composition can have potentially beneficial 
effects on the aggregation process but that very small increases in the ratio make 
the mixture behave similar to Aβ42 in isolation despite the excess of Aβ40 present. 
These observations provide a possible explanation for the early-onset clinical picture 
seen in patients carrying such mutations. Further, our study of various APP mutations 
related to FAD shows that these mutations interfere with the cleavage of APP by β- 
and γ-secretase resulting, respectively, in an increased production of Aβ and a shifted 
spectrum of released Aβ isoforms. The increased release of Aβ is a known risk factor 
for Alzheimer disease [41,42], but we show here that mutations resulting in early-onset 
Alzheimer disease can also affect the release of Aβ38. Aβ peptide lengths other than 
the 40 and 42 amino acid forms had not been associated with FAD before and Aβ38  
is generally considered as less aggregating. Altogether these data suggest that levels 
of Aβ isoforms other than 40 and 42 may inform on disease progress and might serve 
as biomarkers in the blood or CSF, which might bring new diagnostic opportunities. 
We show that Aβ38 is more aggregation prone than Aβ40, in contrast to the postulate 
that shorter Aβ peptides are less prone to aggregation. But more importantly, when 
added to Aβ40 or Aβ42, Aβ38 almost immediately induces aggregation of the resultin 
mixtures. Moreover, Aβ38 surprisingly converted Aβ40 into a cytotoxic species while 
exerting a cytoprotective effect on Aβ42. This finding again indicates the possibility of 
an important role for Aβ38. Molecular dynamic studies indicated that Aβ38 displays 
high molecular plasticity compared to Aβ40 and Aβ42. This peptide has the tendency 
to exhibit conformational fluctuations at short time-scales between structures that 
resemble Aβ40 and Aβ42/43 alternatively. To explain the aggregation and cytotoxic 
inducing effect of Aβ38 on Aβ40 it is possible that the flexibility of the Aβ38 molecules 
acts as a template for Aβ40 and by converting to Aβ42-like conformations drags 
Aβ40 towards an alternative aggregation pathway. On the other hand, the fluctuating 
behavior of Aβ38 could affect the conformation of Aβ42 to be less toxic. Further 
molecular dynamics studies of these peptides in each others’ presence should elucidate 
these effects. Nevertheless, it is interesting to speculate to which extent an ‘infectious’ 
Aβ conformation may apply to Aβ-induced toxicity analogous to prion-like activity. The 
increase in aggregation kinetics observed for mixtures of Aβ38 and Aβ40 might result 
in a less organized and ordered aggregation, which is also suggested by the fibrillar 
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morphology. Maybe this less ordered aggregation goes through different intermediates 
and conformational states than the more organized variant, which could be a possible 
explanation for the induced toxicity observed. Similarly, Aβ38 might temper Aβ42 
aggregation slightly and control the reaction to induce more organized association, 
and decrease toxicity. Seeding experiments can further analyze the effects of Aβ38 on 
nucleation and aggregation of Aβ40 and Aβ42 while cell culture assays and primary 
neuron studies can further help to assess toxicity and to elucidate the pathways 
leading to toxicity. 
The slight structural differences between various isoforms of Aβ that also exert 
different toxic effects, strongly suggest that conformation, and not size or a specific 
association, is related to toxicity [43-45]. Moreover, interaction of Aβ with the oligomer-
recognizing A11 antibody mostly correlated with the outcome of the cell culture assays 
we performed and pre-incubation of the Aβ solution with the antibody abolished 
toxicity. On the other hand when analyzing the mixtures of Aβ, no correlation between 
A11 reactivity and toxicity was found and A11 reactivity seemed inversely correlated to 
thioT intensity. These observations suggest that the A11 antibody recognizes a common 
structural feature of oligomers albeit not exclusively. Being a polyclonal antibody it is 
plausible that this antibody recognizes epitopes other than the specific ‘toxic’ epitope 
of Aβ oligomers. Aβ solutions that rapidly oligomerize but contain only a small portion 
of toxic oligomers show no correlation between A11 reactivity and toxicity. Hence, the 
search for the toxic species might actually be the search for the toxic conformation. 
This toxic conformation might as well be a common trait between the various proteins 
related to conformational diseases. Similar to the prion protein where the cellular form 
has to convert into the prion form, oligomers in neurodegenerative diseases might have 
to undergo a conformational change to adopt the toxic conformation as additional step 
in the aggregation process.
The rather broad interpretation of toxicity in experimental set-ups might also explain 
the poor correlation with A11 reactivity. Depending on the assays used, toxicity can 
have a different meaning. When using cell culture assays, toxicity is assessed as cell 
viability. The advantages of the cell culture set-up - rapid read-outs, easy handling, 
many replications, rather low-budget and with few ethical issues - are balanced by 
the crude read-out, informing on survival or cell death without much nuance, or details 
of the mechanisms involved. Primary cultures which are more labour-intensive and 
less well-accepted from an ethical point-of-view than neuroblastoma cell cultures, 
can provide more detailed information on neuronal health and on the mechanisms 
underlying toxicity. Toxicity in studies involving primary neuronal cultures can be 
extended to provide detailed information on cell (mal)functioning including from an 
organelle perspective, synaptic activity, and activation of apoptotic pathways directly 
related to the type of hippocampal neuronal cells relevant to Alzheimer disease while 
neuroblastoma cells lack the machinery allowing activity measurements. When studying 
cognitive deficits in memory formation and memory loss, cultures are no longer suitable 
and animal behavior studies are necessary. In vivo studies need to be well-considered 
as they are time-consuming, have a less straight-forward read-out compared to 
biophysical or cell culture assays, are more expensive and need to be justified from 
an ethical point of view. In these studies, toxicity is assessed on a behavioral level, as 
a loss of memory e.g., and only in a second step dissection can inform on possible 
molecular events. To obtain a full understanding of the different aspects involved in 
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inducing cognitive deficits in Alzheimer disease it is necessary to combine the various 
disciplines and compare read-outs.
9.4 therApeutic ApproAch to Alzheimer diseAse: which wAy to go?
Current therapeutics can slow disease progress in the early stages of Alzheimer 
disease by improving neuronal communication and minimizing neuronal damage 
[45]. Various strategies aiming to halt or reverse disease progress, or even prevent 
occurrence are being examined [47]. The complex nature of Alzheimer disease on one 
hand brings many opportunities but on the other hand hinders intervention strategies. 
The lack of success with the ample therapeutic attempts made during the last decade 
requires re-consideration of the possible approaches.
A first possible scenario in the fight against Alzheimer disease aims to identify 
those at risk at an early pre-symptomatic stage and to prevent the development of 
the disease. Disease mechanisms are most probably activated many years before 
the first symptoms manifest themselves. Early diagnosis thus implies the need for 
biomarkers indicating changes in these mechanisms. The sporadic nature of Alzheimer 
disease complicates this approach, as it requires large-scale testing of the population, 
preferentially using blood or saliva over CSF samples. Taking into account that 
society is aging, prevalence of Alzheimer disease is increasing and that consensus 
on biomarkers for disease development has not been reached, prevention might 
not be the best strategy at this moment. Possible early biomarkers are related to 
the processing of APP and indicate (i) changes in the balance between the non-
amyloidogenic and amyloidogenic pathway or (ii) changes in the spectrum of Aβ 
peptides, given the fact that these changes are rapidly and accurately reflected outside 
the brain. Other possible biomarkers could be those that indicate neuroinflammation or 
neuronal damage [48-50]. 
Early and accurate diagnosis is also important to cure Alzheimer disease as 
neuronal loss cannot be reversed. Currently, diagnosis is made by ruling out all other 
possible causes for the symptoms, it is not conclusive and often occurs at later disease 
stages. When looking for a cure, diagnostic tools need to be improved to allow fast 
and certain diagnosis. As neuron recovery is possible when exposure to a cytotoxic 
stimulus was limited in time rapid diagnosis can improve the success rate of attempts 
to a cure. It is also not clear yet what the point-of-no-return is for neuronal survival, that 
is at which point a damaged neuron undergoes definite apoptosis. Studies into such 
mechanisms may provide information to which extent it is possible to actually cure 
a neurodegenerative disease such as Alzheimer disease. When cytotoxicity cannot 
be prevented, the treatment has to be administered rapidly after first cytotoxic stimuli 
occurred and has to eliminate or reverse the cytotoxicity. Despite the extensive efforts 
made to understand Alzheimer disease, insights are currently insufficient to provide 
curative therapy.
A third action plan is the treatment of Alzheimer disease. Molecules that effectively 
reduce the brain damage responsible for the most important symptoms could 
significantly postpone disease development. Such compounds could be neuroprotective, 
act on tau, reduce oxidative damage, interfere with neuroinflammation [47,52,53] or 
be ‘multi-target’ compounds. In the sporadic cases of Alzheimer disease where the 
first symptoms are manifested at old age, this approach could bring symptomatic 
relief without acting on disease mechanisms and turn Alzheimer disease into a chronic 
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disorder. Although the costs related to treatment remain, the need for specialized 
care will reduce and the social burden of Alzheimer disease will improve. Effective 
Alzheimer therapeutics might interfere with the molecular mechanisms involved in APP 
processing and Aβ generation. However, blocking these processes has been proven 
ineffective [54]. Modulation of the enzymes involved to carefully manipulate the balance 
of the various processing steps is the latest attempt [54,55]. The problem however is 
the rather basic knowledge of the resulting peptide pool. The data presented in this 
thesis strongly indicate that modulation of Aβ release could be counter-effective and 
indicate that Aβ38, generally considered as safe and focussed on in current drug 
development approaches, might be decisive in the onset of Alzheimer disease. The 
modulation of the Aβ release can benefit from in-depth characterization of the total 
Aβ spectrum in healthy and diseased individuals. Such therapy can be effective when 
restoring the ‘natural’ Aβ balance. Besides, brain deposits are to a lesser extent found 
in elderly without any sign of dementia [56]. This observation suggests that not the 
aggregation itself underlies neurodegeneration. Compounds reducing aggregation or 
circumventing, blocking or eliminating the toxic assemblies on the aggregation pathway 
might be another successful attempt. Further, such compounds might be useful in the 
fight against other conformational diseases as aggregation has a common structural 
basis [57].
9.5 quo vAdis? where do we go from here?
The major cause of Alzheimer disease remains elusive although factors such as 
Aβ and tau behaving aberrantly in disease cases have been identified. The problem 
resembles the ‘chicken or the egg-paradigm’: Is Aβ the true cause of the disease 
leading to cellular imbalances and tau hyperphosphorylation, does the cascade start 
from tau hyperphosphorylation or is there another event causing cellular distress 
affecting Aβ generation and/or tau phosphorylation? 
The research presented in this thesis on the contribution of Aβ peptide variation on 
disease progress does not provide a complete insight into Alzheimer disease progress, 
but brings further insights into the molecular mechanisms underlying this disease and 
emphasizes the importance of understanding the behavior of the total Aβ pool. The 
extensive research conducted already has yielded detailed understanding of the basic 
mechanism in Alzheimer disease such as the pathways leading to Aβ production, 
and the aggregation characteristics of the predominant Aβ peptides. Intervention 
strategies based on this knowledge have not been very successful. Alzheimer 
disease has been identified as a multi-factorial disease in which other parameters 
such as neuroinflammation, oxidative stress, genetic factors and co-factors such 
as apolipoprotein E isoforms play a major role in determining its course [58-60]. 
Even though many studies are now actively seeking the contribution of individual 
parameters to disease progress, a consensus from this perspective has not been 
reached. It has been shown that non-steroidal anti-inflammatory drugs (NSAIDs) have 
some effect in inhibiting disease progress but are not completely capable of halting its 
development [61]. Also single anti-oxidant treatment has shown some, but only partial 
relief [62]. Alzheimer disease should therefore not be treated as a single-cause disease 
using single-target therapy but using a multi-target drug. More recently, experimental 
approaches have headed more towards cell-based studies investigating the cellular 
cascades following exposure to Aβ. The understanding of these cellular events might 
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provide an alternative way to intervene with the cascades inducing cytotoxicity or 
leading to neuronal loss. Further, exploration of the pathways leading to neuronal loss, 
and the biomarkers thereof, might enable early detection of neurodegeneration in 
Alzheimer disease.
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following Aβ peptides were chemicAlly synthesized.
Aβ37 DAEFRHDSGYEVHHQKLVFFAEDVGSNKGAIIGLMVG
Aβ38 DAEFRHDSGYEVHHQKLVFFAEDVGSNKGAIIGLMVGG
Aβ40 DAEFRHDSGYEVHHQKLVFFAEDVGSNKGAIIGLMVGGVV
Aβ42 DAEFRHDSGYEVHHQKLVFFAEDVGSNKGAIIGLMVGGVVIA
Aβ43 DAEFRHDSGYEVHHQKLVFFAEDVGSNKGAIIGLMVGGVVIAT
Aβ42
   D7N DAEFRHNSGYEVHHQKLVFFAEDVGSNKGAIIGLMVGGVVIA
   A21G DAEFRHDSGYEVHHQKLVFFGEDVGSNKGAIIGLMVGGVVIA
   E22G DAEFRHDSGYEVHHQKLVFFAGDVGSNKGAIIGLMVGGVVIA
   E22K DAEFRHDSGYEVHHQKLVFFAKDVGSNKGAIIGLMVGGVVIA
   E22Q DAEFRHDSGYEVHHQKLVFFAQDVGSNKGAIIGLMVGGVVIA
   D23N DAEFRHDSGYEVHHQKLVFFAENVGSNKGAIIGLMVGGVVIA
biotin-Aβ40 biotin-DAEFRHDSGYEVHHQKLVFFAEDVGSNKGAIIGLMVGGVV
Aβ40-K-biotin DAEFRHDSGYEVHHQKLVFFAEDVGSNKGAIIGLMVGGVV-K-biotin
biotin-Aβ42 biotin-DAEFRHDSGYEVHHQKLVFFAEDVGSNKGAIIGLMVGGVVIA
Aβ42-K-biotin DAEFRHDSGYEVHHQKLVFFAEDVGSNKGAIIGLMVGGVVIA-K-biotin
p317-40 LVFFAEDVGSNKGAIIGLMVGVV
p317-42 LVFFAEDVGSNKGAIIGLMVGVVIQ
Appendix
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purity of the chemicAlly synthesized Aβ peptides wAs confirmed by mAldi-tof 
mAss spectrometry And lc-ms (insets).
The mass-to-charge (m/z) spectra of all Aβ peptide variants display one or two 
major peaks that correspond to the single or double charged ion species derived 
from the full length monomeric peptide. Insets show the elution of the peptide from the 
column in a single, monomeric peak.
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Aβ peptides show direct And non-preferentiAl rAndom interAction
Electron spray ionization-mass m/z spectrum (ESI-MS) of monomeric and dimeric 
Aβ prepared from a 1:1 Aβ40:Aβ42 ratio upon 100-fold dilution from DMSO in 
acetonitrile:water (1:1, v/v). The box denotes the spectral location of dimers. Spectral 
contributions by Aβ40 or Aβ42 are denoted by circles or squares respectively.
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Magnification of the ESI-MS (m/z) dimer spectrum of Aβ40 and Aβ42. Spectral 
contributions by Aβ40 or Aβ42 are denoted by circles or squares respectively. 
Quantitation of ESI-MS data indicate that Aβ40 and Aβ42 interact to form dimers in a 
random manner.
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Dimer formation between Aβ42:Aβ40 ratios 1:9 and 3:7 is also random. Both 
heterdimers (Aβ40-Aβ42 m/z 1264.5) and homodimers (Aβ40-Aβ40 m/z 1238; Aβ42-
Aβ42 m/z 1291) are detected.  
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Deconvoluted electrospray ionization mass spectra of the various Aβ42:Aβ40  
ratios at time 0 h.
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Deconvoluted ESI-MS spectra of mixtures of various Aβ lengths were recorded 
immediately after mixing and 100-fold dilution in acetonitrile:water containing 0.1% 
acetic acid. The intensity differences in the peaks corresponding to both Aβ peptides 
indicate that mixtures were not exactly composed of 50% of each peptide. The region 
of the spectrum where dimers are detected is boxed.
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Magnification of the ESI-MS (m/z) dimer spectrum shows that a small population of 
mixed dimers is formed without any preference to form homo- or heterodimers.
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Proteins are the work horses of our body. Amongst other functions, they are part 
of the immune system, ensure transport of oxygen and are necessary for digestion 
amongst others. Each protein is adapted and optimized for its function. There are 
innumerable different proteins coupled to the myriads of biological processes. Some 
proteins require a specific three-dimensional conformation to execute their function 
while others remain unfolded. The nonnative interaction of proteins can cause their 
aggregation. When protein quality control systems cannot prevent these interactions, 
protein aggregates are formed. When proteins are trapped in such aggregates, they 
can no longer execute their function, which leads to diseases like cystic fibrosis. On 
the other hand protein aggregates can induce cellular damage causing disease, as 
occurs in Alzheimer disease. 
Alzheimer disease is characterized by severe memory loss. The disease is mainly 
observed in elderly, but rare hereditary forms cause early-onset (before the age of 
65) of Alzheimer disease. On a molecular level, neuronal loss, extracellular plaques 
of amyloid-β (Aβ) and intracellular tangles of tau characterize Alzheimer disease. The 
actual cause underlying Alzheimer disease has not been identified yet, but evidence is 
pointing to the aggregation of Aβ. 
The Aβ protein is released from a larger protein in the brain. The enzymes that 
ensure this cleavage are a not very precise and introduce heterogeneity in the length 
of the released Aβ peptides. The Aβ peptide can vary in length between 33 and 49 
amino acids. The 40 and 42 forms, Aβ40 and Aβ42, are the predominant peptides 
released. It is assumed that longer forms of Aβ are more aggregation-prone than the 
shorter variants. Mutations related to familial Alzheimer disease affect the enzymes 
releasing Aβ and cause a shift in the window of released Aβ peptides. 
summAry
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As Aβ40 and Aβ42 are the predominant forms, most research has focused on their 
behavior in the past. In this thesis the emphasis is on the influence of more expanded 
heterogeneity of Aβ on aggregation. First, the protocol enabling the dissolution of 
monomeric Aβ allowing for detailed characterization of aggregation is described. This 
procedure yields a solution which is compatible both with cell-culture studies as well as 
with the most common biophysical techniques. The second part of the thesis analyzed 
the aggregation of various Aβ lengths and disease-related mutations (Chapter 3) to 
gain insight into the mechanisms that underly aggregation. The effect of disease-
related mutations on the release of Aβ seems to be more dominant than the influence 
on aggregation of the related Aβ mutants (Chapter 4). In the last part the emphasis 
is on the mutual influence of various Aβ forms. Therapeutic approaches might benefit 
from these insights as various Aβ forms co-exist in the brain. It has been reported 
before that Aβ40 and Aβ42 can alter the aggregation of the other form. The results 
presented here show that very small fluctuations of the amounts of Aβ42 determine 
the aggregation properties of the mixture, and the toxicity that it exerts on neurons 
(Chapter 5). The structural characterization of these mixtures indicates that it is not the 
final aggregates that are affected by the small fluctuations, but rather the smaller, toxic, 
oligomeric species formed during aggregation (Chapter 6). Detailed characterization 
of the mechanisms that release Aβ and the effect of disease-related mutations on 
these processes showed that not only levels of Aβ40 and Aβ42 are affected but that 
levels of Aβ38 are increased as well (Chapter 7). Although it is generally assumed that 
shorter Aβ lengths aggregate more slowly, and are less toxic, the data presented here 
show that Aβ38 aggregates more rapidly than Aβ40. Moreover, the minimally toxic 
Aβ38 affects a majority of Aβ40 and induces toxicity of the mixture while at the same 
time it can moderate toxicity of Aβ42 (Chapter 8).
Altogether the results in this thesis indicate that heterogeneity of Aβ is much more 
involved in Alzheimer disease than assumed before. Less frequent forms of the 
Aβpeptide are likely to be involved in progress of Alzheimer disease. This is an insight 
which might have far-reaching consequences for the development of therapeutics as 
current strategies primarily focus on Aβ40 and Aβ42 without much consideration of 
other Aβ forms.
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Eiwitten zijn de werkpaarden van ons lichaam. Zo maken ze onder andere deel 
uit van het immuunsysteem, staan in voor zuurstoftransport en nemen deel aan 
vertering. Elk eiwit is aangepast aan de specifieke functie die het uitvoert. In elk 
levend wezen moeten ontelbare processen uitgevoerd worden, en dus zijn er ook 
talloze eiwitten.  Om hun specifieke functie uit te voeren moeten sommige eiwitten een 
specifieke structuur aannemen terwijl andere ongevouwen blijven. Wanneer eiwitten 
echter ongewenste interacties aangaan met andere eiwitten gaan ze samenklonteren. 
Wanneer de kwaliteitscontrole systemen van de cel de eiwitten niet kunnen beletten 
om te aggregeren, kunnen de eiwitten hun functie niet meer uitoefenen wat kan leiden 
tot ziektes zoals cystische fibrose. Bijkomend kunnen de geagreggeerde eiwitten 
schade aanrichten zoals gebeurt bij de ziekte van Alzheimer. 
De ziekte van Alzheimer wordt gekarakteriseerd door geheugenverlies, en komt 
voornamelijk voor bij oudere personen. Sommige erfelijke vormen van de ziekte 
veroorzaken een vervroegd ziektepatroon (bij patienten jonger dan 65). Op moleculair 
niveau wordt de ziekte van Alzheimer gekenmerkt door verregaand verlies van 
neuronen, extracellulaire ‘plaques’ van amyloid-β (Aβ) eiwitten en intracellulaire ‘tangles’ 
van tau eiwitten. De eigenlijke oorzaak van de ziekte is nog niet achterhaald maar de 
meeste gegevens wijzen in de richting van Aβ. 
Het Aβ eiwit wordt in de hersenen geknipt uit een groter eiwit. De enzymen die 
instaan voor deze vrijgave zijn niet heel nauwkeurig en introduceren variatie in de 
lengte van het Aβ wat wordt vrijgegeven. De lengte van Aβ kan varieren tussen 33 en 
49 aminozuren, waarbij de 40 en 42 vormen de meest voorkomende zijn. Er wordt 
aangenomen dat de langere vormen van Aβ meer geneigd zijn tot aggregeren dan de 
kortere vormen. Mutaties die leiden tot de erfelijke vormen van de ziekte van Alzheimer 
beïnvloeden de enzymen die Aβ vrijgeven en veroorzaken een verschuiving van het 
sAmenvAtting
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spectrum vrijgegeven Aβ. 
Aangezien Aβ40 en Aβ42 de meest voorkomende vormen zijn, werden in het 
verleden vooral deze vormen bestudeerd. In deze thesis wordt echter de nadruk 
gelegd op de invloed van grotere variatie van de Aβ eiwitten op hun aggregatie. Eerst 
(hoofdstuk 2) wordt een algemene procedure beschreven voor het oplossen van Aβ 
op een manier die het mogelijk maakt om aggregatie vanaf de monomeren te kunnen 
volgen en in een formulering die geschikt is voor celcultuur studies, en de meeste 
biofysische technieken. Het volgende deel van de thesis beschrijft de aggregatie van 
verschillende lengtes en ziekte-gerelateerde mutanten (hoofdstuk 3) om inzicht te 
krijgen in de mechanismen die leiden tot aggregatie. De invloed van ziekte-gerelateerde 
mutaties op de vrijgave van Aβ lijkt een meer doorslaggevende rol te spelen in het 
vervroegd optreden van de ziekte van Alzheimer dan de aggregatie van de mutante 
Aβ eiwitten (hoofdstuk 4). Het derde deel van de thesis gaat na wat de invloed is 
die verschillende vormen van Aβ op elkaar uitoefenen. Deze invloed is zeer relevant 
voor het ontwikkelen van medicatie aangezien de verschillende vormen van Aβin de 
hersenen ook samen voorkomen. Dat Aβ40 en Aβ42 elkaar kunnen beïnvloeden 
was reeds geweten. Maar de resultaten hier tonen dat zeer kleine fluctuaties in de 
hoeveelheid Aβ42 bepalend zijn voor de aggregatie van het mengsel, en voor de 
schade die aangericht wordt aan neuronen (hoofdstuk 5). Structureel onderzoek van 
deze mengsels toont aan dat niet de uiteindelijke aggregaten verschillen, maar wel 
de kleinere toxische oligomere associaties die gevormd worden tijdens het aggregatie 
proces (hoofdstuk 6). Gedetailleerd onderzoek van de mechanismen die de Aβ vrijgave 
beïnvloeden in de ziekte-gerelateerde mutaties bracht aan het licht dat niet alleen 
Aβ40 en Aβ42 niveau’s worden aangetast, maar dat ook de hoeveelheid Aβ38 stijgt 
(hoofdstuk 7). Hoewel algemeen wordt aangenomen dat kortere lengtes van Aβ veilig 
zijn (traag aggregeren, en weinig toxisch zijn), tonen de resultaten hier dat Aβ38 sneller 
aggregeert dan Aβ40. Daarenboven slaagt het weinig toxische Aβ38 er in om grote 
hoeveelheden Aβ40 zo te beïnvloeden dat ze toxisch worden terwijl het de toxiciteit 
van Aβ42 tempert (hoofdstuk 8). 
De resultaten in deze thesis geven aan dat de grote variatie van Aβ een veel grotere 
rol speelt dan voorheen werd aangenomen. Minder frequent voorkomende vormen 
van Aβ zijn betrokken bij de ziekte van Alzheimer, en zijn veel minder onschuldig dan 
wordt gedacht. Dit inzicht is van primair belang voor de ontwikkeling van medicatie 
voor de ziekte van Alzheimer aangezien momenteel vooral wordt gefocust op Aβ40 
en Aβ42, zonder rekening te houden met andere vormen.
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